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Optical imaging has a substantial impact on basic and translational medical research through 
the development of optical imaging modalities for visualization of a wide variety of cellular 
and molecular processes in vivo.1 Optical imaging is considered safe, fast, inexpensive, makes 
use of non-ionizing radiation, and enables real-time anatomical and functional imaging.2 
It has the potential to become a powerful and practical tool for a wide array of applications 
in medicine and in particular in cancer research and treatment, such as noninvasive early 
detection, image-guided biopsy, intraoperative procedures, image-guided pathology, and 
therapeutic monitoring of cancer.3 
This thesis focuses on the development of near-infrared "uorescence imaging applications to 
complement the surgical treatment of breast cancer. In addition, the identi!cation of suitable 
tumor targets is described for targeted imaging applications. 
Basic principles of optical imaging
In optical imaging, information is obtained through measuring photons originating from a 
certain area of interest. Photons can either be emitted as a product of a (bio)chemical reaction 
or as a result of the excitation of "uorescent molecules. Although the amount of photons 
emitted is typically small and therefore undetectable with the human eye, a highly sensitive 
charged-coupled device (CCD) camera can be applied to image emitted photons noninvasively.4 
Optical signals are in"uenced by several variables when propagating through tissue, including 
absorption and scattering of photons. There are many molecular components in biological 
tissue that can absorb photons, collectively known as endogenous tissue chromophores. 
Examples of such chromophores include hemoglobin, melanin, nucleic acids, water molecules, 
and lipids, which all have their own unique spectrum.5 In the visible and ultraviolet spectral 
range (<650 nm), scattering and absorption of photons by tissue chromophores limit e#ective 
light penetration to several millimeters. In the near-infrared (NIR) spectral range (650–900 nm), 
tissue penetration is up to several centimeters as scattering and photon absorption by tissue 
chromophores are minimized. At longer wavelengths (>900 nm), tissue penetration decreases 
again due to absorption of photons by water molecules. The optimal spectral window for 
imaging purposes therefore lies between 650 nm and 900 nm, also known as the diagnostic 
window (Fig. 1). 
Near-infrared !uorescence optical imaging
In near-infrared "uorescence (NIRF) imaging, an external light source of a certain wavelength is 
used to excite a target "uorescent molecule. Upon excitation, the "uorescent molecule emits 
a photon of lower energy at a longer wavelength, which can subsequently be detected by a 
highly sensitive CCD camera system.6 
Due to the favorable optical characteristics of photons in the NIR spectral region, NIRF imaging 
seems of particular interest for clinical translation.7 Already, vibrant developments have been 
made in both imaging systems and tumor-targeted "uorescent probes that are potentially 
suitable for human use and may improve the way cancer is managed and monitored.8,9 NIRF 
imaging could be applied for noninvasive detection and visualization of tumors, improving the 
way cancer is managed and monitored. Moreover, image-guided surgery could assist surgeons 
in localizing the tumor and evaluating the extent of surgery intraoperatively in real-time. As 
"uorescent probes translate from preclinical studies to patients, potential applications of 
optical imaging in clinical care are expected to expand rapidly in the near future.10 
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CHAPTER 1
NIRF OPTICAL IMAGING APPLICATIONS IN BREAST CANCER
Near-infrared !uorescence optical imaging in breast cancer
Breast cancer is the most common form of malignancy in women in the Netherlands, with the
number of newly diagnosed patients approximating 15,000 on an annual basis.11 In the case 
of clinical T1-2N0M0-x breast carcinoma, breast-conserving surgery followed by radiotherapy is 
considered standard treatment. The surgeon hereto removes the primary tumor together with 
a small rim of normal breast tissue, guided by palpation and/or visual inspection. However, 
in 20% to 40% of the patients who underwent breast-conserving surgery, positive surgical 
margins are reported, which is considered an important risk factor for local recurrence.12 In the 
case of more than focal positive margins, a second operation and/or additional radiotherapy 
is therefore indicated, leading to increased complication rates, psychological distress, and 
healthcare costs.13 New approaches are needed to decrease the rate of positive surgical 
margins while preserving cosmetic outcome. 
OUTLINE
Chapter 2 comprises a review of the di#erent techniques that are currently available as well as 
potential future techniques for obtaining negative surgical margins in breast cancer treatment. 
Chapter 3 describes the development and validation of a predictive tool (BreastConservation! 
nomogram) to support both patients and clinicians in clinical decision-making by estimating 
the risk of positive margins prior to surgery. The tool is based on data obtained from twenty 
hospitals in the Northern- and Eastern region of the Netherlands.
Chapter 4 focuses on the potential of NIRF imaging in demarcating cancerous tissue. NIRF 
imaging was performed in a xenograft breast cancer mouse model using tumor-targeted 
"uorescent probes. Tumor delineation was compared between NIRF imaging and 
bioluminescence imaging as a gold standard for tumor tissue using the novel segmentation-
based comparative analysis of planar optical signals (SCAPOS) analysis tool. 
Figure 1. Overview of the spectrum of wavelengths, indicating the spectral range that is visible to the human 
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Chapter 5 describes the development of a breast phantom model with optical characteristics 
similar to normal breast tissue. In a feasibility study, breast phantoms were applied to simulate 
pre- and intraoperative NIRF imaging applications using a novel intraoperative NIRF camera 
system. 
Fluorescence-guided sentinel lymph node detection
In addition to breast-conserving surgery, a sentinel lymph node biopsy is generally performed 
for staging purposes in patients with clinically negative lymph nodes. Hereto, the !rst-draining 
lymph node is removed and evaluated for the presence of possible lymph node metastases. 
Intraoperatively, the surgeon is guided by a combination of vital blue dye and radioisotype, 
which is regarded standard-of-care for localizing the sentinel lymph node. 
Chapter 6 describes an alternative technique for intraoperative visualization of the sentinel 
lymph node using a nonspeci!c "uorescent dye in combination with an intraoperative NIRF 
imaging system. A  technical feasibility study was performed in ten patients to serve as a step-up 
towards targeted imaging of lymph node metastases using tumor-targeted "uorescent agents. 
Chapter 7 comprises a systematic review of conventional techniques used for sentinel lymph 
node mapping in breast cancer and melanoma patients. In addition, NIRF-guided sentinel 
lymph node mapping is judged on its merits and variables in"uencing sentinel lymph node 
detection are described.
Tumor-targeted imaging in breast cancer
To exploit the full potential of NIRF imaging, targeted "uorescent probes should be used that 
are directed towards speci!c markers exclusively expressed on tumor cells. Numerous studies 
have reported the feasibility of "uorescent probes to speci!cally target tumor lesions with 
excellent signal-to-noise ratios.8 Because targeted probes usually consist of relatively large 
molecules, e.g., monoclonal antibodies conjugated to a "uorescent dye, their target should 
ideally be expressed on the tumor cells’ outer membrane to ensure good accessibility. 
Although the portfolio of tumor markers known to play a role in breast cancer is large and still 
expanding, a single tumor-targeted agent that can be applied to all breast cancers is not yet 
available and is unlikely to become available in the future. A panel of targeted agents is therefore 
needed to make patient-tailored optical imaging accessible to the general population. As the 
development of targeted agents is time-consuming and costly, a selection of those markers 
that bear particular potential for clinical translation is desirable. 
Chapter 8 describes the evaluation of ten promising membranous and/or extracellular tumor 
markers for targeted NIRF imaging in breast cancer. For the majority of tumor markers assessed, 
targeted agents are already available for clinical use, facilitating clinical translation. 
In addition to intraoperative localization of the primary tumor, identi!cation of possible lymph 
node metastases could be a potent application of targeted NIRF imaging. Chapter 9 focuses 
on tumor marker expression of lymph node metastases, comparing expression levels with 
corresponding primary tumors. 
In Chapter 10 and Chapter 11, the results of the studies are summarized and suggestions for 
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Inadequate surgical margins represent a high risk for adverse clinical outcome in breast-
conserving therapy (BCT) for early-stage breast cancer. The majority of studies report positive 
resection margins in 20% to 40% of the patients who underwent BCT. This may result in an 
increased local recurrence (LR) rate or additional surgery and, consequently, adverse a#ects 
on cosmesis, psychological distress, and healthcare costs. In the literature, various risk factors 
are reported to be associated with positive margin status after lumpectomy, which may allow 
the surgeon to distinguish those patients with a higher a priori risk for re-excision. However, 
most risk factors are related to tumor biology and patient characteristics, which cannot be 
modi!ed as such. Therefore, e#orts to reduce the number of positive margins should focus on 
optimizing the surgical procedure itself, because the surgeon lacks real-time intraoperative 
information on the presence of positive resection margins during breast-conserving surgery.
This review presents the status of pre- and intraoperative modalities currently used in BCT. 
Furthermore, innovative intraoperative approaches, such as positron emission tomography, 
radioguided occult lesion localization, and near-infrared "uorescence optical imaging, are 
addressed, which have to prove their potential value in improving surgical outcome and 





Breast cancer is the most common form of cancer and second leading cause of death in women 
in Europe and the United States.1,2 During the last 30 years, wide-spread mammographic 
screening and technological developments have led to a rapid increase in the diagnosis of small, 
nonpalpable breast cancer.3,4 Breast-conserving therapy (BCT), consisting of lumpectomy and 
irradiation therapy, has become the standard treatment for T1-T2 breast tumors and is regarded 
generally su%cient in appropriately selected patients.5,6 
Large randomized clinical trials (RCT’s) have reported no signi!cant di#erence in disease-free 
and overall survival between BCT and traditional mastectomy.7-9 BCT is considered to be 
associated with a diminished psychological burden compared to mastectomy, o#ers better 
cosmetic results, and reduces wound infection risk.10 The most important disadvantage of BCT 
is the life-long risk for local recurrence (LR), in which case additional surgery is necessary.11 
Large clinical trials have reported LR rates between 6% and 16%.12-14
Accurate localization is essential for adequate surgical removal of breast tumors, in which 
an optimal balance between good cosmetic results and preservation of resection margins 
is the primary goal. Obtaining tumor free surgical margins decreases the incidence of LR of 
the primary tumor.11,15,16 However, previous studies have shown that the number of patients 
exposed to BCT in whom tumor cells were present at or near the cut edge of the surgical 
specimen after resection of the primary tumor ranged from 5% to 82%, with the majority of 
studies indicating positive margins in 20% to 40% of the patients.10,17-21 To obtain tumor free 
margins, mutilating additional surgical procedures have to be performed.11,15,16 
Alternatively, intraoperative radiation therapy can be applied as a boost to the tumor bed or, 
postoperatively, to the biopsy scar.22,23 Boost radiation, as an additive to standard whole-breast 
radiation therapy, reduces the LR rate; the absolute e#ect of radiation therapy is of greatest 
bene!t to women with higher risk of LR (P<0.0001).23-27 Adverse e#ects associated with 
boost radiation include decreased cosmetic outcome, delayed wound healing, and altered 
postoperative mammographic and ultrasonographic !ndings at the original tumor site in case 
of detection of recurrent disease.27-30
BCT still has limitations in achieving an acceptable therapeutic outcome.10 This review outlines 
the major challenges currently encountered intraoperatively and demarcates risk factors for 
positive resection margins and LR. In addition, current imaging modalities and future directions 
in achieving the highest feasible percentage of negative surgical margins in BCT are addressed. 
CLINICAL IMPACT OF POSITIVE MARGINS 
To assess strategies to decrease LR rates after BCT, several RCTs were performed and revealed 
numerous and varying risk factors that might be associated with LR (Table 1). A large 
meta-analysis of 72 trials, containing information on >42,000 patients, assessed that local 
surgical control at 5 years showed a signi!cant improvement in disease-free survival and 
overall mortality at 15 years follow-up.24 
The in"uence of “close” margins, usually de!ned as tumor cells being present >0 and within 
≤2 mm from the cut edge, is still controversial.4 Several studies reported close margins to be 
a signi!cant risk factor for increased rates of LR, as well as the apparent quantity of cancerous 
cells approaching the cut edge.31-34
2
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OBTAINING ADEQUATE SURGICAL MARGINS IN BREAST-CONSERVING THERAPY
In a recent trial conducted by Zavagno et al., 431 patients who underwent re-excision due 
to margin involvement were evaluated from a total of 1,520 patients who underwent BCT.35 
The authors found LR rates after positive margins and close margins to be 51.8% and 34.1%, 
respectively (P=0.001). However, no correlation was found between the distance of the tumor 
from the cut edge (range: 0.08−3 mm) and LR rate. These !ndings are consistent with the 
results of most of the studies performed on the correlation between margin width and LR rate, 
as reviewed by Singletary.4 Margin closeness is therefore currently not seen as an indication 
for re-excision.  
Zavagno et al. suggest that residual disease in close margin involvement may be largely due to 
the existence of multiple cancerous foci and not to margin closeness by itself.35 Breast tumors 
are shown to grow multifocally in 59%, of which 71% grow at a distance >2 cm from the 
reference tumor.36 Therefore, margin status as such may be considered an important judgment 
factor in planning re-excision, but cannot be seen as an indicator for the presence of residual 
tumor in the surrounding tissue.35 Adequate perioperative imaging of cancerous foci may be 
of great value to the surgeon.
Singletary reviewed 34 studies on margin status and LR, in which a total of >15,000 patients 
were assessed.4 In 30 of 34 reviewed studies, persistent microscopic inadequate (R1) or 
macroscopic inadequate (R2) surgical margins were highly signi!cant for LR compared with 
negative margins (P=0.0001), depicting the relevance of margin status on the outcome of BCT. 
In a study by Jobsen et al. of approximately 2,300 patients, the LR rate was found to be related 
to positive margin status and young age.37 The authors found the 10-year LR-free survival rate 
for young women (≤40 years) with positive margins to be signi!cantly lower compared with 
negative margins (34.6% vs. 84.4%, respectively; P=0.008). The e#ect of positive margin status 
for invasive carcinoma seems to be limited to young women and is not only restricted to local 
control, but also to distant metastases and survival.37 
Because positive margin status is found to be an important risk factor for LR, substantial e#orts 
have been made to understand the causes of the relatively high percentage of positive margins 
after BCT. A number of risk factors for positive margin status in itself have been identi!ed over 
the years (Table 2). Again, young age is reported to be a strong risk factor for positive margin 
status.20,37-41 Vrieling et al. reported that tumor size was signi!cantly larger in young patients 
(≤40 years) compared with older patients (P=0.001).38 Furthermore, re-excisions occurred 
more often in younger patients (34−35% vs. 20−28%; P=0.001), which was probably related 
to a more frequent incomplete excision at the !rst attempt (24−26% vs. 14−21%; P=0.001). 
Vicini et al. suggested that a lesser extent of the excision, for cosmetic reasons, might be the 
cause of less optimal margin resection in younger patients.34 When adequate negative margins 
were obtained, no di#erence in LR was seen in di#erent age groups. 
Other reported risk factors for positive margin status are large tumor size, multifocality, and 
lobular histological type.17,20,39-43 Furthermore, the number of positive lymph nodes (N-status) 
is reported to be a risk factor.44 However, it should be noted that there is a strong variability in 
the reported !ndings of these studies.
An explanation for the high rate of positive margins reported in literature might be the restricted 
visibility of the tumor and coexisting ductal carcinoma in situ (DCIS) during surgery. In order 
to give an adequate perspective on the problems surrounding the pre- and intraoperative 
visibility of the tumor, the techniques currently used are summarized in the following sections 
and judged on their merits. 
20
CHAPTER 2
CURRENT MODALITIES OF IMAGING BREAST CANCER IN BCT
Clinical aspects in patient selection
Approximately one third of all diagnosed breast cancers is clinically occult. As a consequence, 
additional techniques have to be used to localize the tumor adequately. By current standards, 
the tumor is visualized with X-ray mammography or ultrasonography before the surgical 
procedure. However, during the lumpectomy procedure, the surgeon relies mostly on 
palpation of the tumor.45 Palpation of the tumor alone is considered inadequate for optimal 
lumpectomy due to a few basic shortcomings: di%culty to detect occult or multicentric disease 
and di%culty in di#erentiating between malignant tissue and !brosis. Furthermore, tumors 
in younger women are harder to detect because of the !rmer nature of the breast tissue.42 
Therefore, most institutions use additional intraoperative techniques to evaluate surgical 
margins, which may assist in obtaining margin negativity. Because none of these techniques 
fully guarantee the detection of a negative margins status, preoperative imaging is an absolute 
necessity for adequate BCT.
Preoperative mammography
Due to widespread mammographic screening programs, radiographic X-ray mammography 
is currently the most common way of detecting breast malignancy. Mammography gives an 
accurate assessment of tumor size and borders. It also provides information on the presence 
of multicentricity, multifocality, and microcalci!cation, which is considered to be a sign for 
the presence of DCIS.46,47 In a recent meta-analysis on the e%cacy of mammography for the 
detection of tumors, sensitivity and speci!city rates of 94% and 61% were found, respectively.48 
Although mammography is an adequate technique for breast cancer detection, it has a 
relatively high rate of nonspeci!c !ndings.49 Furthermore, it does not give any functional 
information nor does it provide quantitative information on tissue function or composition.50 
Because of the aforementioned shortcomings, ultrasound was introduced as an addition to 
mammography for preoperative tumor assessment. While radiography provides information 
on tissue density and microcalci!cations, ultrasound gives a more accurate image of tumor 
size and growth pattern. Although both imaging modalities act complementary, they fail to 
assess tumor size and growth pattern in a substantial percentage of patients. Deurloo et al. 
found an underestimation in tumor extent of 23% in patients considered eligible for BCT, 
largely due to failure in assessing di#use and multinodular tumors.51,52 Especially patients of 
younger age present di%culties. An earlier study found failure to meet malignancy criteria in 
13% of patients assessed preoperatively by ultrasound alone.53 
Preoperative magnetic resonance imaging
Magnetic resonance imaging (MRI) is a highly sensitive imaging technique, which is reported 
to be a substantial improvement in detecting multinodular disease and assessment of tumor 
spread compared with conventional techniques.54,55 MRI provides highly sensitive information 
on DCIS.56 In a trial conducted in Belgium, MRI detected intraductal extent in 34 out of 50 
(68%) patients who were reported to have an intraductal component, compared with 48.5% 
in mammography and 34.2% in ultrasound.57 Furthermore, MRI has an accurate capability to 
di#erentiate between malignant tissue and !brosis, enabling assessment of breast tissue after 
irradiation or chemotherapy for the presence of recurrent disease.58 MRI is equally accurate 
in distinguishing malignancies in younger women with more extensive !broglandular tissue. 
2
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In a meta-analysis of 2,160 patients from 16 studies, Houssami et al. showed that MRI detects 
additional disease in 16% of patients with breast cancer, leading to conversion of local excision 
to mastectomy in 1.1% (95% con!dence interval (CI), 0.3−3.6) and to otherwise extended 
surgery in 5.5% (95% CI, 3.1−9.5).59 The authors reported a relatively high false positive ratio 
(true positive to false positive ratio of 1.91 (95% CI, 1.09−3.34)), for which further research on 
its clinical value is necessary. Nevertheless, MRI has been shown to have a profound clinical 
impact on selection of patients for BCT and is currently regarded as the preferred imaging 
modality for preoperative assessment and clinical decision making.
It should be emphasized that several studies have shown that MRI assessment before surgery 
fails to improve postoperative margin status and subsequent LR, even compared with 
conventional imaging modalities.60,61 The intraoperative limitation may be due to the limited 
provision of real-time margin assessment.62
INTRAOPERATIVE TUMOR LOCALIZATION
Because of the limited intraoperative capabilities of the current preoperative imaging 
techniques, more invasive imaging and surgical guidance techniques have been developed to 
assess tumor localization intraoperatively. These techniques are addressed in the next section. 
Wire-guided localization
For more than 20 years, the standard technique for intraoperative tumor localization of clinically 
occult tumors has been wire-guided localization (WGL), in which a wire is introduced in the 
tumor guided by ultrasound, X-ray mammography, or MRI. After resection, the excised lump 
can be evaluated mammographically for localization of the tumor and microcalci!cations. 
However, the WGL procedure has been criticized for the last 5 years. Burkholder et al. recently 
analyzed the success rate of WGL in a retrospective study of 511 patients and found positive to 
close (<3 mm) margins in 21.3% of the patients, of which 26.7% had to undergo re-excision.63 
Similar percentages were found by Schmidt-Ullrich et al.64 Two recent studies reported that 
WGL resulted in positive margins in 38% to 43% of the patients who underwent BCT.3,65 
An important disadvantage of WGL is that the guide-wire does not provide a clear three- 
dimensional perspective on the various tumor edges and does not in"uence surgical margins 
as such. Furthermore, the guide-wire is prone to move before or during surgery and may 
for this reason lead to inadequate information on tumor localization. The WGL procedure 
is time consuming and uncomfortable for the patient, resulting in increased levels of stress 
and arousal.66 Because WGL results in an unacceptable high rate of positive margins, other 
techniques have been developed for intraoperative tumor detection.
Intraoperative ultrasound guided resection
Current trends in BCT are moving toward the direction of one combined diagnostic and 
therapeutic procedure, a so-called ‘theranostic’ procedure, in which e#ective visualization 
plays a more prominent role. One of these theranostic procedures is intraoperative ultrasound 
(IOUS)-guided excision. In this technique, the patient is examined with ultrasound (US) before 
and during surgery to improve tumor assessment. After surgery, the excised tissue is examined 
using US to assess margin status. In case of positive or close margins, the patient’s cavity 
margins are shaved in order to remove any residual disease.67 
Several studies investigating the use of IOUS in BCT showed positive margin rates between 
3% and 11%.68-71 Rahusen et al. compared IOUS to WGL in a prospective study in 48 patients.70 
The authors reported that positive or close margin status (≤1 mm) was improved signi!cantly 
using IOUS compared to WGL (11% vs. 45%, respectively; P<0.007). However, Klimberg et al. 
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showed that only half (50%) of the nonpalpable breast tumors can be visualized by 
ultrasonography.72 Another problem of IOUS is the unreliability in detecting DCIS lesions, 
because ultrasonography is not suitable for the detection of microcalci!cations.73 
Karni et al. reported on a radiofrequency-based intraoperative margin assessment device 
(MarginProbeTM, Dune Medical Devices Ltd., Israel), which is able to detect malignant tissue 
within the surgical specimen up to a depth of 1 mm.74 The MarginProbeTM displays device 
readings as ‘negative’ or  ‘positive’ margin, the latter indicating excision of additional breast 
tissue. Sensitivity and speci!city rates of the MarginProbeTM were reported to be 71% and 
68%, respectively.74 Recently, Allweis et al. showed re-excision rates to be lower if the surgeon 
had a MarginProbeTM at his disposal during breast-conserving surgery compared with the 
control group, although not statistically signi!cant (12.6% vs. 18.6%; P=0.098).75 However, 
this reduction in re-excision rate might, in part, have been due to the excision of larger tissue 
volumes in the device group compared with the control group (107 cm3 vs. 94 cm3; P=0.066).
Intraoperative specimen radiography
Another technique for evaluation of surgical margins is intraoperative specimen 
radiography. After excision by the surgeon, the specimen is evaluated by X-ray radiography. 
If microcalci!cations occur close to the edges of the specimen, the surgeon may decide to 
shave the associated cavity edges in order to remove any residual malignant disease. However, 
the use of radiographic X-ray mammography is limited due to limitations in detecting small, 
noncalci!ed lesions and a high rate of nonspeci!c !ndings.76 Lee and Carter examined 
postexcision specimen radiographs of 125 patients and found a sensitivity, speci!city, and 
overall accuracy for detecting margin positivity of 49%, 77%, and 62%, respectively.77 They 
concluded that intraoperative specimen radiography could not be relied on solely but presents 
a valuable addition to BCT. 
Cryoprobe-assisted localization
Cryoprobe-assisted localization (CAL) is a technique of particular value in small, nonpalpable 
tumors. This technique makes use of an ultrasound-guided cryoprobe, which is inserted into 
the breast and freezes the tumor, thereby turning the tumor into a small, palpable sphere 
that can be more easily located and excised. Tafra et al. compared the capability of CAL in 
achieving negative margins to conventional WGL in a prospective trial in 310 patients.78 No 
signi!cant di#erences were found between the CAL and WGL arms in positive surgical margin 
status (28% vs. 31%; P=0.691) and re-excision rates (19% vs. 21%; P=0.764). However, it did 
reduce the amount of healthy surrounding tissue excised and therefore improved cosmetic 
outcome (P<0.001). Furthermore, excision time and ease were signi!cantly improved using 
the CAL method (P<0.001). 
INTRAOPERATIVE PATHOLOGICAL EXAMINATION 
Frozen section analysis
Frozen section analysis (FSA) is a commonly applied technique for intraoperative pathological 
margin assessment in many oncologic procedures. The excised specimen is frozen, sliced, 
and analyzed microscopically.79 Because of the relative ease and the wide experience gained, 
this technique has been applied frequently to assess tumor margins during lumpectomy. 
The procedure is performed directly after the tumor has been excised. In case FSA indicates 
residual disease, the wound can be re-opened immediately for additional cavity shaving, thus 
preventing a costly re-excision procedure at a later stage. The FSA procedure takes an average 
of 30 minutes, which adds signi!cantly to the operating time.80 
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Reported sensitivity rates for detecting residual disease ranged between 65% and 78%, 
whereas speci!city rates ranged between 98% and 100%.40,81,82 The relatively high variance in 
sensitivity might be explained by di#erences in experience between pathologists. 
Several studies retrospectively analyzed the in"uence of FSA on BCT outcome and found that 
24% to 27% of the patients underwent additional tissue excision based on FSA, whereas 5% to 
9% required a second re-excision procedure after de!nitive histopathological examination.80,82,83 
FSA during BCT did not improve overall LR rates (3.8% and 1.2%, respectively).80,83 Considering 
the costs of the FSA procedure (the average Medicare charge for FSA is estimated at US$90), 
these low re-excision rates clearly indicate the bene!ts of the procedure compared with 
permanent pathological evaluation alone. Nevertheless, in evaluating small tumors (diameter 
<10 mm) and presence of DCIS, the technique is less reliable.80,81 Other disadvantages of FSA 
are the prolonged duration of operation time and the requirement of a relatively large part 
of the specimen, which compromises de!nitive evaluation by the pathologist for histological 
aspects and tumor staging. In conclusion, although FSA is a relatively safe and cost-e#ective 
procedure that reduces the rate of re-excisions signi!cantly, its reliability for negative margin 
status is questionable due to relatively high variance in diagnostic sensitivity.
Intraoperative touch preparation cytology
Intraoperative touch preparation cytology (IOTPC) or ‘imprint cytology’ is a promising 
alternative to FSA. The technique is based on the histological characteristics of the cell surface 
of malignant cells, which stick to glass surfaces, whereas benign mammary fat tissue does not. 
To assess margin status, a glass slide is brought against the borders of the excised specimen. 
Next, cells sticking to the glass surface are !xated, stained and microscopically evaluated.84 
Several studies have concluded that IOTPC is inexpensive, accurate, quick and saves tissue for 
permanent sectioning and histopathological examination.84-86 
Klimberg et al. evaluated IOTPC for accuracy in diagnosis as well as margin assessment 
during surgery in a prospective trial in 428 patients.84 They reported a diagnostic sensitivity 
and speci!city of 96% and 100%, respectively, and a margin status sensitivity and speci!city 
of both 100%. Weinberg et al. compared the e%cacy of IOTPC to other histopathological 
assessment techniques such as de!nitive histopathological assessment and intraoperative 
FSA in a database of 1,713 patients.87 They reported that intraoperative margin assessment 
using IOTPC signi!cantly reduced LR rates compared with conventional methods (2.8% vs. 
8.8%;  P<0.0001). 
Although the overall results seem promising, IOTPC is not as commonly used as might be 
expected based on reported LR rates and detection rates of positive margins. A possible 
explanation might be the likelihood of artifacts caused by draught and surface cautery.4 
Also, IOTPC is proven less e#ective in distinguishing lobular carcinoma.85 Another important 
shortcoming of IOTPC is that close margins are not taken into account, since only super!cial 
tumor cells are detected with the technique. Therefore, no information is gathered on margin 
width, multifocality, and quantity of cancerous cells approaching the cut edge.
STANDARDIZED CAVITY SHAVING
To avoid the earlier-mentioned di%culties in intraoperative cytological or histological 
techniques, some authors suggested that standardized surgical cavity shaving could 
achieve the intended reduction in positive-margin rates.88 Hereto, all cut edges are shaved 
systematically after excision of the primary tumor to remove any residual disease. 
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Huston et al. compared the number of systematically shaved cavity edges to the achieved 
de!nitive histopathological margin status and found an inverted correlation between the rate 
of positive margin status and the total volume of breast tissue removed.89 Similar results were 
found by Janes et al.90 Because cavity shaving requires additional tissue resection, cosmetic 
outcome, and thereby one of the primary objectives of BCT, is comprised as a consequence.89,90 
Furthermore, standardized cavity shaving still does not provide certainty in achieving negative 
margins due to the lack of intraoperative assessment of margin status.
FUTURE DIRECTIONS
Because most of the current techniques result in a relatively high rate of positive resection 
margins together with a clear impact on LR rates and cosmetic results, new innovative surgical 
approaches and methods for intraoperative margin assessment are needed.6,10 In the following 
section, innovative applications of radioguided surgery and optical imaging are addressed. 
Positron emission tomography imaging 
18F-"uoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET) imaging is 
considered a powerful imaging modality for diagnosis, staging, and monitoring of various 
malignancies, including breast cancer.91 
The oncologic applications of PET are still expanding with the development of new positron-
emitting radiopharmaceuticals and imaging techniques.92 Recently, the suitability of 18F-FDG
as a tracer for tumors has led to an interest in its use in PET-guided BCT (Fig. 1). The 
radiopharmaceutical 18F-FDG demarcates sites of high glucose metabolic activity, such 
as tumors, in"ammation, and infection.93 Because breast cancers frequently overexpress 
the facilitative glucose transporter GLUT1, uptake of the glucose analogue 18F-FDG may be 
increased in breast cancer cells.94,95 
Hand-held PET-probes have become available, which allow for the detection of high-energy 
gamma rays during surgery and may facilitate localization of breast carcinoma by o#ering the 
surgeon real-time, intraoperative evaluation of tumor localization and margin status.96,97 The 
use of hand-held probes for the detection of 18F-FDG accumulating tumors has been shown 
previously for various malignancies.91,92,97-99 
Figure 1. New evolving imaging modalities for intraoperative margin assessment in breast-conserving therapy: 
(A) radioguided occult lesion localization (ROLL), (B) positron emission tomography (PET); and (C) near-infrared 
"uorescence (NIRF) optical imaging.
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Sensitivity and speci!city of PET are relatively high for 18F-FDG-avid breast tumors.100,101 
However, because of limited spatial resolution of PET-imaging, small tumors (<1 cm) are 
di%cult to detect, whereas breast screening programs and technological developments 
have led to a considerable reduction in the size of breast cancers being detected.97,102,103 The 
same limited spatial resolution is of major concern for the intraoperative detection of positive 
margins in itself. Also, PET has a limited role in patients with well-di#erentiated and lobular 
types of breast cancer.104 Additionally, PET lacks speci!city, because normal physiologic 
uptake of 18F-FDG can be demonstrated to varying degrees in nonmalignant tissues, such as 
in"ammatory tissue.91 Finally, PET has the disadvantage of high costs and radiation exposure 
to primary operating personnel during the intraoperative 18F-FDG PET procedure is expected 
to be relatively high.101,102
Further development of more speci!c radiopharmaceuticals may compensate in part for the 
current limitations associated with 18F-FDG PET imaging. In carefully selected patients, the 
intraoperative use of a PET-probe may provide a useful tool to improve surgical outcome.93 
However, its use in BCT warrants further exploration on feasibility and validation and at this 
stage cannot be considered to compete with the current techniques.91
Radioguided occult lesion localization  
Radioguided occult lesion localization (ROLL), introduced by Luini et al. in 1996, is an upcoming 
surgical technique and theranostic tool for intraoperative localization and simultaneous 
resection of nonpalpable tumors of the breast.105 
The technique makes use of a nonspeci!c radioisotope, which is injected into the tumor under 
stereotactic or ultrasonographic guidance. The exact position of the primary tumor can be 
assessed intraoperatively by use of a hand-held gamma probe. After excision of the primary 
tumor, the probe can also be used to search for any residual areas of high radioactivity.106 
The injection of the nonspeci!c radioisotope into the tumor is a fundamental step in the ROLL 
procedure and has to be very accurate in order to minimize false negative and false positive 
results. Several studies showed that the radioisotope was correctly positioned in 95% to 100% 
of patients.3,65,106-110 However, spillage of radiotracer within the mammary gland during the 
ROLL procedure might decrease accuracy of location of the lesion.111 Furthermore, the amount 
of tracer injected needs to correlate with tumor size. 
Alternatively, a radioactive iodine (125I) seed can be implanted at the tumor, followed by 
radioguided localization and excision of the tumor together with the radioactive seed.112 
Hughes et al. analyzed 383 patients treated with radioguided seed localization (RSL) 
compared with 99 patients treated with WGL and considered the technique to be safe, 
e#ective, and more patient friendly compared with WGL.113 Additionally, RSL was reported 
to reduce the incidence of inadequate surgical margins compared with WGL (26% vs. 57%; 
P=0.02).112 However, although RSL might prove valuable for BCT in the future, experience with 
this technique is still limited.
Sarlos et al. analyzed the oncologic safety of the ROLL procedure and the e#ectiveness of tumor 
localization in a prospective, controlled trial.110 In 20% of the patients with invasive ductal 
carcinoma (IDC), the tumor was excised inadequately (margin ≤1 mm) at the initial surgical 
procedure. These results are consistent with margin positivity reported by others, ranging from 
11% to 17%.3,65,114 The detection rate of nonpalpable breast tumors during surgery was found 
to be 98%. 
Although the clinical e%cacy of ROLL compared with WGL was found to be similar in two 
prospective RCTs, there were several aspects in which ROLL exceeded the current standard 
of  WGL.3,107 Rampaul et al. concluded that ROLL was less painful for the patient and was 
an easier technique to perform surgically.107 Furthermore, the ROLL procedure could be 
combined with lymphatic mapping and sentinel lymph node biopsy, which makes it more 
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patient-friendly compared with WGL.112,115 ROLL was reported to signi!cantly reduce pre- and 
intraoperative localization time of nonpalpable breast tumors.3 However, the total duration 
of the surgical procedure was not reduced by ROLL.3,65,107,114 Regarding costs, WGL is probably 
exceeded by ROLL, although this e#ect could be leveled o# by the potential net savings that 
accompany a reduction of re-excision rates.3 
In conclusion, ROLL seems to be a simple, accurate, and relatively safe technique in comparison 
with the current standard of WGL.106-109 Further research is needed to elucidate the position of 
ROLL for the treatment of nonpalpable breast tumors. Currently, a multicenter clinical trial is 
being conducted in the Netherlands, in which ROLL is being compared to WGL regarding the 
percentage of positive margins, cost e#ectiveness, patient comfort, and cosmetic outcome.116 
Near-infrared !uorescence optical imaging
In recent years, signi!cant progress has been made in the development of optical imaging 
systems and "uorescent contrast agents for clinical applications.117-119 Several animal and 
clinical studies have shown the potential use of near-infrared "uorescence (NIRF) optical 
imaging to improve the therapeutic outcome of surgery.120-126 
It must be emphasized that NIRF imaging on itself is not possible without the use of 
near-infrared (NIR) "uorescent molecular probes ("uorochromes), for which several groups 
can be distinguished. One group consists of ‘targeted "uorochromes’, which are speci!c 
for certain tumor markers involved in breast cancer, like vascular endothelial growth factor 
(VEGF) receptor, epidermal growth factor (EGF) receptor, or the HER2 receptor.127-132 Another 
group is formed by the ‘activatable probes’, which show virtually no "uorescence activity in 
their native state, thereby minimizing background signals.119 However, after activation by a 
speci!c enzyme, the probe emits a bright "uorescence signal when appropriately excited 
(Fig. 2).119,121,123 A number of enzymes that play a role in carcinogenesis and tumor spreading 
can already be visualized with activatable probes, including proteases, such as cathepsin B, 
cathepsin D, and matrix metalloproteinase 2 (MMP2).121,133-137 
An optical imaging technique commonly used is two-dimensional (2D) "uorescence 
re"ectance imaging (FRI), also known as epi-illumination "uorescence imaging. FRI with a 
hand-held imaging device could complement BCT by visualizing tumor delineation, remnant 
disease, and pinpointing suspicious lymph nodes, thereby enabling the surgeon to detect 
(diagnostic) and excise (therapeutic) malignant tissue and possible residual disease at the same 
time (Figs. 1, 3).119,121,122,138 
Figure 2. Schematic example of the mechanism behind an activatable probe. The probe is dark in its native state, 
thereby keeping unwanted background signals to a minimum (A). After cleavage of the backbone carrier by a 
speci!c enzyme, the probe will "uoresce when excited with light of a speci!c wavelength (B).
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The use of NIRF optical imaging o#ers additional advantages: the technology is safe, 
simple to operate, fast, high resolution (as low as 10 μm), relatively inexpensive, and makes 
use of non-ionizing radiation.119,122,124,139-141 Besides the aforementioned advantages, NIRF 
optical imaging does have limitations, which originate from the intrinsic characteristics of 
light propagation through tissue.142 Especially, besides absorption and scattering of light, 
auto"uorescence can reduce detection sensitivity and imaging performance due to absorbance 
and subsequent emission of light by intrinsic tissue "uorochromes.143,144 Although the use of FRI 
for noninvasive detection of breast cancer is restricted because of limited depth resolution and 
a nonlinear dependence between the signal detected on the surface of tissue and the depth 
of the activity, the technique is well suited for intraoperative imaging applications.119,121,122,139 
Clinical applications for NIRF optical imaging are expected to expand rapidly, although further 
work is needed to overcome the aforementioned limitations of the technique.117,145 
Figure 3. NIRF optical imaging with a protease-activatable "uorescent probe before (B) and after (D) surgical 
excision of the primary breast tumor in a nude mouse model. After initial excision of the tumor, a small area of 




Current imaging techniques used in BCT result in positive surgical margins in 20% to 40% of the 
patients who undergo breast-conserving surgery. Risk factors associated with positive margins 
are predominantly related to tumor biology factors or patient characteristics and, therefore, 
cannot be in"uenced directly to improve surgical outcome. Instead, multidisciplinary research 
should focus on techniques that provide the surgeon with a so-called ‘theranostic’ tool, 
enabling the surgeon to obtain an optimal balance between safe surgical margins and good 
cosmetic results. Current techniques present signi!cant di%culties in this perspective. New 
innovative techniques, such as radioguided and NIRF-guided surgery, are emerging. Further 
studies are being performed to elucidate their potential value in improving surgical outcome 
and reducing the need for re-excision in BCT.
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Breast-conserving therapy, consisting of lumpectomy and adjuvant radiotherapy, is considered 
standard treatment for early-stage breast cancer. One of the most important risk factors of local 
recurrence is the presence of positive surgical margins following lumpectomy. We aimed to 
develop and validate a predictive model (nomogram) to predict for positive margins following 
the !rst attempt at lumpectomy as a preoperative tool for clinical decision-making. 
Methods
Patients with clinical T1-2N0-1Mx-0 histology-proven invasive breast carcinoma who underwent 
BCT throughout the North-East region of the Netherlands between June 2008 and July 2009 
were selected from the Netherlands Cancer Registry (n=1,185). Results from multivariate 
logistic regression analyses served as the basis for development of the nomogram. Nomogram 
calibration and discrimination were assessed graphically and by calculation of a concordance 
index, respectively. Nomogram performance was validated on an external independent 
dataset (n=331) from the University Medical Center Groningen.
Results
The !nal multivariate regression model included clinical, radiological, and pathological 
variables. Concordance indices were calculated of 0.70 (95% CI: 0.66−0.74) and 0.69 (95% 
CI: 0.63−0.76) for the modeling and the validation group, respectively. Calibration of the 
model was considered adequate in both groups. A nomogram was developed as a graphical 
representation of the model. Moreover, a web-based application was build to facilitate the use 
of our nomogram in a clinical setting (http://www.breastconservation.com).
Conclusion
We developed and validated a nomogram that enables estimation of the preoperative risk 
of positive margins in breast-conserving surgery. Our nomogram provides a valuable tool for 





Breast-conserving therapy (BCT), consisting of lumpectomy and adjuvant radiotherapy, is 
considered standard treatment for early-stage breast cancer.1,2 The presence of a positive 
(surgical) margin, usually de!ned as tumor cells being present at the inked margin of the 
lumpectomy specimen, has been reported to be the most consistent risk factor for local 
recurrence (LR) following BCT.3,4 The percentage of patients with positive margins following 
the !rst attempt at lumpectomy ranges from 20% to 40% in the majority of studies.5 To reduce 
the risk of LR in the case of positive margins, additional surgery and/or radiotherapy are 
required with adverse a#ects on cosmesis, psychological distress, and healthcare costs.6
Previous studies reported large tumor size, lobular histological type, positive N-stage, 
multifocal disease, lymphovascular invasion, co-existing ductal carcinoma in situ (DCIS), micro-
calci!cations on mammography, and young age to be independent risk factors associated with 
positive margins following lumpectomy (Supplementary Table 1). To allow for simultaneous 
consideration of multiple risk factors, statistical tools can be applied to calculate the overall 
probability of a speci!c outcome.7 These so-called nomograms are tailored to the pro!le of an 
individual patient.8 User-friendly graphical interfaces and web-based calculators can facilitate 
the use of nomograms in clinical practice. 
Several nomograms have been developed in the !eld of breast cancer, including one for 
predicting the risk of positive surgical margins after BCT.9 However, this study was based and 
validated on single-center data, which might impair generalizability of the model. The aims 
of the current study were i) to develop a user-friendly graphical and web-based nomogram 
based on multicenter data to predict individual probability of positive margins following the 
!rst attempt at lumpectomy based on clinicopathological variables and ii) to validate the 
nomogram in an independent dataset. 
METHODS
Patient population
A modeling and a validation group were constituted for development and validation of the 
nomogram, respectively. The modeling group consisted of breast cancer patients selected 
from the Netherlands Cancer Registry (NCR). Based on pathological noti!cation through the 
PALGA (automated pathology archive) system,10 trained registration clerks gathered data 
concerning patient, tumor, and treatment characteristics from the patient !les. Additionally, 
the NCR registered surgical margin status following lumpectomy between June 2008 and July 
2009. During this time frame, data was collected from 1,495 patients who underwent BCT in 
one of 24 institutions throughout the Northern- and Eastern region of the Netherlands. 
Supplementary radiological and clinical variables were collected retrospectively for 1,349 
patients from 20 out of 24 institutions. Three institutions were excluded due to a relatively 
limited contribution to the NCR database (<15 patients). One institution did not participate 
because of a change in the preoperative work-up during the investigated time frame, which 
might have in"uenced surgical outcome. Approval was obtained from the institutional review 
board of all participating institutions prior to initiation of the study. 
Women with clinical T1-2N0-1MX-0 histology-proven invasive breast carcinoma who underwent 
BCT were included. Patients with uncon!rmed malignancy prior to surgery, unde!ned margin 
status, neo-adjuvant treatment, or absence of reported radiological tumor size were excluded. 
A total of 1,185 out of 1,349 patients (88%) were eligible for the modeling group. 
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The validation group consisted of 439 patients who underwent BCT at the University Medical 
Center Groningen (UMCG), Groningen, the Netherlands between July 2004 and June 2008 
or July 2009 and May 2011. Patients who underwent BCT between June 2008 and July 2009 
were assigned to the modeling group as they were part of the NCR database. Inclusion and 
exclusion criteria were identical to those applied in the modeling group. A total of 331 patients 
(75%) were eligible for the validation group. 
Clinicopathological evaluation
The following variables were incorporated from the NCR database: surgical margin status, 
age, preoperative N-stage, preoperative T-stage, tumor location, histological type, histological 
grade, estrogen receptor (ER) status, progesterone receptor (PR) status, HER2 receptor status, 
and presence of co-existing DCIS. 
Positive surgical margin status was de!ned as microscopically con!rmed invasive carcinoma 
(IC) and/or DCIS at the inked margin of the lumpectomy specimen following the !rst attempt 
at lumpectomy. Staging was performed according to the !fth edition of the TNM atlas. 
Preoperative T-stage was based on the maximum tumor diameter as measured on MRI (if 
available) or ultrasonography. Preoperative N-stage was based on clinical and/or radiological 
examination as well as preoperative histological examination (if available) of the axillary 
region. Topography and morphology were coded according to the International Classi!cation 
of Diseases for Oncology (ICD-O).11 Grading of invasive carcinoma was scored according to the 
Nottingham (Elston-Ellis) modi!cation of the Scarf-Bloom-Richardson grading system. Positivity 
of estrogen and progesterone receptors was de!ned as at least 10% of immunostained nuclei 
of tumor cells. HER2 status was considered positive in case of HER2 3+ (strong and complete 
membranous expression in >30% of tumor cells) or HER2 2+ (weak complete membranous 
expression in >10% of tumor cells) con!rmed with positive "uorescence in situ hybridization 
(FISH). Co-existing DCIS was de!ned as the presence of any DCIS component. All pathological 
variables were assessed on !nal pathology due to the fact that no preoperative core needle 
biopsy (CNB) was routinely performed in the vast majority of patients.
The NCR database was supplemented with data collected from patient !les at the participating 
institutions, including clinical (family history, referral from screening, palpability, breast cup size, 
and prior surgery to the ipsilateral breast), and radiological variables (BI-RADS classi!cation, 
suspicion of multifocality, preoperative MRI, microcalci!cations, density of the breast, and area 
of the breast on the preoperative digital mammogram). Family history was recorded as negative, 
!rst-degree (FDR), or second-degree relatives (SDR). Tumors were classi!ed as nonpalpable if 
a needle-localization procedure was required for excision. BI-RADS classi!cation was recorded 
according to the fourth edition of the breast imaging reporting and data system.12 Suspicion 
of multifocality was de!ned as the presence of two or more tumor foci within the same 
quadrant of the ipsilateral breast as assessed on MRI (if available) or radiography. The presence 
of microcalci!cations was assessed on mammography and reported as present or absent. 
Density of the breast was assessed on mammograms and reported as one out of four BI-RADS 
categories: mostly fatty (<25% dense), scattered !broglandular tissue (25−50% dense), hetero-
geneously dense (50−75% dense), and extremely dense (75−100% dense).12 Area of the breast 
was determined in mm2 by manually delineating the breast on the lateral projection of the 
preoperative digital mammogram. Calculations were performed using the default radiological 
software package available at each hospital. Last, postoperative variables were scored for the 
purpose of describing patient and tumor characteristics, including postoperative T-stage, 
postoperative N-stage, weight of the excised lump, and tumor-to-lump index (de!ned as the 
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maximum tumor diameter in mm divided by the weight of the excised lump in grams). Within 
the validation group, clinicopathological variables were collected from patient !les in the 
UMCG database. Variables were scored identically to those in the modeling group
Statistical analysis
The primary outcome for this study was the proportion of positive surgical margins following 
lumpectomy. Multivariate logistic regression analysis (MVA) was used to test the association 
between clinicopathological variables and the likelihood of positive margins. Stepwise 
backward variable selection was performed to determine informative variables based on 
the corrected Akaike’s Information Criterion (AICc).
13 The nested model with the lowest AICc 
value was used to construct a graphical nomogram. A corresponding web-based calculator 
was developed. Moreover, a second calculator was developed including solely clinical and 
radiological variables, which can be applied in the absence of a preoperative CNB. 
Model performance was quanti!ed in both the modeling group and the validation group with 
respect to discrimination and calibration. Discrimination was assessed by calculating the area 
under the receiver operating characteristic (AUROC) curve, resulting in a so-called concordance 
index (c-index). Calibration was studied graphically after grouping patients into deciles with 
respect to their predicted probabilities and plotting the mean predicted probabilities against 
the mean observed probabilities. Bootstrapping was applied to calculate 95% con!dence 
intervals. Overall !t of the model was evaluated using the Hosmer-Lemeshow goodness-of-!t 
test. Reported P-values are two-sided with alpha 5%.
Statistical analyses were performed using the statistical packages SPSS (SPSS for Windows, 
version 18.0.3, SPSS Inc., Chicago, USA) and STATA Software, version 10.0 (StataCorp, College 
Station, USA). Graphs were created using GraphPad Prism (GraphPad Prism for Windows, 
version 5.00, GraphPad Software, San Diego, USA). 
RESULTS
Patient and tumor characteristics of the modeling and validation group are listed in Table 1. 
Positive margins in BCT were present in 19.7% and 24.5% of the patients in the modeling 
and validation group, respectively (Supplementary Table 2). Marked di#erences between 
the modeling and the validation group were observed with respect to age, weight of the 
excised lump, tumor location, pN-stage, prior surgery to the breast, family history, BI-RADS 
classi!cation, and presence of DCIS. 
Margin positivity ranged from 11% to 38% throughout the 20 institutions that constituted 
the modeling group. No di#erence was observed between positive surgical margin rates from 
university-a%liated and community hospitals (P=0.883). Moreover, no signi!cant di#erence in 
the occurrence of positive margins was observed between individual hospitals when evaluated 
using MVA (P=0.282). Of the 233 patients with positive margins in the modeling group, 92 
(39.5%) patients had a relumpectomy with clear margins, 2 (0.9%) patients had a second 
lumpectomy with persistent positive margins, 16 (6.9%) patients underwent mastectomy, and 
123 (52.8%) patients had no further surgery despite positive margins. Data on further surgical 
management was available for all 233 (100%) patients. 
Data on breast cup size was available for only 101 out of 1,185 patients (8.5%) in the modeling 
group and 45 out of 331 patients (13.6%) in the validation group (data not shown). We 
therefore used the area of the breast on the digital mammogram to substitute for cup size, as 
the correlation between both variables was strong (Spearman’s rho: 0.893, P<0.0001).
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MRI was performed in 122 patients (10.3%) in the model group for preoperative tumor 
assessment. Ultrasonography was performed in the remaining 1,064 patients (89.7%). In the 
validation group, preoperative MRI was performed in 31 patients (9.4%), while the remaining 
300 patients (90.6%) had ultrasonography. Sentinel lymph node biopsy was performed in the 
vast majority of patients, including 1,113 (93.9%) patients from the modeling group and 307 
(92.7%) from the validation group. Axillary lymph node dissection (ALND) was performed in 
293 (24.7%) and 87 patients (26.3%), respectively. A total of 221 (18.6%) and 63 (19.0%) patients 
received an ALND in addition to a SLNB procedure.
Multivariate analysis
The nested MVA model with the lowest AICc (959.6) was selected. Clinicopathological 
variables constituting the !nal model were microcalci!cations, preoperative MRI, suspicion 
of multifocality, palpability, preoperative N-stage, preoperative T-stage, density of the breast, 
histological type, histological grade, ER status, and presence of DCIS. Corresponding odds 
ratios are listed in Table 2. Non-signi!cant variables were included if they improved accuracy 
of the model. 
Evaluation of the model
The model !tted the data according to the Hosmer-Lemeshow goodness-of-!t test 
(χ2 = 2.733, 8 degrees of freedom, P=0.950). Discrimination (Fig. 1) and calibration (Fig. 2) were 
!rst assessed for the modeling group. The c-index was calculated to be 0.70 (95% CI 0.66−0.74, 
P<0.001). Calibration was considered adequate. External validation on the UMCG dataset 
resulted in a c-index of 0.69 (95% CI 0.63−0.76, P<0.001; Fig. 1). Calibration was considered 
acceptable (Fig. 2). 
Nomogram and web-based calculators
A graphical nomogram was developed based on the results of MVA (Fig. 3). The underlying 
statistical formula was also implemented in a web-based calculator, freely accessible at 
www.breastconservation.com. Additionally, a second web-based calculator was developed 
including solely clinical and radiological variables that can be used in the absence of a 
preoperative CNB. Discrimination of this model ranged from 0.62 to 0.64 for the modeling and 
validation group, respectively (Supplementary Fig. 1). Calibration was considered acceptable 
for both groups (Supplementary Fig. 2). Both calculators provide the user with a patient-tailored 
estimation of the preoperative risk of positive margins, strati!ed as low (<15%), intermediate 
(15−25%), or high (>25%) risk. The calculators support Internet Explorer, Safari, Firefox, and 
Google Chrome. An example on how to use the online nomogram is provided on the website.
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Modeling group Validation Group
Characteristic N % N % P-value
No. of patients 1185 100 331 100
Age (years)
       Mean (±SE) 59.8 (±0.31) 56.5 (±0.63) <0.001a
       Median 60.3 56.0
       Range 27–95 26–91 <0.001b
       ≤40 39 3.3 28 8.5
       41–69 919 77.6 255 77.0
       ≥70 227 19.2 48 14.5
Tumor size (mm)
      Mean (±SE) 15.6 (±0.22) 15.2 (±0.48) 0.107 c
      Median 14.0 13.0
      Range 1.5–58.5 2.1–57.9 0.087
      pT1a 54 4.6 22 6.6
      pT1b 243 20.5 81 24.5
      pT1c 599 50.5 164 49.5
      pT2 284 24.0 62 18.7
      pT3 5 0.4 2 0.6
Area on mammogram (mm2)
     Mean (±SE) 17916 (±6807) 17575 (±6937) 0.617
     Median 17163 16498
     Range 3551–46895 5212–50619 0.396
     ≤15000 450 38.0 138 42.4
     15000–25000 554 46.8 142 44.7
     ≥25000 181 15.3 45 13.8
Weight excised lump (gram)
     Mean (±SE) 62.5 (±39.7) 56.3 (±40.0) 0.027
     Median 53.0 47.0
     Range 6−277 6−299 0.044
     ≤50 270 44.5 167 51.0
     51–99 172 28.3 78 23.9
     ≥100 165 27.2 82 25.1
Tumor-to-lump index
     Mean (±SE) 0.338 (±0.012) 0.354 (±0.020) 0.503
     Median 0.266 0.288
     Range 0.02−3.67 0.02−4.41 0.132
    ≤0.25 278 45,8 121 39.2
     0.25–0.50 228 37.6 135 43.7
     ≥0.50 101 16.6 53 17.2
Palpability 0.104
       Palpable 637 53.8 195 58.9
       Nonpalpable 548 46.2 136 41.1
Tumor location <0.001
       LOQ 122 10.3 42 12.7
       UOQ 535 45.1 170 51.4
       UIQ 189 15.9 50 15.1
       LIQ 150 12.7 26 7.9
       Central 103 8.7 6 1.8
Table 1. Patient and tumor characteristics for the modeling and valiation group.
Table continues on the next page
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Modeling group Validation Group
Characteristic N % N % P-value
Histological type 0.062
       Ductal 957 80.8 286 86.4
       Lobular 119 10.0 23 6.9
       Speci!ed d 109 9.2 22 6.6
Histological grade 0.214
       Grade I 330 28.1 107 32.8
       Grade II 531 45.2 133 40.7
       Grade III 313 26.6 86 26.5
ER status 0.661
       Positive 1002 85.3 276 84,4
       Negative 172 14.7 51 15.6
PR status 0.443
       Positive 750 71.4 226 69.1
       Negative 300 28.5 101 30.9
HER2 receptor status 0.486
       Positive 125 10.7 40 12.3
       Negative 1041 89.3 290 87.7
Multifocal disease 0.170
       Yes 47 4.0 19 5.7
       No 1138 96.0 312 94.3
pN-stage 0.004
      Positive 310 26.2 113 34.4
      Negative 875 73.8 218 65.6
Prior surgery to the breast <0.001
      Yes 46 3.9 34 10.3
      No 1139 96.1 297 89.7
Family history <0.001
     FDR 91 8.9 75 22.8
     SDR 188 18.2 56 17.0
     Negative 749 72.9 199 60.2
Referred from screening 0.755
     Yes 578 49.1 158 47.7
     No 601 50.9 172 52.3
BI-RADS classi!cation 0.001
     II e 3 0.3 8 2.5
     III 93 8.1 31 9.7
     IV 611 52.9 155 48.3
     V 447 38.7 127 39.5
Preoperative MRI 0.680
     Yes 122 10.3 31 9.4
     No 1063 89.7 300 90.6
Microcalci!cations
     Yes 245 20.8 74 22.4 0.542
     No 937 79.2 257 77.6
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Table continues on the next page
Modeling group Validation Group
Characteristic N % N % P-value
DCIS component present <0.001
     Yes 529 44.6 188 56.8
     No 656 55.4 143 43.2
Breast density 0.816
     0–25 % 323 31.0 101 31.2
     25–50% 467 44.9 146 45.0
     50–75% 217 20.8 70 21.6
     75–100% 34 3.3 7 2.2
Institution -
     University-a%liated 642 54.2 331 100
     Community hospital 543 45.8 - -
ER, estrogen receptor; FDR, "rst-degree relative; LIQ, lower inner quadrant; LOQ, lower outer quadrant; MRI, magnetic 
resonance imaging; PR, progesterone receptor; SDR, second-degree relative; UIQ, upper inner quadrant; UOQ, upper 
outer quadrant.
Variables which di#er signi!cantly (P<0.05) between both groups are highlighted in grey.
a Independent-samples t-test. 
b Fisher’s exact test. 
c Independent-samples t-test following logarithmic transformation to promote data normality.  
d Speci!ed histological types included mucinous, medullary, tubular, and papillary carcinomas. 
e BI-RADS classi!cation II with malignancy proven by !ne needle aspiration or core needle biopsy. 
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Predictor Odds ratio 95% CI P-value
Suspicion of multifocal disease (vs. unifocal) 2.81 1.30–6.06 0.008
Preoperative MRI scan absent (vs. available) 1.80 1.02–3.18 0.043
Positive preoperative N-stage (vs. negative) 1.73 0.97–3.07 0.062
Nonpalpable tumor (vs. palpable) 1.51 1.07–2.13 0.020
Microcalci!cations on mammogram (vs. none) 1.37 0.95–2.00 0.094
Preoperative T2 stage (vs. T1) 1.33 0.87–2.02 0.185
Breast density on mammogram 1.22 1.00–1.49 0.053
Presence of DCIS component (vs. absence) 3.11 2.19–4.42 <0.001
Lobular histological type (vs. other) 2.90 1.71–4.91 <0.001
Positive ER status (vs. negative) 1.80 1.04–3.13 0.037
Elston III grade (vs. Elston I/II) 1.44 0.96–2.16 0.082
Table 2. Preoperative clinical, radiological, and pathological variables included in the !nal model.
Figure 1. Discrimination of the !nal model for the modeling and validation group.The area under the receiver-
operating characteristic (AUROC) curve, comparable to the concordance index, indicates the discriminative 
power of the model. The reference line indicates an AUROC value of 0.5, for which the probability of positive 
surgical margins is equal to the toss of a coin. An AUROC value of 1.0 would resemble perfect discrimination.
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Reported odds ratios indicate a ratio of the probability of positive margins following lumpectomy versus the 
probability of negative margins. Statistical signi!cant P-values (<0.05) variables are highlighted in grey.
CI, con"dence interval; DCIS, ductal carcinoma in situ; ER, estrogen receptor; MRI, magnetic resonance imaging 
Figure 2. Calibration of the !nal model in the modeling and validation group. All patients were grouped into 
deciles (blue triangles and orange dots) based on their predicted probabilities. Mean predicted probabilities 
were plotted against the actual incidence of positive margins for each decile. Moreover, 95% con!dence intervals 
are shown for both groups. The reference line represents perfect equality of observed frequencies and predicted 
probabilities. 
DISCUSSION
We developed a nomogram and corresponding web-based calculators to estimate the risk 
of positive margins following lumpectomy using clinicopathological variables. Variables 
predicting for positive surgical margins on MVA included microcalci!cations on mammogram 
(OR 1.37, P=0.094), absence of preoperative MRI (OR 1.80, P=0.043), suspicion of multifocality 
(OR 2.81, P=0.008), nonpalpable tumor (OR 1.51, P=0.020), positive preoperative N-stage 
(OR 1.73, P=0.062), large tumor size (OR 1.33, P=0.185), high density of the breast (OR 1.22, 
P=0.053), lobular histological type (OR 2.90, P<0.001), high histological grade (OR 1.44, 
P=0.082), positive ER status (OR 1.80, P=0.037), and presence of DCIS (OR 3.11, P<0.001). In 
the absence of preoperative pathological variables (e.g., no CNB available), a second online 
calculator is available at http://www.breastconservation.com that solely includes clinical and 
radiological variables.
Assessment of pathological variables in the current study was based on !nal pathology due to 
the fact that !ne needle aspiration biopsy instead of CNB was performed in the vast majority 
of patients. Nonetheless, CNB may provide important information on preoperative prognostic 
factors and shows good correlation with !ndings on !nal pathology.14 Histological type 
can be accurately predicted on CNB and is reported to be concordant with the subsequent 
surgical specimen in 93% to 100% of the cases.15 For ER status, reported concordance rates 
between CNB and the surgical specimen range from 86% to 100%.16-18 Current evidence shows 
that histological grade can be assessed on CNB and is concordant with !nal pathology in 
approximately 75% of the cases.19 The highest level of agreement is achieved in high grade 
carcinomas, with an associated concordance rate of 84%.14 The presence of co-existing DCIS 
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Figure 3. Nomogram including clinical, radiological, and pathological variables for predicting positive surgical 
margins following the !rst attempt at lumpectomy. 
Instructions for use: Locate the patient’s status on the ‘preoperative MRI’ axis. Draw a line straight upward to the 
‘points’ axis to determine how many points are assigned to the individual patient. Repeat this process for the 
axes below. Tot up the points achieved for each variable and locate the sum on the ‘total points’ axis. From here, 
draw a line straight downward to obtain the probability of positive surgical margins following lumpectomy. 
Note: Due to the relatively high frequency of false negative !ndings when assessing the presence of co-existing 
DCIS in a core needle biopsy (CNB), absence of DCIS should be interpreted with caution. We therefore recommend 
to determine a suitable probability interval by calculating the probability of positive surgical margins for both 
true and false negative outcomes. A more user-friendly web-based version of the nomogram is available at 
http://www.breastconservation.com.
can also be assessed on CNB and is associated with an increased risk of positive margins.20-22 
However, false negative !ndings reported in the literature range from 36% to 54%, indicating 
that the absence of DCIS in the CNB should be interpreted with caution.21,23 The risk for false 
negative results of CNB can be minimized by accurate targeting, su%cient biopsy size, and 
obtaining a larger number of cores.20 Jimenez et al.21 reported that CNB predicts the presence 
of co-existing DCIS in the subsequent surgical specimen with a sensitivity and speci!city of 
54% and 92%, respectively. The corresponding negative and positive predictive values were 
70% and 85%. To account for the relatively high risk of false negative !ndings, we recommend 
determining a suitable probability interval by calculating the probability of positive margins 
for both true and false negative outcomes when using our nomogram (Fig. 3). The web-based 
calculator will automatically provide the user with such a probability interval if applicable. 
The ability to estimate the preoperative risk of positive margins following lumpectomy could 
support clinicians in counseling patients regarding the likelihood of requiring further surgery, 
allowing for a more patient-tailored approach. Although broadly supported for positive 
margins, some authors have also reported an increased risk for LR in the case of close surgical 
margins.4,24 However, the importance of close margins is still a matter of debate.25,26 Moreover, 
consensus over what is the most appropriate margin is lacking, with de!nitions of close 
margins ranging from <1 mm to <5 mm distance to the inked margin.27 Because the clinical 
implications of close margins are uncertain, they were not taken into account in this study. 
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In patients identi!ed as high-risk (>25%), we advise to perform a preoperative MRI to assist 
the clinician in de!ning the extent of local disease and detect areas of co-existing high-grade 
DCIS that are occult on mammography. Indeed, preoperative MRI was reported to reduce the 
risk of inadequate tumor excision.28 In the current study, MRI was performed in those patients 
with preoperative suspicion of multifocal disease or with BRCA1 of BRCA2 mutations. Despite 
correction for these factors, MRI was found to signi!cantly decrease the risk of positive margins 
(P=0.043; Table 2). However, the true value of MRI in reducing the risk of inadequate tumor 
excision in patients preoperatively identi!ed as high-risk needs to be assessed in future studies. 
In addition, high-risk patients might bene!t from a more extensive surgical excision. Lovrics et 
al.29 reported the amount of breast parenchyma excised during BCS to be inversely correlated 
with the likelihood of positive margins. In the current study, we also found a signi!cant 
association between low tumor-to-lump index (i.e., relatively small lump compared to size 
of the tumor) and positive surgical margins (P=0.002). However, although excising relatively 
voluminous specimens is more accurate in predicting margin status than any predictive model, 
it has profound repercussions on cosmesis. To allow for relatively extensive excisions while 
maintaining adequate cosmetic results, oncoplastic surgery was suggested as a technique 
to minimize breast deformities by immediate reconstruction of large resection defects.30 
The technique might be of particular value for those patients identi!ed as high risk with our 
nomogram, although further studies are needed to address this topic. 
The rate of positive margins observed in the modeling (19.7%, range: 11%−38%) and the 
validation group (24.5%) are in line with positivity rates reported in the literature.5 The slightly 
higher positive margin rate in the validation group can partially be explained by the high 
rate of co-existing DCIS (56.8% vs. 44.6% in the modeling group, P<0.001), which is known to 
increase the risk of positive margins.31
Very recently, Shin et al.9 reported on a nomogram for predicting positive surgical margins 
after BCT. The nomogram was based on retrospective single-center data derived from 1,034 
Korean breast cancer patients with invasive or in situ breast carcinoma. MVA indicated 
microcalci!cations (OR 1.57, P=0.034), dense breasts (OR 4.52, P=0.005), 0.5 cm di#erence 
in tumor size between MRI and ultrasonography (OR 10.00, P<0.001), presence of DCIS (OR 
1.58, P=0.044), and lobular histological type (OR 3.99, P=0.015) to be independent predictors 
for positive surgical margins. Validation was performed on an independent cohort of 563 
patients. The concordance indices of the modeling and the validation groups were reported 
to be 0.82 (95% CI: 0.79−0.86) and 0.85 (95% CI: 0.80−0.89), respectively. Although the 
reported concordance indices are relatively high when compared to the current multicenter 
study, this di#erence may partly be explained by the relative lack of heterogeneity in single-
institution data, impairing generalizability of the model.8 Our nomogram was constructed 
based on multicenter data derived from 20 institutions, including community-based and 
university-a%liated hospitals. Validation was performed in an independent dataset that 
showed marked di#erences when compared to the modeling group, providing su%cient data 
heterogeneity to assess generalizability of the nomogram. 
Several other nomograms are available in the !eld of breast cancer, including nomograms 
for predicting the likelihood of cancer spread to the sentinel lymph nodes,32 cancer spread to 
nonsentinel lymph nodes,33 and the bene!t of systemic adjuvant therapy (Adjuvant! Online).34 
Moreover, Rudlo# et al.35 developed a nomogram (c-index: 0.704) for predicting the 5- and 
10-year probability for ipsilateral breast tumor recurrence after BCT for DCIS. The nomogram 
was developed on the basis of unicenter data derived from 1,681 patients and included 
ten clinical, pathological, and treatment variables (age at diagnosis, family history, initial 
presentation, radiation, adjuvant endocrine therapy, nuclear grade, necrosis, margins, number 
of excisions, and year of surgery). Sanghani et al.36 constructed a web-based nomogram for 
predicting the probability of ipsilateral breast tumor recurrence after BCT. Data was derived 
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from 7,811 patients and included both clinical and pathological variables (adjuvant RT or 
endocrine therapy, age, margin status, number of excisions, and treatment time period). 
Werkhoven et al.37 developed a comparable nomogram (c-index: 0.68) based on data from 
1,603 patients. Rouzier et al.38 developed several nomograms that can be applied to predict the 
probability of successful BCT in patients who underwent neo-adjuvant treatment. 
We acknowledge that there are certain limitations to our study. First, our study is subject to 
limitations that are inherent to retrospective data collection. Second, as discussed earlier, 
pathological variables were obtained on !nal pathology due to the fact that preoperative 
CNB was not routinely performed in the vast majority of patients. We were therefore unable 
to evaluate the concordance between pathological variables as assessed on CNB and !nal 
pathology. However, numerous studies have evaluated this topic with the majority of studies 
reporting good concordance rates. Third, we used surgical margin status after the !rst 
lumpectomy attempt as a primary endpoint. Although information on positive margin rate 
after a second lumpectomy might be of particular clinical interest, the absolute number of 
patients with positive surgical margins after a second lumpectomy in our study was considered 
insu%cient to obtain adequate sample size for nomogram development. Larger patient 
cohorts are therefore needed to address this topic. Last, our nomogram is based on female 
Dutch inhabitants, who are primarily Caucasian women. We therefore advise caution against 
extrapolation of the nomogram to di#erent populations.
CONCLUSION
We developed and validated a nomogram to predict the probability of positive surgical 
margins following lumpectomy using clinicopathological variables. Our nomogram could 
support clinicians in identifying high-risk patients who might bene!t from preoperative MRI 
and/or oncoplastic surgery.  
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Supplementary Table 1. Studies reporting independent risk factors associated with positive surgical margins in 
breast-conserving therapy. Studies were included on the basis that they provided odds ratios.
CI, con"dence interval; CNB, core needle biopsy; DCIS, ductal carcinoma in situ; EIC, extensive intraductal component; 
ER, estrogen receptor; FNA, "ne needle aspiration; LVI, lymphovascular invasion; OR, odds ratio.
a Risk factors associated with positive margin status for invasive lobular carcinoma. 
b Trend for tumor size at pathology assessment from smaller to larger by 1 mm increments. 
c Trend for age at diagnosis from younger to older by 1 year increments.
d Trend from smaller to larger across three categories: <1 cm, 1–2 cm, and >2 cm.
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Study Year N Predictor OR  95% CI P-value
Park et al.1 2011 705 Presence of EIC (vs. absence) 3.85 2.30–6.45 <0.001
Lobular histological type (vs. ductal) 7.17 2.24–22.98 0.001
pN2/N3 status (vs. pN0/N1 status) 2.47 1.20–5.11 0.015
T2 stage (vs. Tis stage) 2.40 0.80–7.21 0.12
Positive ER status (vs. negative) 1.35 0.80–2.26 0.26
T1 stage (vs. Tis stage) 1.47 0.54–4.02 0.46
Age >35 years (vs. ≤35 years) 0.96 0.44–2.10 0.91
Sakr et al.2 a 2011 73 Multifocal disease (vs. unifocal) 19.1 4.83–75.5 <0.0001
Tumor size b 1.10 1.02–1.17 0.0095
Full thickness excision (vs. oncoplastic surgery) 4.57 1.08–19.4 0.039
Kurniawan et al.3 2008 1648 Tumor size ≥30 mm (vs. <30 mm) 4.22 2.56–6.96 <0.0001
Multifocal disease (vs. unifocal) 2.85 2.02–4.02 <0.0001
Microcalci!cations on mammogram (vs. none) 1.97 1.33–2.93 0.001
Presence of DCIS component (vs. absence) 1.45 0.99–2.13 0.059
Age ≥60 years ( vs. <60 years) 0.76 0.44–1.32 0.33
High histological grade (vs. low) 1.26 0.77–2.04 0.36
Absence of mammographic mass (vs. presence) 0.93 0.65–1.33 0.681
Cabioglu et al.4 2007 264 Excisional biopsy (vs. other) 7.5 3.1–18.5 <0.0001
Multifocal disease (vs. unifocal) 3.0 1.2–7.8 0.020
Tumor size >20 mm (vs. ≤20 mm) 3.3 1.1–9.5 0.028
Aziz et al.5 2006 1430 Age c 0.96 0.95–0.98 <0.0001
Ductal histological type (vs. lobular) 0.67 0.42–1.07 0.09
Positive ER status (vs. negative) 1.46 0.95–2.25 0.09
Presence of DCIS component (vs. absence) 1.40 0.93–2.11 0.11
Positive nodal status (vs. negative) 0.73 0.48–1.11 0.14
Presence of LVI (vs. absence) 1.35 0.89–2.06 0.16
Tumor sized 0.97 0.74–1.27 0.82
Chagpar et al.6 2004 2658 Tumor size d 0.80 0.72–0.89 <0.001
Lobular histological type (vs. ductal) 0.61 0.38–0.97 0.036
Excisional biopsy (vs. FNA and CNB) 1.21 0.91–1.59 0.18
Age c 1.00 0.99–1.01 0.56
Palpable (vs. nonpalpable) 1.05 0.81–1.35 0.72
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Modeling group Validation Group
Positive margins Positive margins
Characteristic N N % N N %
No. of patients 1185 233 19.7 331 81 24.5
Age (years)
       ≤40 39 8 19.5 28 2 7.1
       41–69 919 189 20.2 255 69 27.1
       ≥70 227 39 17.2 48 10 20.8
T-stage 
      pT1a 54 16 29.6 22 9 40.9
      pT1b 243 48 19.8 81 16 19.8
      pT1c 599 104 17.4 163 35 21.5
      pT2 284 62 21.8 62 19 30.6
      pT3 5 3 60.0 2 1 50.0
Area on mammogram (mm2)
      ≤15000 450 90 38.6 138 36 45.6
      15001–24999 554 109 46.8 142 34 43.0
      ≥25000 181 34 14.6 45 9 11.4
Weight excised lump (gram)
      ≤50 270 74 56.1 167 41 51.2
      51–99 172 30 22.7 78 22 27.5
      ≥100 165 28 21.2 82 17 21.3
Tumor-to-lump index
      ≤0.25 278 49 17.6 121 25 20.7
      0.26–0.49 228 49 21.5 135 31 23.0
      ≥0.50 101 34 33.7 53 22 41.5
Palpability
      Palpable 637 116 18.2 195 42 21.5
      Nonpalpable 548 117 21.4 136 39 28.7
Tumor location
      LOQ 122 21 17.2 42 10 23.8
      UOQ 535 104 19.4 170 44 25.9
      UIQ 189 30 15.9 50 14 28.0
      LIQ 150 36 24.0 26 3 11.5
      Central 103 21 20.4 6 1 16.7
Histological type
      Ductal 957 184 19.2 286 64 22.4
      Lobular 119 33 27.7 23 8 34.8
      Speci!ed a 109 16 14.7 22 9 40.9
Histological grade
      Grade I 330 48 14.5 107 25 23.4
      Grade II 531 111 20.9 133 31 23.3
      Grade III 313 72 23.0 86 24 27.9
Estrogen receptor
      Positive 1002 206 20.6 276 62 22.5
      Negative 172 25 14.5 51 17 33.3
Progesterone receptor
      Positive 750 139 18.5 226 50 22.1
      Negative 300 49 16.3 101 29 28.7
HER2 receptor
      Positive 125 30 24.0 40 9 22.5
      Negative 1041 198 19.0 290 71 24.5
      No 1063 214 20.1 300 74 24.7




Table continues on the next page
Modeling group Validation Group
Positive margins Positive margins
Characteristic N N % N N %
No. of patients 1185 233 19.7 331 81 24.5
Age (years)
Multifocal disease 
      Yes 47 17 36.2 19 11 57.9
      No 1138 216 19.0 311 69 22.2
pN-stage 
      Positive 310 87 28.1 113 29 25.7
      Negative 875 146 16.7 218 52 23.9
Prior surgery to the breast
       Yes 46 6 13.0 34 6 17.6
       No 1139 227 19.9 297 75 25.3
Family history
      FDR 91 16 17.6 75 19 25.3
      SDR 188 35 18.6 56 13 23.2
      Negative 749 151 20.2 199 48 24.1
Referred from screening
      Yes 578 109 18.9 158 34 21.5
      No 601 124 20.6 172 46 26.7
      Unknown 6 0 0 - - -
BI-RADS classi!cation
      II b 3 2 66.7 8 2 25.0
      III 93 19 20.4 31 10 32.3
      IV 611 134 21.9 155 39 25.2
      V 447 72 16.1 127 29 22.8
Preoperative MRI 
      Yes 122 19 15.6 31 7 22.6
      No 1063 214 20.1 300 74 24.7
Microcalci!cations
      Yes 245 67 27.3 74 29 39.2
      No 937 166 17.7 257 52 20.2
DCIS component present
      Yes 529 152 28.7 188 61 32.4
      No 656 81 12.3 143 20 14.0
Breast density
      0–25 % 323 60 18.6 101 22 21.8
      25–50% 467 90 19.3 146 35 24.0
      50–75% 217 49 22.6 70 19 27.1
      75–100% 34 10 29.4 7 2 28.6
Institution
      University-a%liated 642 125 19.5 331 81 24.5
      Community hospital 543 108 19.9 - - -
ER, estrogen receptor; FDR, "rst-degree relative; LIQ, lower inner quadrant; LOQ, lower outer quadrant; MRI, magnetic 
resonance imaging; PR, progesterone receptor; UIQ, upper inner quadrant; UOQ, upper outer quadrant
a Speci!ed histological types included mucinous, medullary, tubular, and papillary carcinomas. 
b BI-RADS classi!cation II with malignancy proven by !ne needle aspiration or core needle biopsy.
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Supplementary Figure 1. Discrimination of the basic web-based calculator for the modeling and validation 
group. The area under the receiver-operating characteristic (AUROC) curve, comparable to the concordance 
index (c-index), indicates the discriminative power of the model. The reference line indicates an AUROC value 
of 0.5, for which the probability of positive surgical margins is equal to the toss of a coin. An AUROC value of 1.0 
would resemble perfect discrimination.
Supplementary Figure 2. Calibration of the basic web-based calculator in the modeling and validation group. 
All patients were grouped into deciles (blue triangles and orange dots) based on their predicted probabilities. 
Mean predicted probabilities were plotted against the actual incidence of positive margins for each decile. 
Moreover, 95% con!dence intervals are shown for both groups. The reference line represents perfect equality of 
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ABSTRACT
Background
Near-infrared "uorescence (NIRF) imaging has great potential to improve the outcome of 
the surgical treatment of solid cancers. With the current diversity in "uorescent agents and 
the accompanying di#erences in biodistribution, we aimed to develop a methodology that 
enables correction for discrepancies in tumor demarcation as a result of the application of 
di#erent imaging systems and "uorescent probes in NIRF imaging.   
Methods
Bioluminescence and NIRF imaging were performed in a breast cancer mouse model using 
di#erent imaging systems and "uorescent probes in separate groups. Bioluminescence served 
as a gold standard for cancerous tissue. Segmentation-based comparative analysis of planar 
optical signals (SCAPOS) was applied to correct for false negative NIRF signals in each group. 
Results
SCAPOS enabled correction for discrepancies in demarcated tumor areas when using di#erent 
imaging systems and "uorescent agents. Analysis resulted in a NIRF correction factor of 0.202 
and 0.047 for group I and II, respectively (P=0.018). SCAPOS-based correction resulted in a 
decrease in false negative results, i.e., tumor not covered by NIRF, from 9 out of 13 (69%) mice 
to none (0%). 
Conclusion
We exhibited a methodology (SCAPOS) to correct for discrepancies in tumor demarcation due 




Innovations in healthcare have come a long way in the past few decades. However, surgical 
treatment of solid cancers is still regularly confronted with impaired therapeutic outcome as a 
result from incomplete tumor resection.1,2 Currently, intraoperative tumor localization is mainly 
limited to inspection and palpation. To improve and extend the intraoperative tools available 
to the surgeon-oncologist, more sensitive optical imaging techniques are being developed.3 
Herein, special attention is paid to near-infrared "uorescence (NIRF) epi-illumination imaging, 
which has great potential for supporting the surgeon intraoperatively by providing real-time 
feedback on tumor localization and surgical margin status.4-7 The surgeon-oncologist could 
then detect (diagnostic) and excise (therapeutic) residual disease during the same surgical 
intervention, also denominated as theranostics. 
In NIRF epi-illumination imaging, an external light source is used with a de!ned wavelength in 
the near-infrared (NIR) spectral range to illuminate the subject. Immediately after excitation, 
the "uorescence signal can be detected using a highly sensitive CCD camera.8 New 
developments in NIRF imaging hardware, software, and (tumor-targeted) "uorescent probes 
have greatly enhanced the possibilities for intraoperative NIRF epi-illumination imaging.3-7 
From literature, little is known on how well NIRF signals correlate with cancerous tissue in vivo.9 
Importantly, Kossodo et al. reported di#erences in probe biodistribution when simultaneous 
NIRF imaging was performed with di#erent "uorescent probes, leading to discrepancies in 
tumor demarcation.10 Before being broadly applicable for clinical use, thorough assessment 
and optimization of NIRF imaging is therefore necessary, as di#erences in the characteristics 
of imaging systems and biodistribution of "uorescent probes may cause discrepancies in the 
demarcation of areas designated as tumor tissue. These discrepancies could be estimated in 
a preclinical setting by comparing signals obtained with NIRF imaging to those obtained with 
bioluminescence imaging (BLI). 
BLI is a highly sensitive method for the detection of cancer cells and can be used as a gold 
standard for the presence of cancerous tissue. It is widely used in small laboratory animals in 
vivo, permitting real-time, noninvasive monitoring of tumorload at low cost.11-13 However, BLI 
necessitates the incorporation of a bioluminescent gene into the tumor cells’ DNA, making the 
technique unsuitable for clinical use. 
Sarantopoulos et al. described a validation method for imaging the biodistribution of 
"uorescent probes ex vivo using multispectral epi-illumination cryoslicing imaging.14 The 
authors assessed the three-dimensional distribution of "uorescent probes in high resolution by 
both "uorescence and color imaging. Although this method has great potential for validating 
the distribution of "uorescent probes in support of imaging studies, its applicability in vivo for 
direct comparison and correction of captured NIRF images seems limited. 
In this proof-of-principle study, we aimed to develop a platform to detect and correct for 
potential discrepancies concerning tumor demarcation in NIRF epi-illumination imaging. 
Hereto, signals obtained with BLI and NIRF imaging were compared and analyzed with an 
analytical tool denominated as segmentation-based comparative analysis of planar optical 
signals (SCAPOS). The potential of SCAPOS was evaluated in a xenograft model for human 
breast carcinoma. To assess its feasibility in various circumstances, SCAPOS was applied using 
di#erent imaging systems and "uorescent probes. 
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METHODS 
The potential of SCAPOS to detect and correct for discrepancies in tumor demarcation was 
assessed in a bioluminescent breast cancer mouse model. Both BLI and NIRF imaging were 
performed to enable calculation of a SCAPOS-based NIRF correction factor. Bioluminescence 
served as a gold standard for the presence of cancerous tissue. 
Cell line
The bioluminescent human breast carcinoma cell line MDA-MB-231-luc-D3H2LN (Caliper Life 
Sciences, Hopkinton, USA) was used. This cell line is derived from MDA-MB-231-luc human 
adenocarcinoma cells and stably expresses the !re"y luciferase gene, allowing for BLI. Cells 
were cultured in RPMI 1640 (Invitrogen, Carlsbad, USA) supplemented with 10% fetal calf 
serum (PAA Laboratories, Pasching, Austria) and 1% L-glutamine (Sigma-Aldrich, St. Louis,  USA) 
at 37 oC in a humidi!ed atmosphere containing 5% CO2. MDA-MB-231-luc-D3H2LN cells were 
trypsinized (0.25% trypsin with EDTA), centrifuged, and resuspended in phosphate-bu#ered 
saline (PBS; Invitrogen, Carlsbad, USA) to a concentration of 2x106 cells in 200 μl.
Animal model
Experiments were conducted using 15 athymic nude mice (Crl:NU/NU-Foxn1nu, Charles 
River Research Laboratories, Margate, UK) aged 6 to 8 weeks. Mice were anaesthetized with 
2% iso"urane in oxygen. Subsequently, tumor cells (2x106 cells in 200 μl) were orthotopically 
injected into the pectoral mammary fat pad. Shortly after injection with luciferase-expressing 
human breast cancer cells, BLI was performed to make sure that inoculation was successful. 
One mouse was excluded from the study because it did not hatch a tumor. Nine mice (group I) 
were imaged using a customized intraoperative imaging system in combination with a targeted 
"uorescent probe. To evaluate the feasibility of SCAPOS in various circumstances, a commercial 
preclinical imaging system (IVIS® Spectrum) combined with an activatable "uorescent probe 
was applied in an additional 5 mice (group II). Both groups were randomized into a model and 
a validation subgroup for determination and validation of the SCAPOS-based NIRF correction 
factor, respectively. All animal experiments were performed in compliance with the Guide for 
the Care and Use of Laboratory Animal Resources (1996) and the guidelines of the local Animal 
Care and Use Committee.15
Optical imaging systems
Two di#erent optical imaging systems were used. First, a customized clinical prototype 
NIRF camera system developed at Technical University Munich was applied for both BLI and 
NIRF epi-illumination imaging.5 The system contains an iXonEM+ EMCCD camera (ANDORTM 
Technology, Belfast, UK) and allows for simultaneous acquisition of color, NIR emission 
("uorescence), and NIR excitation (intrinsic) images. The intrinsic images allow for correction 
of heterogeneous illumination artifacts caused by spatial variation of excitation laser 
illumination.5,16 Second, images were acquired with a commercially available IVIS® Spectrum 
preclinical system (PerkinElmer Inc., Waltham, USA), which consists of a highly sensitive cooled 
charged-coupled device (CCD) camera mounted onto a light-tight box. The IVIS® Spectrum is 




Two commercially available "uorescent probes (MMPSense® 680 and IntegriSense® 680; 
PerkinElmer, Waltham, USA) were used with excitation and emission pro!les in the NIR spectral 
range. Twenty-four hours prior to NIRF imaging, "uorescent probes were injected in the tail 
vein under general anesthesia.
Mice in group I (n=9) were injected with 2 nmol of the αvβ3 integrin receptor-targeted 
"uorescent probe IntegriSense® 680 in 100 μL PBS. Overexpression of αvβ3 integrin receptor 
has been shown for various solid cancers and is believed to play an important role in tumor 
progression, especially for invasive tumors that preferentially metastasize to bone, such as 
breast carcinoma.17,18
Mice in group II (n=5) were injected with 2 nmol of the activatable "uorescent probe 
MMPSense® 680 in 100 μL PBS. The probe remains in a quenched state upon injection, in 
which its "uorescence activity is signi!cantly impaired.6 However, when MMPSense® 680 
comes into contact with matrix metalloproteinases (MMPs), the probe is activated, enhancing 
"uorescence activity signi!cantly. MMPs have been shown to be overexpressed in several 
solid cancers, including breast cancer, and are known to degrade the extracellular matrix and 
stimulate tumor development, growth, and neovascularization.19-21
Bioluminescence and near-infrared imaging
Three weeks following inoculation, both BLI and NIRF imaging were performed under general 
anesthesia in all mice that hatched a tumor (n=14). To enable BLI, 250 μl D-luciferin (150 mg/
kg, Caliper Life Sciences, Alameda, USA) in PBS was injected intraperitoneally 10 minutes prior 
to imaging. Animals were placed on a low-"uorescence diet (Harlan TD.97184, Madison, USA) 
in order to reduce auto"uorescence from the gastrointestinal tract. 
In group I (n=9), the customized clinical camera system was applied for BLI (emission: open; 
exposure time: 20 s; binning: small) and NIRF imaging (excitation: 673 nm laser; emission: 
716±20 nm; exposure time: 5 s; binning: small). One mouse was excluded from the study due 
to the absence of BLI signal upon imaging. 
In group II (n=5), BLI (emission: open; exposure time: 20 sec; f-stop: 1; binning: small) and NIRF 
imaging (excitation: 675±35 nm, emission: 720±20, 740±20, and 760±20 nm; exposure time: 
5 sec; binning: small) was performed using the IVIS® Spectrum system.
Histological analysis
After imaging, mice were euthanized by a lethal dose of ketamine. Tissue indicated as cancerous 
by BLI was excised to con!rm the presence of cancer cells by histological analysis. Hereto, 
tissue specimens were !xed in 10% formalin solution, processed through para%n, and stained 
with hematoxylin and eosin for microscopic evaluation by an oncology pathologist (JB). 
Preprocessing of captured images
Imaging data acquired with the customized camera system (group I) was corrected for 
heterogeneous illumination artifacts according to the acquired intrinsic signal.5,16 Outliers in 
pixel intensity were set to mean pixel value.  BLI and NIRF images were automatically registered 
using !ve reference points and an a%ne transformation. 
Images acquired with the IVIS® Spectrum (group II) were preprocessed using Living Image® 
version 3.0 analysis software (Caliper Life Sciences, Alameda, USA). Spectral unmixing 
was performed to separate the authentic MMPSense® 680 "uorescence signal from 
auto"uorescence using the in-build unmix function.22
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Automated tumor demarcation
Following preprocessing of imaging data (Fig. 1-I), automated tumor demarcation of the 
primary tumor was performed for both BLI and NIRF signals. The methodology consists of 
several sequential steps (Fig. 1), which can be customized to !t a wide range of images by 
changing a limited number of parameters.
Images were cropped to a surgical region of interest (ROI) to minimize interference from 
surrounding organs (Fig. 1-II). Hereto, the center of the BLI signal was selected manually, after 
which a square ROI was automatically positioned around the speci!ed middle. Second, the 
borders of the tumor were estimated using Canny Edge detection (Fig. 1-III).23 Single-pixel 
thick continuous edges were generated as the outline of a single operation of dilation, !lling, 
and erosion (Fig. 1-IV). Next, a mask was obtained for both BLI and NIRF signals by !lling the 
estimated tumor outline (Fig. 1-V). Both signal masks were combined in a composite image 
and corresponding labels (‘NIRF’, ‘BLI’, and ‘NIRF+BLI’) were assigned (Fig. 1-VI; 2A). 
SCAPOS methodology
SCAPOS was applied to detect and correct for discrepancies in tumor demarcation between 
NIRF imaging and BLI as the gold standard for the presence of cancerous tissue. In both group 
I and II, an individual correction factor was calculated for each tumor in the model subgroups 
by determining the margin required to cover all BLI signal (Fig. 2B) as a proportion of the 
maximum diameter, automatically indicated by MATLAB. 
Regional extension was implemented as morphologic dilatation. Dilation with a correction 
factor allows for an appropriate safety margin surrounding the NIRF signal, thereby eliminating 
false negative results (i.e., BLI not covered by NIRF signal). The !nal SCAPOS-based NIRF 
correction factor is de!ned as the mean of the individual correction factors in each group plus 
the standard deviation of the mean multiplied by three (meanIndividual correction factor + 3xSDmean). 
When normal distribution of the data is assumed, addition of three standard deviations 
theoretically leads to the elimination of false negative NIRF signals in a vast majority of cases 
(>99%). Lastly, the !nal SCAPOS-based NIRF correction factor was validated on a separate 
subgroup (Fig. 2C).
Figure 1. Sequential steps in automated tumor demarcation are shown for a representative mouse (group I). 
First, bioluminescence (AI) and normalized "uorescence (BI) images were imported in MATLAB®. Images were 
cropped to a region of interest (II), followed by automated Canny Edge detection (III) and estimation of a 
single-pixel thick continuous tumor outline (IV). Next, the estimated tumor outline was !lled (V) and segment 
overlays (VI) were created. Light blue, dark blue, and yellow labels represent NIRF (false positive), BLI (false 
negative), and overlapping signal (true positive), respectively.
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Figure 2. Schematic overview of SCAPOS-based NIRF correction for the model and the validation group. First, a 
composite image (AII, BI) was created by combining NIRF (AI) and BLI (AIII) signal masks. For every tumor in the 
model group, the NIRF mask was extended (BII) until full coverage of the BLI signal mask was obtained (BIII). The 
SCAPOS-based NIRF correction factor as calculated from the model group was applied to the NIRF signal mask of 
the validation group (CI-III). Next, a composite image was created (CIV) by combining the corrected NIRF signal 
(CIII) with the BLI signal mask (CV-VI) to assess false and true negative proportions.   
RESULTS
Animal model
In group I, 9 out of 10 (93%) mice hatched after inoculation, as con!rmed by BLI. One mouse 
was excluded from group I due to the absence of BLI signal upon imaging, leaving 8 mice for 
SCAPOS analysis in this group. In group II, 5 mice (100%) hatched a tumor. None of the mice 
showed severe weight loss (≥10% compared to the weight measured on day 0) during the time 
course of the experiment. Mice were in good condition prior to imaging.  
SCAPOS-based NIRF correction
Prior to SCAPOS correction, false negative results were observed in 8 out of 8 mice (100%) in 
group I and 1 out of 5 mice (20%) in group II. Application of the SCAPOS-based NIRF correction 
factor resulted in elimination of false negative results in all mice (Fig. 3), i.e., all BLI signal- 
containing areas were entirely covered by the corrected NIRF signal. The correction factor 
di#ered signi!cantly between group I and II (0.20 vs 0.05, P=0.018). The mean proportion of 
false positive NIRF signal following SCAPOS-based NIRF correction was 0.55 (range: 0.53−0.66) 
for group I and 0.63 (range: 0.62−0.64) for group II (Fig. 3). SCAPOS analysis was performed on 
a normal laptop within seconds. 
Histological analysis
Tissue samples were harvested and send to the Department of Pathology and Laboratory 
Medicine for histological analysis. Histology con!rmed the presence of tumor cells in all tissue 
indicated as cancerous by BLI (data not shown).
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Figure 3. Relative signal distribution prior to (AI, AII) and following (CI, CII) SCAPOS-based NIRF correction. Labels 
corresponding to the signals are presented (B). Prior to SCAPOS correction, NIRF imaging did not fully cover the 
BLI signal (i.e., tumor tissue) in all mice from group I (AI) and in one mouse from group II (AII). SCAPOS-based 
NIRF correction resulted in a full coverage of the BLI signal in all mice while increasing the proportion of false 
positive results (CI, CII). To put these numbers into perspective, the proportion of healthy breast tissue (orange 
bars) in relation to cancerous tissue that is normally excised during breast-conserving surgery as a margin of 
safety is presented for breast tumors (green bars) ranging from 1 to 5 cm in diameter (D). These proportions were 
based on a gross safety margin of 1 cm healthy breast tissue surrounding the primary tumor, which is considered 
standard-of-care in breast-conserving surgery.
DISCUSSION
NIRF epi-illumination imaging has great potential for intraoperative applications in which the 
tumor is localized relatively super!cially.3,24 Recent developments in imaging systems and 
"uorescent probes have added to its potential. For a successful introduction of NIRF imaging 
in the clinic, potential discrepancies in tumor demarcation due to variation between optical 
imaging systems and the biodistribution of "uorescent probes should be taken into account. 




Automated tumor demarcation indicated substantial di#erences regarding the occurrence of 
false negatives (i.e., BLI not detected by NIRF imaging) between group I and II (Fig. 3). NIRF 
imaging underestimated the amount of BLI in 8 out of 8 mice (100%) in group I, while under- 
estimation was observed in only 1 out of 5 mice (20%) in group II. Parameters used between 
group I and II di#ered signi!cantly, making direct comparison inappropriate. However, within 
groups, the calculation of the false negatives is performed under the same circumstances.  
In addition to the di#erence in imaging systems and preprocessing methods, we suggest an 
explanation for di#erences in the biodistribution of the "uorescent probes. IntegriSense® 680 is 
targeted towards integrins and therefore expected to be quite evenly distributed throughout 
the tumor.17,18 MMPSense® 680 is activated mainly at the tumor border (i.e., invasion sites) and 
in the zone of in"ammation surrounding of the tumor, where the level of MMPs is high.19-21 
Indeed, Kossodo et al. reported di#erent distribution patterns for integrin-targeted and 
protease-activated "uorescent probes when simultaneous NIRF imaging was performed.10 
SCAPOS-based NIRF correction decreased the occurrence of false negative results to zero 
in both groups, indicating that SCAPOS successfully corrected for discrepancies in tumor 
demarcation. Although it is of the utmost importance in surgical oncology to obtain surgical 
margins that are free of tumor, the extent of surgery should be as limited as possible to obtain 
good (cosmetic) outcome.3,25 Studies reporting on breast-conserving surgery advise to obtain 
a gross margin of healthy breast tissue ranging from 1 cm to 3 cm surrounding the tumor.26,27 
When a 1 cm gross margin is taken into account, the proportion of healthy breast tissue in 
relation to cancerous tissue excised during breast-conserving surgery ranges from 0.50 to 
0.85, depending on the diameter of the primary tumor (Fig. 3D). For a 3 cm gross margin, this 
proportion even ranges from 0.83 to 0.98. Noteworthy, the proportion of false positive NIRF 
signal (i.e., healthy tissue indicated as cancerous) following SCAPOS-based NIRF correction 
ranged from 0.53 to 0.66. The SCAPOS-based correction factor therefore did not exceed the 
generally applied surgical margin of safety that is considered standard-of-care in breast- 
conserving surgery (Fig. 3). 
Considerations concerning SCAPOS
Part of the automated tumor demarcation was based on Canny Edge detection, which 
identi!es high-contrasting regions delineating the tumor.23 Due to this characteristic of the 
Canny Edge algorithm, factors that decrease contrast (e.g., auto"uorescence, background 
signals, and increasing tumor depth) might pose di%culties in automated tumor delineation. 
As a consequence, best results are obtained after preprocessing captured images. Furthermore, 
the proposed method is relatively insensitive to changes in exposure time, injected doses 
of "uorescent probes, and image resolution. The !rst two mainly in"uence the total signal 
intensity, while the distribution of the signal is in"uenced only marginally. Therefore, the Canny 
Edge algorithm is likely to mark the same border. The in"uence of the image resolution is low, 
because the correction factor is expressed as a proportion of the diameter of the demarcated 
area. The used parameters for the Canny Edge algorithm in"uence the number of indicated 
edges, but again not their position.
Interference of auto"uorescence (especially form the gastrointestinal region) is increased 
in small animals compared to humans because of the smaller distance between con"icting 
organs and the high content of "uorophores in animal chow. This may pose di%culties on 
di#erentiating tumor from background signal. The distorting e#ects of auto"uorescence can 
be minimized by: i) providing the animals with a low-"uorophore chow, ii) preprocessing of 
imaging data (e.g., spectral unmixing), and iii) selection of a speci!c ROI for image analysis. 
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In order to assess the feasibility of SCAPOS in various circumstances, we chose to use di#erent 
imaging systems and "uorescent probes. Several preprocessing steps were regarded as system 
depended, as they are performed on the imaging system itself. Changing more than one variable 
between groups prohibits de!nite conclusions concerning possible causal relations. However, 
the scope of the current study was solely to demonstrate the methodology of SCAPOS instead 
of quantifying variations between imaging systems or biodistribution of "uorescent probes. 
Although study size was small, this proof-of-principle study is deemed su%cient to exhibit 
the basic principle of SCAPOS. Our methodology could theoretically be applied to most solid 
cancers. However, further studies are needed to validate SCAPOS in larger study populations 
and di#erent settings. 
CONCLUSION
We exhibit a generally applicable platform denominated as segmentation-based comparative 
analysis of planar optical signals (SCAPOS) to optimize tumor demarcation in planar NIRF 
imaging. SCAPOS could provide a useful step in the translation of NIRF imaging applications 
towards the clinic by detecting and correcting for variation in the hardware/software of 
imaging systems and the biodistribution of "uorescent probes that may cause discrepancies 
in the demarcation of tumor tissue. Further studies are needed to validate SCAPOS in larger 
study populations and di#erent settings.
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Near-infrared ! uorescence (NIRF) 
imaging in breast-conserving surgery: 
assessing intraoperative techniques in 



















Breast-conserving surgery (BCS) results in tumor-positive surgical margins in up to 40% 
of the patients. Therefore, new imaging techniques are needed that support the surgeon 
with real-time feedback on tumor location and margin status. In this study, the potential of 
near-infrared "uorescence (NIRF) imaging in BCS for pre- and intraoperative tumor localization, 
margin status assessment and detection of residual disease was assessed in tissue-simulating 
breast phantoms.
Methods
Breast-shaped phantoms were produced with optical properties that closely match those of 
normal breast tissue. Fluorescent tumor-like inclusions containing indocyanine green (ICG) 
were positioned at prede!ned locations in the phantoms to allow for simulation of 
i) preoperative tumor localization, ii) real-time NIRF-guided tumor resection, and iii) 
intraoperative margin assessment. Optical imaging was performed using a customized clinical 
prototype NIRF intraoperative camera.
Results
Tumor-like inclusions in breast phantoms could be detected up to a depth of 21 mm using a 
NIRF intraoperative camera system. Real-time NIRF-guided resection of tumor-like inclusions 
proved feasible. Moreover, intraoperative NIRF imaging reliably detected residual disease in 
case of inadequate resection.
Conclusion
We evaluated the potential of NIRF imaging applications for BCS. The clinical setting was 
simulated by exploiting tissue-like breast phantoms with "uorescent tumor-like agarose 
inclusions. From this evaluation, we conclude that intraoperative NIRF imaging is feasible 
and may improve BCS by providing the surgeon with imaging information on tumor location, 
margin status, and presence of residual disease in real-time. Clinical studies are needed to 




Breast cancer is the most frequent malignancy in women worldwide with an estimated 1.4 
million new cases in 2010.1 Breast-conserving therapy (BCT), consisting of breast-conserving 
surgery (BCS) followed by radiation therapy, has become the standard treatment for T1–T2 
breast tumors and is generally regarded as su%cient for this subset of patients.2 Unfortunately, 
a majority of studies on the surgical margin status after BCS have shown that positive margins 
are detected in 20% to 40% of patients, necessitating additional surgical intervention or 
radiotherapy.3 Two major points for improving outcome after BCS involve i) a more reliable 
intraoperative tumor localization and ii) improved real-time feedback on the presence of 
possible residual disease during or after excision of the tumor.4 Intraoperative application of an 
optical imaging technique known as near-infrared "uorescence (NIRF) imaging may improve 
the clinical outcome of BCS.3,5 
Near-infrared !luorescence imaging
In recent years, signi!cant progress has been made in the development of optical imaging 
systems and "uorophores for clinical applications.6,7 Several animal5,8-10 and clinical11,-15 studies 
have shown the potential clinical use of NIRF imaging to improve the therapeutic outcome 
of surgery. Compared to light in the visible spectral range (400–650 nm), application of 
near-infrared (NIR) light minimizes absorption by physiologically abundant molecules such as 
hemoglobin and lipids, which increases penetration depth.16,17 Additionally, auto"uorescence 
(the intrinsic "uorescence signal present in all living cells due to various normal metabolites 
and tissue constituents) is strongly reduced in the NIR spectral range. Taken together, these 
aspects of NIR light make it particularly suitable for use in intraoperative optical imaging 
applications. However, clinical application of NIRF imaging in BCS is currently limited to the 
nonspeci!c intraoperative detection of the sentinel lymph node.11,12,14,18-20 
Tumor-targeted near-infrared !uorophores
With the introduction of clinical grade tumor-targeted NIR "uorophores, NIRF imaging may be 
extended towards the intraoperative detection of the primary tumor.10 Several target molecules 
have been indenti!ed for breast cancer that may be of value for such an approach, including 
HER2 receptor,9,21,22 vascular endothelial growth factor (VEGF) receptor,23,24 endothelial growth 
factor (EGF) receptor,25 and folate receptor-α.26 
In tumor-targeted NIRF imaging, a tumor-targeted NIR "uorophore is administered several 
hours or days prior to the imaging procedure. Subsequently, an external laser is used to 
irradiate the breast with light in the NIR spectral range (650–900 nm).17 Upon excitation, the 
"uorophore will release photons of a longer NIR wavelength. Because NIR light is invisible to 
the naked eye, a dedicated optical imaging system is necessary to capture the NIR signal from 
the surgical !eld and digitally convert it into a visible image. Recently, we and our co-workers 
developed a multispectral NIRF intraoperative camera system that is suitable for intraoperative 
use with NIR "uorophores.27 
Simulation of NIRF-guided surgery
In the current preclinical study, we evaluated intraoperative NIRF imaging applications in a 
simulated clinical setting as a step-up toward NIRF-guided BCS. To this end, we used tissue- 
simulating gelatin-based breast phantoms that mimic the optical properties of normal breast 
tissue.28,29 Tumor-like "uorescent inclusions of di#erent size and shape were positioned at 
5
71
NEAR-INFRARED FLUORESCENCE IMAGING IN BREAST PHANTOMS
prede!ned sites in the phantoms, allowing for simulation of i) preoperative tumor localization, 
ii) real-time NIRF-guided tumor resection and iii) intraoperative macroscopic margin 
assessment. The tumor-like inclusions contain the nonspeci!c NIR "uorophore indocyanine 
green (ICG) to simulate the use of tumor-targeted near-infrared "uorophores in BCS.  
Currently, ICG (absorption and emission maximum at ~780 and ~820 nm, respectively) is one 
of the few FDA-approved NIR "uorophores available for clinical use.9 Sevick-Muraca et al. 
have previously shown the feasibility of NIRF imaging following microdose administration of 
ICG.12 Although ICG in itself is nonspeci!c, their !ndings suggest that comparable microdose 
concentrations can be used to label cancer cells with tumor-targeted NIR "uorophores 
for intraoperative NIRF imaging. Importantly, new "uorophores in the NIR spectral range 
are currently being developed (e.g., IRDye 800CW) with properties more promising for 
intraoperative use than those of ICG.25
METHODS
Assessment of ICG !uorescence self-quenching
Because increasing concentrations of ICG may not correspond to an increased "uorescence 
signal due to the phenomenon of self-quenching, di#erent concentrations of ICG in agarose 
were evaluated for "uorescence activity.29,30 Brie"y, an ICG stock solution was serially diluted 
in 10 ml sterile water (ranging from 0.5 µM to 350 µM ICG), after which 2% agarose was added. 
The mixture was then heated to 70 °C and stirred until the agarose was completely dissolved. 
After solidi!cation of the agarose mixture for 15 min at 4 °C, "uorescence re"ectance imaging 
(FRI) was performed to determine maximum photon counts/sec (settings: exposure time: 1000 
ms, excitation: 780 nm, emission: 820 nm). 
Assessment of maximal penetration depth 
In order to determine the maximal penetration depth of the NIRF signal, a cubic "uorescent 
inclusion of 5x5x5 mm containing 14 µM ICG was positioned in phantom tissue at a depth of 
30 mm. Subsequently, the surgeon excised 3−4 mm layers of phantom towards the inclusion 
(remaining depths were 27, 24, 21, 18, 15, 11, 7, and 4 mm, respectively). At all depths, FRI 
was performed with the intraoperative NIRF camera system (exposure time: 3000−60000 ms, 
excitation 780 nm, emission 820 nm, binning: small-medium). Maximum photon counts per 
second exposure time were calculated as well as the full width at half maximum (FWHM) of the 
"uorescence signal. The FWHM is a measure for scattering and indicates the diameter of the 
"uorescence signal when the intensity of the signal is reduced to half the maximum. Scattering 
both contributes to signal loss and loss in resolution. The FWHM indicates the minimal distance 
between two distinct sources to be recognized as separate.
Tissue-simulation breast phantoms
Composition of the tissue-simulating gelatin-based breast phantoms was aimed at obtaining 
uniform optical properties that closely match the optical characteristics of normal breast tissue, 
as described in detail before.29 Additionally, the breast phantoms mimic the elastic properties 
of human tissue.31 
Brie"y, 10% gelatin 250 (Natural Spices, Watergang, the Netherlands) was dissolved in 1l 
TBS (50 mmol Tris-HCl, 150 mmol NaCl, pH 7.4). To remove molecular oxygen and prevent 
microbial infection, 15 mmol NaN3 (Merck, Darmstadt, Germany) was added. The gelatin slurry 
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was completely dissolved by heating to 50 °C and subsequently cooled down to 35 °C and 
maintained at this temperature. Under constant stirring, 170 µmol hemoglobin (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) and 1% Intralipid® 20% (Sigma-Aldrich) were added. Next, the 
gelatin mixture was poured in a custom made prechilled breast-shaped mold (end volume 
500 ml) to a level that corresponded to the prede!ned depth of the agarose inclusion. After 
solidi!cation for 30 min at 4 °C, a tumor-like NIR "uorescent agarose inclusion was positioned 
on the surface and temporarily !xed with a small needle. Next, the remaining of the warmed 
gelatin mixture was added to !ll up the remaining mold volume, allowing for adherence of 
both layers. The phantom was then stored in the dark to solidify for another 30 min at 4 oC, after 
which it was gently removed from its mold. 
In total, four breast phantoms were constructed with tumor-like NIR "uorescent agarose 
inclusions of di#erent size and shape (Fig. 1A) positioned at prede!ned depths. Imaging of the 
phantoms was performed directly after production of all four phantoms. 
Breast phantom #1 contained 2 similar-sized (Ø1.0 cm) sphere-shaped agarose inclusions 
at di#erent depths (2.0 and 4.0 cm). Phantom #2 contained 2 sphere-shaped inclusions at 
the same depth (1.5 cm), di#ering in size (Ø 0.5 cm and Ø 2.0 cm). Phantom #3 contained 1 
sphere-shaped (Ø1.0 cm) and 1 prolate sphere-shaped (Ø1.0 cm) agarose inclusion at the same 
depth (1.5 cm). Finally, phantom #4 contained 2 irregular shaped agarose inclusions of similar 
size (Ø1.5 cm) at di#erent depths (1.5 and 3.0 cm).
Figure 1. Fluorescent tumor-like agarose inclusions di#ering in size and shape (AI-III) were integrated in 
breast-shaped phantoms (CI) prior to surgery. Preoperatively, the location of the tumor-like inclusion was assessed 
noninvasively using a NIRF camera system (B). Intraoperatively, the inclusion was excised under real-time NIRF 
guidance or guided solely by visual and tactile information (CII). At the end of the surgical procedure, the NIRF 
camera system was applied to inspect for residual disease and evaluate the extent of surgery (CIII).
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Tumor-like NIR !uorescent agarose inclusions
For tumor-like NIR "uorescent agarose inclusions, 2% agarose (Hispanagar, Burgos, Spain) 
was used instead of 10% gelatin. Agarose has a higher melting point, which prevents the 
inclusions from dissolving and leaking ICG (see below) during and after the positioning of the 
inclusions in the gelatin phantom. In short, a 2% (W/V) agarose slurry was heated to 70 °C and 
stirred until the agarose was completely dissolved. Subsequently, ICG (ICG-PULSION®; Pulsion 
Medical Systems, Munich, Germany) was dissolved to a !nal concentration of 14 µM. Finally, in 
order to resemble the optical appearance of the surrounding breast phantom tissue, 170 µM 
hemoglobin,15 mM NaN3, and 1% Intralipid® 20% were added to the tumor-like "uorescent 
inclusions. Tumor-like "uorescent inclusions of di#erent size (range: 0.5 cm to 2.0 cm) and 
shape (prolate sphere, sphere, and irregular shape, Fig. 1A) were produced. The inclusions 
were integrated in the breast phantoms as indicated and chilled in the dark for 30 min at 4 °C. 
Imaging of each individual breast phantom was performed within 6 h.
Near-infrared !uorescence imaging system
A customized NIRF camera system was developed in collaboration with SurgOptix (SurgOptix 
Inc., Redwood Shores, USA) for real-time intraoperative imaging. The system implements 
a correction scheme that improves the accuracy of epi-illumination "uorescence images 
for light intensity variations in tissue. Implementation is based on the use of three cameras 
operating in parallel. The camera is mounted on a !ve degrees of freedom bracket, the sixth 
degree (rotation) can be performed digitally. This camera allows for simultaneous acquisition 
of color videos and normalized "uorescence images in real-time, yielding a lateral resolution 
up to 66.58 µm and a variable !eld of view (FOV) of 13.5W x 11H to 115W x 95H (mm). A 
description in full detail is provided by Themelis et al.27 The invisible NIRF imaging signal was 
digitally converted into a pseudocolor and superposed on a color video image of the operating 
!eld, allowing for real-time, intraoperative anatomical positioning of the "uorescence signal.
Simulation of intraoperative NIRF imaging
Breast phantoms with tumor-like NIR "uorescent agarose inclusions were used to simulate 
and evaluate the potential of NIRF imaging applications in BCS (Fig. 1). In all phantoms, the 
location of the tumor-like "uorescent inclusions was assessed preoperatively with noninvasive 
NIRF imaging. In phantoms #1 and #2, the tumor-like "uorescent inclusions were subsequently 
excised using conventional surgical equipment, guided solely by visual inspection, tactile 
information, and preoperatively obtained NIRF imaging data. The surgeon was asked to 
indicate when he believed a complete excision of the tumor was reached. Subsequently, the 
NIRF camera system was applied to assess the feasibility of NIRF-guided macroscopic margin 
assessment of the surgical cavity and excised tissue fragments. In case of an incomplete 
excision, the surgeon was asked to perform a re-excision under real-time NIRF guidance.
In phantoms #3 and #4, the tumor-like "uorescent inclusions were localized and excised under 
real-time NIRF guidance. While approaching the tumor-like "uorescent inclusions, the surgeon 
was supported with both visible and audible information. In short, the detected "uorescent 
signal was depicted on a TFT-screen and was made quantitatively audible using a digitally 
generated sound pitch. In this approach, an increase in sound pitch represents an increase in 




ICG !uorescence self-quenching in agarose
To determine the optimal ICG concentration in agarose, a serial range of increasing ICG 
concentrations was analyzed for "uorescence characteristics. The optimal "uorescence 
signal was observed at a concentration of approximately 10 µM ICG (Fig. 2). These results are 
comparable to self-quenching characteristics of ICG as previously determined in gelatin.29
Maximal penetration depth of ICG !uorescence 
The maximal tissue penetration depth of a detectable "uorescent ICG inclusion was reached at 
a depth of 21 mm (Fig. 3C and Supplementary video 2). 
Simulation of intraoperative NIRF imaging
Preoperative NIRF-guided localization of tumor-like "uorescent agarose inclusions was 
performed in 4 di#erent breast phantoms. The various tumor-like inclusions positioned at a 
depth of ≤2.0 cm were detectable with the NIRF camera system (Fig. 4A-I). Tumor-like inclusions 
positioned at depths of 3.0 and 4.0 cm could not be detected preoperatively. 
Figure 2. Optimal ICG concentration in 2% agarose was determined in breast phantom tissue. Seventeen 
di#erent concentrations (each 10 ml, ranging from 0.5 µM to 350 µM) were imaged at once with the 
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Tumor-like inclusions in phantom #1 and #2 were excised using conventional techniques for 
tumor localization. In phantom #1, one out of two tumor-like inclusions proved to be only 
partially excised, as evidenced by a remnant strong "uorescence signal in the surgical cavity 
detected by the NIRF camera system (Fig. 4C-III). In phantom #2, the excision of one out of 
two inclusions was found to be incomplete. In case of residual "uorescence, the surgeon 
could detect and excise (theranostic procedure) the remnant inclusion under real-time NIRF 
guidance (Fig. 4C-IV and Supplementary video 1). In all cases, NIRF-guided re-excision resulted 
in a complete excision, without the need for additional excision of large breast phantom 
fragments (Fig. 4C-V). 
In phantoms #3 and #4, the tumor-like inclusions were located (Fig. 4B) and excised (Fig. 4C) 
under real-time NIRF guidance. Although the inclusion at 3.0 cm depth in phantom #4 could 
not be detected preoperatively (Fig. 4B-I), it was detectable using the NIRF camera system after 
an incision of approximately 1 cm of super!cial phantom tissue (Fig. 4B-II). In phantom #3, 
no residual tumor-like inclusion material could be detected after initial NIRF-guided excision, 
while the excision of one out of two irregular inclusions in phantom #4 was found to be 
incomplete. Again, subsequent NIRF-guided re-excision resulted in a complete excision. 
During the surgical simulation procedure, the approximation of the surgeon towards tumor-like 
"uorescent agarose inclusions was guided by both visual information on a TFT screen and 
audible sound-pitched information (Supplementary videos 1-2). The approach resulted in a 
clear change in the signal strength of the "uorescence image that was accompanied with an 
increase of the sound pitch at ~15 mm prior to excision of the tumor-like agarose inclusion. 
These signals assisted the surgeon in carefully advancing the margins.
Figure 3. Fluorescent signal intensity related to depth-location in tissue-like phantoms is shown for 
"uorescent agarose inclusions placed at varying depths in phantom tissue (A). Depth (mm) of the inclusion 
and maximum photon counts per second exposure time are depicted on the horizontal and vertical axis, 
respectively. Moreover, scattering of the "uorescence signal is shown (B), with depth (mm) and full width at 
half maximum (pixels) on the horizontal and vertical axis, respectively. For determination of the NIRF signal 
penetration depth with the NIRF intraoperative camera system (C), the surgeon repeatedly excised 3−4 mm 
tissue layers, working his way towards a "uorescent inclusion placed at 30 mm depth in breast phantom 
tissue. At 30, 27, and 24 mm inclusion depth, no NIRF signal could be detected (not shown). Images were 
corrected for (normalized) an exposure time of 1000 ms.
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Figure 4. Overview of NIRF applications in breast-conserving surgery. In the case of relatively super!cial lesions 
(≤2 cm), NIRF allows for preoperative localization of "uorescent tumor-like inclusions (A). Intraoperative NIRF 
imaging guides the surgeon towards the tumor-like agarose inclusion (B+C) and allows for intraoperative 
assessment of surgical margin status (CII-V) and detection of residual disease (CIII). Color bars next to the color 
overlay indicate a threshold at 800 counts. Pixels with values above the threshold were superposed on the color 
video (overlay). Exposure time was set to 150 ms for all images.
DISCUSSION
Tissue-like phantoms and tumor-like inclusions
The composition of the breast phantoms was based on data published by De Grand et al., who 
developed and validated phantoms to mimic the basic optical characteristics (absorption and 
scattering coe%cients) of breast tissue.29 The absorption of photons by both cellular organelles 
and blood was simulated by hemoglobin, which gives the phantoms a deep red color.32,33 
Additionally, Intralipid® was added to mimic scattering properties of breast tissue.28 
In order to resemble the clinical situation as close as possible, tumor-like "uorescent agarose 
inclusions were incorporated in the breast phantoms. The agarose-based inclusions simulate 
the !rm-elastic consistency of tumor tissue and allow for surgical margin status assessment, 
both intraoperatively (NIRF-guided surgery) and ex vivo (NIRF-guided macroscopic margin 
assessment). The relatively low concentration of ICG used in this study resembles the potential 
application of microdose tumor-targeted "uorophores (ranging from 1 to 100 µM) in BCS. 
Although the phantoms used in this study are homogeneous, and therefore do not possess the 
complex structures that characterize mammary tissue, they do provide a tool for assessing the 
value of theoretical assumptions and indicate generally important features of future clinical 
NIRF imaging applications in BCS. 
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Near-infrared !uorescence imaging
NIRF imaging o#ers a promising technique for real-time NIRF-guided surgery in BCS with little 
interference in the standard surgical procedure or changes in the design of the operating 
theatre. The technology is considered safe, fast, makes use of non-ionizing radiation, and has a 
high resolution.3,10 However, NIRF imaging does have limitations originating from the intrinsic 
characteristics of light propagation through tissue, including scattering and absorbance.17 
Additionally, due to limited depth resolution and a nonlinear dependence of the signal 
detected and the depth of the "uorescence activity, NIRF imaging by epi-illumination with 
our current camera system seems of limited value for preoperative localization of tumors. This 
applies in particular to situations where the tumor is located relatively deep (>2 cm) in fatty 
and glandular tissue of the breast. However, since the surgeon, by de!nition, will bring the 
area of interest closer to the surface during surgery, our multispectral NIRF camera system is 
well-suited for intraoperative imaging applications.
Nonspeci"c versus tumor-targeted imaging agents
Several possibilities exist for delivering "uorophores to the tumor. One possibility would be 
to inject a nonspeci!c "uorophore (e.g., ICG) into the tumor under stereotactic or ultrasono-
graphic guidance.34,35 However, there are some signi!cant drawbacks to this approach. First, 
the injection of the nonspeci!c "uorophore into the tumor is a critical step in the procedure 
and has to be very accurate to minimize false negative and false positive results. Additionally, 
spillage/leakage of "uorophore within the mammary gland during the procedure will 
decrease accuracy of both localization of the tumor and macroscopic margin assessment. 
Therefore, we believe NIRF-guided surgery should ideally be combined with tumor-targeted 
"uorophores, which provide molecularly-speci!c detection of cancer cells. In these agents, the 
NIR "uorophore has been conjugated to a speci!c targeting ligand or monoclonal antibody. 
This allows for tumor-speci!c binding of the "uorophore, increasing SN ratios and minimizing 
spillage of the "uorophore during the surgical procedure.3,10 Several studies have shown the 
feasibility of using tumor-targeted "uorophores in vivo to image tumors intraoperatively, 
including the use of tumor-targeted ICG-conjugated agents.5,9,22,25,26,36,37 However, there are 
some signi!cant drawbacks, including the heterogeneity of (breast) tumors which should be 
solved before applying tumor-targeted NIRF imaging in the clinic. In BCS, the preoperative 
biopsy taken prior to surgery could provide important information on molecular targets for 
NIRF imaging. As this biopsy is considered standard practice, it will not require an additional 
invasive procedure, while o#ering the possibility to determine the expression of di#erent kinds 
of molecular targets present on the breast cancer cells by immunohistochemical analysis. The 
surgeon could then look for NIRF agents suited for each individual tumor, o#ering a more 
patient-tailored approach.
CONCLUSION
We have preclinically assessed the applicability of NIRF imaging applications in BCS by 
exploiting tissue-simulating breast phantoms. NIRF-guided intraoperative tumor localization 
and detection of remnant disease showed feasible. Clinical studies are needed to further 
validate these results for use in BCS.
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Optical imaging for lymph node surveillance 
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The sentinel lymph node (SLN) procedure is widely accepted as a method for lymph node 
staging in cT1-2N0 breast carcinoma. In the case of a positive SLN, remaining axillary lymph 
nodes (ALNs) are generally removed. However, these ALNs do not contain metastases in 
40% to 80% of the patients, indicating substantial overtreatment. In this paper, near-infrared 
"uorescence (NIRF) imaging is outlined as a technique for intraoperative detection of the SLN. 
Moreover, the potential of intraoperative detecting of tumor load within the SLN for a one-step 
SLN/ALN dissection is outlined.
Methods
Ten (10) women with biopsy-proven cT1-2N0 breast carcinoma underwent the standard SLN- 
procedure (preoperative injection with radiolabeled colloid and intraoperative injection 
with patent blue). Additionally, all patients received a peritumoral injection with 1 ml (0.5 
mg/ml) indocyanine green (ICG) intraoperatively. The SLN was visualized with a customized 
multispectral NIRF camera system. 
Results
The SLN was successfully identi!ed in all patients. Total numbers of lymph nodes detected with 
radiolabeled colloid, patent blue and ICG were 18, 9, and 14, respectively. The use of the NIRF 
optical imaging system did not interfere with the standard operative procedure. No adverse 
reactions were encountered.
Conclusion
The intraoperative detection of the SLN with a NIRF optical imaging system is technically 
feasible. In the near future, tumor-targeted optical contrast agents may allow for a one-stage 
intraoperative evaluation of lymph node tumor status and intraoperative decision making 




Breast cancer is the leading type of cancer in women with an estimated 1.4 million new 
cases worldwide in 2010.1 Treatment of primary breast cancer depends on the resection of 
the primary tumor and identi!cation of cancer spread to the lymph nodes (LNs). Both are 
independent prognostic factors for survival and recurrence of the disease.2 For identi!cation of 
tumor involvement in axillary lymph nodes (ALNs), the !rst-draining node, also denominated 
as the sentinel lymph node (SLN), is removed and analyzed by histology.3 The best results 
for intraoperative SLN localization are obtained with a combination of radiolabeled colloid 
(technetium-99m) and vital blue dye (e.g., patent blue).4,5 The intraoperative use of a gamma 
probe combined with visual inspection of the surgical !eld (i.e., blue-stained lymphatic vessels 
and SLNs) leads to a successfull identi!cation of the SLN in 97% of the patients.4 However, 
there are disadvantages to both the blue dye and the radiolabeled colloid, including allergy 
to the blue dye, a shine-through e#ect at the injection site of the radiocolloid, di%culties 
with detecting SLNs in obese patients, and the need for appropriate logistics for radioactive 
matter.6-8  
As an alternative technique, several groups have reported on the use of the "uorescent optical 
contrast agent indocyanine green (ICG) for intraoperative SLN identi!cation.9-15 ICG has been 
used in patients for the last three decades for the study of organ perfusion and ophthalmology 
and has a safe and well-known pharmacological pro!le. When excitated at the appropriate 
wavelength, ICG will emit photons in the near-infrared (NIR) spectral range (~820 nm). Because 
NIR light is invisible to the human eye, a dedicated optical imaging system is needed to 
visualize the "uorescence signal within the surgical !eld. Such a system was recently presented 
by Troyan et al. in a study on lymphatic mapping in breast cancer.15 The described camera is 
capable of visualizing "uorescence signals originating from the SLNs in real-time, superposing 
them on color images of the surgical !eld for orientation. At the University Medical Center 
Groningen (UMCG), we recently introduced a similar imaging device, that allows for 
intraoperative video-rate near-infrared "uorescence (NIRF) imaging of lymphatic vessels 
and SLNs. In addition, our system is capable of multispectral imaging and is equiped with an 
algorithm for instand normalization of imaging data.16 
In the current pilot study, our imaging system is applied for lymphatic mapping with ICG 
alongside the routine technique using blue dye and radiolabeled colloid in early-stage breast 
cancer patients. After describing the camera system and its use in a clinical setting, we discuss 
the potential of targeted NIRF imaging for intraoperative detection of tumor load within lymph 
nodes, allowing for a one-step SLN/ALN dissection procedure.
METHODS
A total of ten women diagnosed with biopsy-proven stage I-II breast cancer who were 
scheduled to undergo sentinel lymph node biopsy (SLNB) for staging and treatment of their 
disease, were included in this study. Exclusion criteria were de!ned as pregnant or breast 
feeding condition, age younger than 21, signi!cant renal (serum creatinin ≥400 μmol/L), 
cardiac or pulmonary disease (ASA III-IV), history of iodine allergy or anaphylactic reactions 
to insect bites or medication, present or former hyperthyroidism, and recent surgery on the 
armpit. Informed consent was obtained prior to surgery and all information regarding the 
patients was anonymized. The study was approved by the Institutional Review Board (IRB) of 
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the UMCG and the National Committee for Clinical Research (CCMO). This study was performed 
in accordance with the ethical standards of the Helsinki Declaration and was registered prior to 
execution at the Dutch Trial Registry no. 2083.
Preoperative procedure
Technetium-99m labeled colloid was routinely administered in four equally-divided peritumoral 
injections (total volume: 0.4 ml) one day prior surgery. Additionally, a preoperative lympho- 
scintigram was obtained to determine the de!nitive position of the SLN and its lymphatic 
drainage pattern from the primary tumor. 
Surgical procedure
After the induction of general anesthesia, the patient was injected peritumorally into the 
breast parenchyma with a 2 ml mixture of patent blue and ICG. The mixture consisted of 
1 ml undiluted patent blue (Guerbet, Roissy-Charles-de-Gaulle, France) added to 0.5 mg 
(0.65 mmol) indocyanine green (Pulsion, Munich, Germany) dissolved in 1 ml of sterile water 
(B. Braun Medical, Hillcross, Martindale). The total volume of the mixture was equally divided 
over four peritumoral injections. 
Immediately after injection, "uorescence images were acquired with the NIRF camera and 
displayed on two wide-screen monitors, of which one was in direct vision of the operating 
surgeon (Fig. 1). Images of the injection site and the axillary area were acquired with video-rate 
acquisition. During the surgical procedure, the SLN was identi!ed in the usual way with the 
combination of a hand-held gamma probe and visual inspection. After an incision was made on 
the site with the highest count, as determined by the gamma probe, the NIRF camera system was 
directed at the surgically exposed area to capture an image and quantify "uorescence activity. 
The radioactive and/or blue SLNs were subsequently excised. After excision, the axillary basin 
was reassessed for radioactivity and blue spots as well as for NIRF signals. Residual radioactive 
and/or blue nodes were removed when necessary. In case of remaining "uorescent hot spots, 
a maximum of one additional SLN was excised by the surgeon. Nodes that were solid and 
highly suspicious for metastatic tumor on tactile inspection were also removed, irrespective 
of radioactivity or patent blue staining. The excised SLNs were imaged ex vivo with the NIRF 
camera system immediately after removal. 
All SLNs were sent to the Department of Pathology of the UMCG for histopathological analysis. 
Postoperatively, patients were monitored for at least 24 hours for the appearance of fever or 
skin rash, which could be an indication for an allergic or anaphylactic reaction to ICG. 
Near-infrared !uorescence camera system
For this study, "uorescence imaging was conducted with a multispectral state-of-the-art 
intraoperative NIRF camera system (Fig. 1). The system contains a halogen white light source, 
which illuminates the operating !eld without interfering with the "uorescence channels. Also, 
the system contains a laser diode, providing light of a speci!c wavelength for excitation of the 
"uorescent optical contrast agent. 
After excitation, photons emitted by the "uorescent optical contrast agent can be detected 
with a highly sensitive charged-coupled device camera (CCD camera 1). Intrinsic "uorescence 
signals can be detected with a second camera (CCD camera 2). Customized software permits 
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Figure 1. (A) Schematic overview of the clinical (IRB-approved) intraoperative NIRF optical imaging system. 
(B) Close-up of the intraoperative multispectral "uorescence camera in the operating room. (C+D) Positioning 
of the camera system covered with sterile draping during the surgical procedure.
simultaneous real-time acquisition of images from both NIRF cameras at up to 15 frames 
per second (fps). The authentic "uorescence signal from CCD camera 1 can be converted 
and projected onto a color video image of the operating !eld obtained with CCD camera 3, 
allowing for real-time, intraoperative anatomical positioning of the "uorescence signal. 
For intraoperative use, the entire NIRF camera system was covered in sterile drapes. In order to 
cover the lens of the camera, a sterile splash shield was used as commonly used in endoscopic 
surgery. The entire system was granted approval by the Institutional Review Board (IRB) of the 
UMCG. A detailed description of the technical characteristics of the NIRF camera system used 
in this study is published previously by Themelis et al.16
RESULTS
In all patients, a total of 18 SLNs could be identi!ed with an average of 2 SLNs (range: 1−4 SLNs) 
per patient. Patient characteristics are listed in Table 1. Mean patient age was 65 years. Nine 
patients (90%) were diagnosed with invasive ductal carcinoma (IDC), one patient with adenoid 
cystic carcinoma.
Transcutaneous visualization of the SLN was not found feasible in the majority of patients 
(70%), in part due to spillage of ICG at the injection site. The number of SLNs detected 
intraoperatively with radiolabeled colloid, patent blue, and ICG were 18 (100%), 9 (50%), and 
14 (78%), respectively. Fig. 2 shows the integration of "uorescence signals and color video 
images of the surgical !eld as seen by the surgeon on a monitor in the operating room. 
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Figure 2. NIRF signal observed during the sentinel lymph node procedure in a breast cancer patient, approxima-
tely 5 minutes after peritumoral injection with patent blue and indocyanine green. (A) Color image as seen by 
the surgeon. (B) Normalized "uorescence signal. (C) Fluorescence signal converted into pseudocolor (green) and 
superposed on color image for anatomical positioning of the signal. Still images originate from a video taken at 
15 frames per second during surgery.
Importantly, NIRF imaging detected 4 out of 4 SLNs containing (micro)metastases, revealed 
by conventional histopathology. The total duration of the surgical procedure combined with 
intraoperative NIRF optical imaging was prolonged for 30 minutes. This was mainly due to 
the learning curve for moving the camera in and out together with the time necessary for 
data acquisition during the operative procedure. The surgeons judged the camera system in 
combination with the wide-screen monitors convenient for intraoperative use and comparable 
to the use of monitors in laparoscopic surgery. It was regarded fairly easy to detect the NIR 
highlighted SLNs guided by the images on the screen. In addition, the surgeons appreciated 
the real-time, ‘live’ images, which gave them a sense of direct feedback on the presence 
of residual SLNs during the operation. No adverse reactions or wound infections were 
encountered after the administration of ICG.
DISCUSSION
Systematic studies have shown that tumor cells migrating from the primary tumor metastasize 
to the !rst draining lymph node (SLN) before spreading to other ALNs.17 When histo-
pathological evaluation of the SLN indicates the presence of (micro)metastases, the standard 
treatment is to perform a complete axillary lymph node dissection (ALND).18 Histopathological 
evaluation of excised SLNs at the time of dissection is considered to be a highly accurate 
method for assessing the spread of the disease.19 
However, in a large meta-analysis of over 7,500 breast cancer patients who underwent SLNB, 
no additional positive ALNs could be identi!ed following ALND in 47% of the patients who 
had a positive SLN.20 Furthermore, in 65% to 80% of patients with micrometastases (>0.2, 
≤2 mm) in the SLN, no metastases were found in the remaining ALNs.21,22 When only isolated 
tumor cells are present (metastases ≤0.2 mm), the percentage of patients with tumor-free ALNs 
even increases towards 90%.22 Consequently, non-a#ected ALNs are often needlessly removed 
due to the fact that the surgeon lacks real-time intraoperative feedback on LN tumor load 
status. As such, the SLN procedure, although highly speci!c and sensitive, leads to substantial 
overtreatment in breast-conserving surgery (BCS) with the known accompanying risks of 
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to be a clear need for noninvasive assessment of the SLN tumor burden status. This would 
signi!cantly reduce comorbidity associated with the unnecessary removal of nonmetastatic 
ALNs, but could also implicate a one-step procedure in case of a positive SLN for an ALND if 
the tumor burden is larger than 2 mm. NIRF-imaging with a tumor-speci!c probe may provide 
such a lymph node surveillance tool for detecting and assessing the actual SLN status.
Several studies have reported on a near-infrared "uorescence (NIRF) optical imaging system, 
with which the SLN can be detected noninvasively after subcutaneous injection with the 
"uorescent optical contrast agent indocyanine green (ICG).9,11,13-15,26 ICG "ows along with 
the lymph "uid and accumulates in the SLNs within minutes, enabling rapid detection and 
visualization of SLNs as "uorescent hot spots. Furthermore, no adverse reactions were reported 
in any of the conducted trials.9,11,13-15,26 
The NIRF camera system at the University Medical Center Groningen enables real-time 
intraoperative "uorescence imaging of lymphatic vessels and SLNs while capturing color 
video images of the surgical !eld simultaneously. NIRF optical imaging enhanced with optical 
contrast agents that emit in the NIR spectral range (e.g., ICG) o#ers some considerable 
advantages to the current SLN procedure: the technique o#ers a high resolution, is inexpensive, 
makes use of non-ionizing radiation, and o#ers high sensitivity and speci!city rates.27
The most important limitation of "uorescence imaging is its limited penetration depth 
(1−2 cm) due to the absorption and scattering of photons when propagating through tissue.28 
This may cause di%culties when aiming to visualize SLNs noninvasively or in obese patients. 
However, by selecting "uorescent optical contrast agents that emit photons in the NIR spectral 
region, tissue penetration of optical signals can be maximized due to reduced scattering and 
absorption of photons. In addition, maximal signal-to-noise ratios can be obtained in the NIR 
spectral region because tissue auto"uorescence is minimized.28  
In this pilot study, the surgeons appreciated the real-time feedback on the location of the 
SLNs during the surgical procedure and found the system easy to work with. It was very well 
possible to excise the NIRF highlighted SLNs guided by the "uorescence signal on the screen.
The total operation time was prolonged mainly due to the intraoperative use of the NIRF 
optical imaging system. However, in the course of these surgeries, we experienced a steep 
decrease in the time necessary to set up and install the system. We anticipate that, in the near 
future, the total prolongation of the surgical procedure will not exceed 30 minutes. 
The current study shows that NIRF-guided lymphatic mapping with ICG is feasible next to the 
routine blue dye/radiolabeled colloid technique in early-breast cancer patients. These !ndings 
con!rm the results reported by others.9-13,15 At our institution, intraoperative NIRF imaging will 
be expanded towards tumor-targeted detection of (micro)metastases in the SLN using NIR 
dyes like IRDye CW800 (LI-COR Inc., Lincoln, USA) conjugated to tracers of interest. Several 
studies have shown the feasibility of tumor-labeling with targeted optical contrast agents.29-32 
Sevick-Muraca et al. have shown the feasibility of NIR optical imaging following microdose 
administration of ICG. Although ICG is nonspeci!c, these !ndings suggest that comparable 
concentrations can be used for tumor-targeted NIR optical contrast agents for noninvasive SLN 
status assessment in humans.14  
In the near future, it may be possible to visualize a tumor-targeted optical contrast agent and 
a nonspeci!c optical contrast agent with di#erent wavelengths for simultaneous detection 
and assessment of the SLN. Such a multispectral imaging approach may improve therapeutic 
outcome of BCS by allowing for a one-step SLN/ALN dissection procedure based on the 
tumor burden within the SLN, which will ultimately reduce the number of unnecessary ALN 
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dissections and associated morbidity. The value of multispectral imaging needs yet to be 
evaluated by studies using uniformly designed and calibrated camera systems and optical 
agents for tumor-targeted imaging.
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ABSTRACT
Introduction
Sentinel lymph node biopsy (SLNB) has become a widely accepted staging procedure for both 
breast carcinoma and melanoma. The aim of our study was to systematically review di#erent 
SLNB techniques and perform a meta-analysis for corresponding identi!cation and false 
negative rates.
Methods
A systematic review of the literature on SLNB in patients with early-stage breast carcinoma and 
melanoma was performed. Only articles were included that studied SLNB in early-stage breast 
carcinoma and melanoma patients, with an original study group. The SLN identi!cation rate 
and false negative rate were pooled for patients with breast carcinoma or melanoma according 
to radiocolloid tracer, blue dye, indocyanine green (ICG), or a combination of a radiocolloid 
tracer with a blue or ICG dye.
Results
Between 1992 and 2012, a total of 154 studies (88 breast carcinoma and 66 melanoma) were 
reported that met the eligibility criteria. These studies included a total of 44,172 patients. 
The pooled value for the SLN identi!cation rate in breast carcinoma and melanoma patients 
using solely blue dye was 85% (range: 65−100%) and 84% (range: 59−100%), using solely 
radiocolloid 94% (range: 67−100%) and 99% (range: 83−100%), using a combination of blue 
dye and radiocolloid 95% (range: 76−100%) and 98% (range: 68−100%), using solely ICG 95% 
(range: 77−100%) and 100% (range: 100−100%), and using a combination of radiocolloid and 
ICG 96% (range 94.9−96.7%) and 100% (range: 100−100%).
Conclusion
The current meta-analysis provided data that favor the use of radiocolloid solely or radiocolloid 
combined with a blue dye for the identi!cation of the SLN. Performing SLNB with radiocolloid 
solely is the technique of choice for experienced surgeons, since blue dye has multiple 





Breast carcinoma and melanoma are annually diagnosed in 1.38 million and 197,000 people, 
representing 10.9% and 1.6% of all cancers in the world, respectively.1 Fortunately, the majority 
of both cancers are initially diagnosed stage I or II.2 
The lymphatic route is a principal way for breast carcinoma and melanoma to metastasize from 
their original focus. Cancer cells progressing via the lymphatic vessels are trapped in the !rst 
lymph node they encounter, denominated as the sentinel lymph node (SLN).3,4 
Lymph node metastases can either be detected clinically or through the use of a sentinel 
lymph node biopsy (SLNB). The concept of the SLN was !rst described in 1960 by Gould et al.
and is based on two basic principles: the existence of an orderly and predictable pattern of 
lymphatic drainage to a regional lymph node basin, and the functioning of a !rst lymph node 
as an e#ective !lter for tumor cells.5,6 Clinical implementation of the concept was deployed on 
a broad scale by Cabanas et al. in penile cancer.7 
Morton et al. described a method for SLNB in 1992, using peritumoral intradermal injections 
of blue dye in patients with primary cutaneous melanoma.4 The blue-stained lymphatic vessel 
was followed surgically until it was seen entering a blue-stained lymph node. In 1993, Alex et al. 
added the use of a radiotracer, injected intradermally around the primary tumor site, followed 
by imaging and subsequent intraoperative use of a handheld gamma probe to localize and 
remove the SLN.8 In the same year, Krag et al. described the application of this technique in 
breast carcinoma patients.9 Albertini et al. combined both the blue dye and the radioactive 
tracer in 1996, which is currently the most commonly used technique for SLNB in most centers.10 
The two most widely accepted clinical applications of SLNB are for cutaneous melanoma 
≥1 mm and T1-2 breast carcinoma.
11-13 SLNB is preferred over direct lymph node dissection (LND) 
because the risk of morbidity is lower.14,15 Moreover, SLNB allows the pathologist to study the 
few removed SLNs in greater detail for tumor burden compared with examination of the large 
number of lymph nodes removed by LND.16 
Despite its wide global use, the SLNB procedure has not been standardized internationally due 
to variation in the method and material used between surgeons and institutions. Although a 
combination of blue dye and a radiotracer is considered standard-of-care, a signi!cant number 
of surgeons work with blue dye or a radiotracer alone. In addition, the "uorescent optical 
contrast agent indocyanine green (ICG) was recently introduced in the clinic as an alternative 
agent for SLNB guidance.17 
In the present study, a systematic review was performed on peer-reviewed scienti!c articles to 
evaluate di#erent SLNB techniques and their corresponding identi!cation- and false negative 
rates in breast carcinoma and melanoma. In addition, we aimed to identify technical aspects 
in"uencing the outcome of the SLNB procedure.  
METHODS
Literature search and inclusion/exclusion criteria
A comprehensive, systematic review was conducted in October 2012 of the medical literature 
published after 1992. Details of the methods of the search and inclusion/exclusion criteria are 
speci!ed in Supplementary !le 1. 
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Study quality assessment
Authors MGN and RGP performed the quality assessment of selected articles. Study quality 
was evaluated using the “QUADAS” (quality assessment of diagnostic accuracy studies) tool to 
extract relevant study design characteristics.18 The core QUADAS items used in this review are 
outlined in Supplementary !le 2. In brief, QUADAS items included: availability of representative 
spectrum of patients, clear description of selection criteria, adequate reference standard, 
execution of index and reference test described in su%cient detail, independent interpretation 
of index test, availability of relevant clinical data, reporting of uninterpretable results, adequate 
explanation of study withdrawals, availability of adequate reference standard for veri!cation 
purposes, adequate follow-up, and reporting of false negatives. Each item was scored as ‘yes’, 
‘no’, or ‘unclear’. 
Statistical analyses
Univariate and multivariate logistic regression analyses were performed to identify factors 
associated with SLN identi!cation rate and false negative rate for the di#erent SLNB techniques. 
Analyses were strati!ed to technique and performed separately for breast carcinoma and 
melanoma. Factors included in this analysis were: type of study (prospective or retrospective), 
study period (1992−2000, 2001−2006, or 2007−2012), age (in years), de!nition of SLN 
(radioactivity higher than background or 10% rule), tumor size (in mm), number of SLNs 
removed, quality of the study (QUADAS score), type of dye (patent blue, isosulfan blue, 
lymphozuran blue, methylene blue, a combination of blue dyes, ICG, or unknown) or 
radiocolloid (99tcsulfer colloid, 99tctin colloid, 99tcphytate, 99tchuman serum albumin, 99tcdextran 
500, or 99tctilmanocept), concentration of dye or radiocolloid (in mg/ml or in Mbq), injected 
volume of dye or radiocolloid (in ml), injection site (peritumoral, parenchymal, subareolar, 
intradermal, subdermal, combination, or unknown), timing of injection (<15 minutes, 15 
minutes−1 hour, 1−10 hours, >10 hours), and massage after injection of dye or radiocolloid. 
The false negative rate (FNR) was de!ned as the probability of a negative SLN when the patient 
has positive lymph nodes in the LND or in the follow-up period of the study. 
Calculations were performed using the statistical packages SPSS (IBM SPSS Statistics for 
Windows, Version 21.0, Armonk, USA). P-values <0.05 were considered statistically signi!cant.
Meta-analysis
Identi!cation rate (IR) and FNR were extracted from the studies and pooled (on a study 
level) according to SLNB technique, breast carcinoma or melanoma, and period (1992−2000, 
2001−2006, and 2007−2012). Summary identi!cation rate, false negative rate, and the 
corresponding 95% con!dence interval (CI) were calculated using STATA/SE version 12.0 
(StataCorp, College Station, USA) using the metan command. Pooled values were calculated, 
using either a random-e#ects or a !xed-e#ects model, depending on the number of included 
studies and the amount of heterogeneity observed.
RESULTS
Literature search
Our comprehensive literature search resulted in 335 studies that were selected for further 
analysis, dating from January 1992 to October 2012. Of these studies, 198 comprised SLNB 
in breast carcinoma and 137 in melanoma. After thorough review, 154 studies (88 breast 
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carcinoma and 66 melanoma) met our inclusion criteria (Tables 1−3). A total of 108 out of 154 
studies reported on the IR of SLNB using blue dye only, 111 on using radiocolloid only, and 
118 on using the combination of blue dye and radiocolloid. Nineteen studies analyzed the IR 
of SLNB using ICG solely and 12 studies analyzed ICG in combination with radiocolloid. When 
data from all included articles is aggregated, a total of 44,172 patients underwent SLNB with 
a median of 103 patients (range: 4−5,611) per study. In the studies where the number of SLNs 
identi!ed was reported, blue dye identi!ed 12,623 SLNs in 6,052 patients with a mean of 2.09 
SLNs per patient, radiocolloid identi!ed 1,6175 SLNs in 7,455 patients with a mean of 2.17 SLNs 
per patient, blue dye and radiocolloid both identi!ed 37,680 SLNs in 19,917 patients with a 
mean of 1.89 SLNs per patient. The SLN was positive in 14.6% in SLNs detected with blue dye, 
11.5% detected with radiocolloid, and 23.9% detected with both blue dye and radiocolloid. 
ICG identi!ed 2,697 SLNs in 947 patients with a mean of 2.85 SLNs per patient. Combined with 
radiocolloid, ICG identi!ed 353 SLNs in 194 patients with a mean of 2.87 SLNs per patient. Table 
1 and Table 2 provide an overview of the number of patients per study, the mean SLN, IR, FNR, 
and the duration of follow-up for all breast carcinoma and melanoma studies, respectively. In 
Table 3, an overview is shown for SLNB using ICG alone or combined with radiocolloid.
Identi"cation rate and false negative rate
IR and FNR for SLNB using solely blue dye, solely radiocolloid, and these two combined are 
presented in Table 1 and Table 2, for breast cancer and melanoma patients, respectively. IR and 
FNR for SLNB for SLNB using ICG, either solely or combined with radiocolloid and/or blue dye, 
are presented in Table 3. The pooled IR and FNR for all techniques are presented in Table 4 and 
Table 5, pooled per tumor type for the time periods 1992−2000, 2001−2006, and 2007−2012.
Multivariate analysis
In breast carcinoma, multivariate factors signi!cantly associated with SLN IR were the following: 
when solely blue dye was used in SLNB (median: 0.87), massage of the breast following 
injection of blue dye (vs. no massage; OR 3.5, range: 1.2−10.6, P=0.02) was identi!ed as an 
independent factor to increase SLN detection. When solely radiocolloid was used (median: 
0.96), a prospective study design (vs. retrospective; OR 6.9, range: 1.3−38.4, P=0.03) was 
associated with a higher SLN detection rate. When radiocolloid and blue dye were combined 
(median: 0.97), SLN detection rate was found to increase with ascending year of publication 
since the time period of 1992−2000 (vs. 2001−2006; OR 13.0, range: 1.4−119.1 and 2007−2012; 
OR 20.0, range: 2.0−203.3, P=0.04). No independent factors were identi!ed for SLN detection 
rate when solely ICG (median: 0.98) or a combination of radiocolloid and ICG (median: 0.96) 
was used.    
In melanoma, multivariate factors signi!cantly associated with SLN IR were the following: when 
solely ICG was used, the volume of injection (in ml) was associated with SLN IR (OR 9.5, range: 
1.1−71.0, P=0.03). When radiocolloid and blue dye were combined, the volume of injection 
of blue dye was identi!ed as an independent factor (OR 19.7, range: 1.3−289.1, P=0.04). No 
signi!cant factors were identi!ed for the use of solely blue dye, radiocolloid, and radiocolloid 
combined with ICG.
In addition to SLN IRs, logistic regression was performed to identify factors associated with FNRs. 
Again, analyses were strati!ed to technique and performed separately for breast carcinoma and 
melanoma. In both breast carcinoma and melanoma, no univariate or multivariate signi!cant 
predictive factors were identi!ed for any of the techniques. 
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Giuliano49 1997 Blue 107 93.5% 0.0%
Barnwell50 1998 Combi 42 1.0 90.0% 0.0%
Crossin51 1998 Radio 50 2.0 84.0% 2.4%
Flett52 1998 Blue 68 82.4% 5.4%
Kapteijn53 1998 Blue 30 1.4 86.7%
Krag3 1998 Radio 443 2.6 93.2% 11.0%
Ratanawichitrasin54 1998 Blue 40 1.6 87.5%
Snider55 1998 Radio 80 2.2 87.5% 7.0%
Jaderborg56 1999 Combi 79 1.5 81.0% 5.0%
Kollias57 1999 Blue 19 94.7%
Radio 51 68.6%
Combi 47 89.0% 6.5%
Mo#at58 1999 Radio 70 2.1 98.6%
Morgan59 1999 Blue 44 72.7% 16.7%
Morrow39 1999 Blue 50 88.0%
Combi 42 86.0%
Veronesi60 1999 Radio 376 98.7% 6.7%
Combi 54 68.5%
Winchester61 1999 Radio 180 3.1 90.0% 2.2%
Canavese62 2000 Blue 55 65.5% 23.0%
Combi 48 94.0% 12.5%
Cox63 2000 Bluea 1147 2.1 80.3%
Radioa 1147 2.1 88.6%
Combi 1147 2.1 96.0% 1.0%
Doting64 2000 Combi 136 1.7 93.0% 5.1%
Fraile65 2000 Radio 132 2.0 96.2% 4.0%
Lauridsen38 2000 Bluea 80 90.0%
Radioa 80 92.5%
Combi 80 2.0 98.0% 0.0%
Liu66 2000 Combi 41 1.5 93.0%
Rodier67 2000 Blue 74 82.4% 8.0%
Tsugawa68 2000 Bluea 48 75.0%
Radioa 48 66.6%
Combi 48 90.0% 4.7%
Derossis22 2001 Bluea 2000 82.9%
Radioa 2000 90.1%
Combi 2000 97.0%
Feggi69 2001 Radio 73 1.0 100.0%
Mateos70 2001 Bluea 65 72.3% 16.7% 20^
Radioa 80 1.2 91.2% 17.0%
Combi 80 91.0%
Sato71 2001 Radio 75 1.9 98.7%
Simmons72 2001 Blue 30 1.8 90.0%
Tafra73 2001 Combi 535 1.6 87.0% 5.2%
Tanis74 2001 Combi 60 2.2 97.0% 8^
Xavier75 2001 Blue 6 100.0%
Combi 50 100.0% 2.0%
Watanabe76 2001 Radio 87 2.0 100.0%
Feezor77 2002 Radio 118 1.8 98.3%
Kern78 2002 Combi 187 2.4 98.0% 0.0%
Jastrzebski79 2002 Combi 123 88.0%
Table 1. Identi!cation rates reported in studies for sentinel lymph node biopsy using blue dye, radiocolloid, or a 
combination of these two in breast carcinoma patients.
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Shimazu80 2002 Bluea 62 1.5 79.9%
Radioa 93 92.5%
Combi 93 2.0 96.0% 5.6%
Nos81 2003 Blue 324 2.1 85.5% 11.1%
Reitsamer82 2003 Combi 157 2.0 99.0%
Simmons83 2003 Bluea 112 92.9% 84*
Radioa 112 89.3%
Combi 112 96.0%
Eldrageely84 2004 Bluea 164 90.2%
Radioa 164 94.5%
Combi 164 1.5 98.0%
Gray85 2004 Combi 546 1.3 99.0%
Lin33 2004 Blue 150 82.7%
Radio 94 96.8%
Combi 76 97.0%
King27 2004 Bluea 1719 84.3%
Radioa 1719 97.3%
Combi 1719 99.0%
Nour86 2004 Blue 54 83.3% 0.0%
Radovanovic87 2004 Blue 50 1.7 68.0% 18.0%
Combi 150 83.0% 4.5%
Wessem, van88 2004 Bluea 132 84.1% 32*
Radioa 132 95.5%
Combi 132 1.4 97.0% 6.0%
Hung89 2005 Blue 57 1.8 86.0% 5.0%
Combi 61 2.1 100.0% 0.0%
Syme90 2005 Blue 93 1.3 95.7% 20.8%
Combi 257 1.8 89.0% 2.8%
Teal91 2005 Bluea 99 2.2 81.8%
Radioa 99 2.2 98.0%
Combi 99 2.2 99.0%
Argon25 2006 Bluea 100 1.4 88.0%
Radioa 100 1.8 96.0%
Combi 100 1.6 98.0%
Golshan92 2006 Blue 141 2.0 96.5%
Lo93 2006 Radio 175 1.1 94.3% 2.5%
Combi 758 2.0 89.0% 5.8%
Povoski94 2006 Radio 400 95.0%
Combi 267 97.0%
Takei95 2006 Bluea 308 1.7 96.8% 33^
Radioa 308 1.4 95.8%
Combi 308 1.9 99.0%
Zaman96 2006 Combi 32 97.0% 0.0%
Kargozaran97 2007 Bluea 124 1.6 92.7% 23^
Radioa 124 1.7 97.6%
Combi 124 98.0%
Krag37 2007 Combi 5536 1.3 97.0%
Nathanson98 2007 Bluea 600 89.3%
Combi 600 96.0%
Rodier36 2007 Bluea 449 94.7% 48^
Radioa 449 97.1%
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Varghese99 2007 Blue 173 1.5 96.5% 3.7%
Combi 156 2.5 99.0% 2.5%
Yen100 2007 Radio 213 3.5 97.2% 4.4%
Bines26 2008 Radio 208 2.0 93.8%
Combi 167 1.9 96.0%
Mudun101 2008 Radio 228 97.4% 3.1%
Thompson40 2008 Combi 236 1.6 96.0%
Zakaria102 2008 Bluea 401 88.0%
Combi 401 100.0%
Climaco103 2009 Combi 46 76.0%
Koukouraki104 2009 Bluea 250 94.4%
Combi 250 100.0%
Mathelin105 2009 Bluea 100 2.7 65.0% 28*
Radioa 100 2.7 94.0%
Combi 100 2.7 99.0%
Hayashida106 2010 Bluea 640 2.4 79.7%
Radioa 640 2.4 94.7%
Combi 640 2.4 98.0%
Kang23 2010 Radio 1353 2.9 98.4%
Combi 2049 2.7 98.0%
Krikanova107 2010 Blue 332 94.6%
Narui108 2010 Blue 234 3.4 99.6% 54^
Straver109 2010 Bluea 1953 88.3%
Radioa 1953 95.8%
Combi 1953 97.0%
Yararbas110 2010 Radio 200 98.0%
Lida111 2011 Combi 258 99.0% 7.7%
Mieog112 2011 Bluea 30 1.5 83.3%
Radioa 30 1.5 100.0%
a  Blue dye and radiocolloid were used in the same procedure. SLN identi!cation rates were recorded separately. 
b Follow-up period in median (^) or months (*).
Table 1 (continued)
SLN, sentinel lymph node
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Thompson113 1995 Combi 118 87.0% 5.2%
Albertini114 1996 Bluea 106 69.5%
Combi 106 1.9 96.0% 0.0% 60*
Thompson115 1997 Bluea 21 83.0%
Radioa 21 87.2%
Combi 21 2.2 91.3%
Wells116 1997 Bluea 58 2.3 67.0%
Combi 36 95.0% 0.0% 12^
Bartolomei117 1998 Bluea 25 72.0%
Radioa 25 100.0%
Combi 25 1.5 100.0% 0.0% 11*
Bedrosian118 1999 Blue 23 74.0%
Combi 80 1.8 94.7%
Bostick119 1999 Bluea 87 95.1%
Radioa 87 92.3%
Combi 87 1.6 97.6% 0.0% 16*
Gennari120 1999 Combi 133 1.6 99.0% 3.8% 19^
Gershenwald121 1999 Combi 612 1.7 95.0% 40^
Morton122 1999 Blue 453 94.9%
Combi 727 98.3% 3.7%
Jansen123 2000 Combi 200 2.2 99.5% 3.9%
Jansen124 2000 Combi 30 2.3 90.0% 9.1% 23*
Landi125 2000 Blue 25 1.5 88.0%
Combi 425 1.6 99.5% 1.2% 18^
Oliveira Filho126 2000 Bluea 64 76.0%
Radioa 64 97.0%
Combi 64 1.4 100.0% 1.9% 11^
Temple127 2000 Combi 56 2.2 98.0% 4.5% 12^
Tremblay128 2000 Radio 36 2.0 97.2% 0.0% 14^
Villa129 2000 Bluea 88 1.9 94.3%
Radioa 49 98.0%
Combi 49 98.0%
McMasters130 2001 Bluea 1184 69.0%
Combi 1184 2.4 99.7% 2.0%
Medina-Franco131 2001 Bluea 38 68.4%
Radioa 38 89.5%
Combi 38 97.0% 2.9% 15*
Neubauer132 2001 Radio 41 1.3 95.1%
Rasgon133 2001 Bluea 24 66.7%
Radioa 24 3.0 91.7%
Combi 24 92.0% 10.5% 18*
Tavares134 2001 Radioa 19 95.0%
Combi 19 1.7 95.0% 0.0%
Eicher135 2002 Bluea 43 27.9%
Radioa 43 90.7%
Combi 43 3.6 98.0% 0.0%
Ferrone136 2002 Combi 126 2.0 100.0% 25*
Patel137 2002 Bluea 48 73.0%
Radioa 56 2.4 93.0%
Combi 48 96.0% 1.9% 20^
Table 2. Identi!cation rates reported in studies for sentinel lymph node biopsy using blue dye, radiocolloid, or a 
combination of these two in melanoma patients.
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Chao138 2003 Bluea 254 2.1 59.1%
Radioa 321 2.8 97.0% 2.2% 16^
Estourgie139 2003 Combi 250 2.3 100.0% 3.2% 72^
Schmalbach140 2003 Blue 80 2.2 96.0% 4.5% 25^
Vidal-Sicart141 2003 Bluea 315 70.1%
Radioa 435 1.8 98.8% 1.9% 26*
Weiss142 2003 Bluea 30 67.0%
Radioa 30 100.0%
Combi 30 1.9 100.0%
Alex143 2004 Bluea 16 81.3%
Radioa 43 97.6% 2.6% 82*
Combi 16 100.0%
Chakera144 2004 Radioa 241 2.6 98.0%
Combi 194 1.7 100.0% 1.1% 15^
Gipponi145 2004 Blue 39 1.4 89.7%
Combi 126 1.9 100.0% 4.4% 17^
Rossi146 2004 Combi 1313 2.0 99.3% 3.5% 31^
Topping30 2004 Combi 347 2.1 99.0% 1.7% 60^
Shpitzer147 2004 Blue 8 1.7 88.0%
Combi 22 2.0 96.0% 3.8% 31^
Carlson148 2005 Radioa 132 2.1 96.9% 6.4% 35*
MacNeill149 2005 Combi 44 93.0% 0.0% 22*
Doting150 2006 Bluea 36 63.9%
Radioa 36 91.7%
Combi 36 2.7 92.0% 6.9% 54^
Gad151 2006 Combi 278 2.2 98.0% 2.5% 31^
Lin152 2006 Combi 114 4.0 97.0% 4.0% 84*
Oliveira Filho153 2006 Blue 47 1.5 100.0%
Radio 47 1.6 100.0%
Combi 94 1.6 100.0% 2.7% 20^
Cecchi154 2007 Combi 30 1.3 100.0% 21.1% 27*
Kilpatrick155 2007 Bluea 316 88.4%
Radioa 316 97.4%
Combi 316 2.8 97.8% 4.7% 19*
Koskivuo156 2007 Combi 305 2.4 97.0% 2.0% 21*
Teltzrow157 2007 Radio 106 2.3 89.0% 9.0% 47*
Gomez-Rivera158 2008 Combi 111 3.2 100.0% 5.6% 34^
Liu159 2008 Bluea 159 60.2%
Combi 159 100.0%
Mattsson160 2008 Combi 422 2.1 97.0% 4.2% 12^
Roulin28 2008 Combi 327 2.0 99.1% 2.8% 34*
Kelly161 2009 Combi 40 68.0% 9.5% 40^
Kovacevic162 2009 Bluea 40 95.0%
Radioa 40 100.0%
Combi 40 1.9 100.0% 16.7% 18*
Koskivuo163 2011 Combi 423 96.0% 2.5% 36^
Leong164 2011 Radioa 47 2.3 98.9%
Liu165 2011 Combi 571 3.4 100.0%
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Noro167 2011 Blue 47 83.0%
Combi 74 95.9%
Rughani29 2011 Combi 697 1.9 99.7% 3.0% 46^
Table 2 (continued)
a  Blue dye and radiocolloid were used in the same procedure. SLN identi!cation rates were recorded separately. 
b Follow-up period in median (^) or months (*).
SLN, sentinel lymph node
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Motomura168 BC 1999 Green 150 1.7 76.7% 1.1%
Motomura169 BC 2001 Green 93 1.8 83.9% 1.9%
G+R 138 94.9% 0%
Kitai17 BC 2005 Green 18 2.8 94.4%
Tagaya170 BC 2008 Greena 25 5.4 100% 6*
Bluea 25 2.3 92.0%
Murawa171 BC 2009 G+R 30 96.7% 0.1%
Tanaka172 MM 2009 Radioa 4 100.0%
Greena 4 100.0%
G+R 4 100.0%
Hirche173 BC 2010 Green 43 2 97.7% 6.6%
Abe174 BC 2011 Greena 128 3.1 100%
Bluea 128 65.6%
Aoyama175 BC 2011 Green 312 3.4 100% 1.7% 49^
Tagaya176 BC 2011 Green 50 3.7 100% 6*
Fujisawa177 MM 2011 Bluea 6 2 100.0%
Radioa 5 1.8 100.0%
Greena 6 2.2 100.0%
G+R+B 6 2.2 100.0%
Namikawa178 MM 2011 Bluea 49 2 85.7% 5.6%
Radioa 49 2.5 95.9% 5.6%
Greena 49 4 61.2% 3.89%
G+R+B 49 4 100.0% 0% 20^
Hirche179 BC 2012 Green 47 2 97.9% 5.3%
Polom180 BC 2012 G+R 49 2.3 95.9%
Brouwer181 MM 2012 Bluea 7 1.3 71.4%
Fujisawa182 MM 2012 Bluea 15 1.7 93.0%
Radioa 15 1.7 100.0%
Greena 15 2 100.0%
G+R+B 15 2 100.0%
Polom183 MM 2012 Radioa 10 100.0%
Greena 10 100.0%
G+R 10 2.3 100.0%
Sto#els184 MM 2012 Radioa 22 100.0%
Greena 22 100.0%
G+R 22 2.8 100.0% 0% 1.3*




Table 3. Identi!cation rates reported in studies combining radiocolloid, vital blue dye, and/or indocyanine green 
in breast carcinoma and melanoma patients.
BC, breast carcinoma; G+R, SLNB using green dye + radiocolloid; G+R+B:,SLNB using green dye + radiocolloid + blue 
dye; MM, malignant melanoma; SLN, sentinel lymph node
a Blue dye, radiocolloid, and/or indocyanine green were used in the same procedure. SLN identi!cation rates 
were recorded separately.  bIndocyanine green was used in 67 out of 562 patients.
b Follow-up period in median (^) or months (*).
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Table 4. Pooled identi!cation rate for sentinel lymph node biopsy for all studies, breast carcinoma studies, and 
melanoma studies per technique.
Pooled value Breast carcinoma Melanoma





Blue dye alone Whole period 84% 83-86% 85% 83-88% 84% 83-84%
1992-2000 84% 81-87% 81% 76-86% 91% 91-92%
2001-2006 81% 78-84% 86% 82-91% 72% 61-84%
2007-2012 88% 85-91% 87% 84-91% 89% 82-96%
Radiocolloid alone Whole period 95% 95-96% 94% 93-95% 99% 99-99%
1992-2000 92% 90-93% 88% 84-91% 100% 100-100%
2001-2006 95% 94-97% 96% 94-97% 97% 96-97%
2007-2012 98% 97-98% 97% 96-98% 100% 99-100%
Combination radio- 
colloid and blue dye
Whole period 96% 96-97% 95% 94-95% 98% 98-98%
1992-2000 95% 94-95% 91% 88-94% 97% 97-98%
2001-2006 97% 96-97% 96% 95-96% 99% 98-99%
2007-2012 98% 97-98% 97% 96-98% 99% 98-99%
ICG Whole period 99% 98-99% 95% 95-96% 100% 100-100%
1992-2000 77%* 76-77% 77%* 76-77% No studies
2001-2006 89% 79-99% 89% 79-99% No studies
2007-2012 100% 100-100% 100% 100-100% 100% 100-100%
Combination radio- 
colloid and ICG
Whole period 99% 99-100% 96% 95-97% 100% 100-100%
1992-2000 No studies No studies No studies
2001-2006 95%* 95-95% 95% 95-95% No studies
 2007-2012 100% 100100% 96% 96-97% 100% 100-100%
CI, con"dence interval; ICG, indocyanine green.
* Derived from only one study.
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Table 5. Pooled false negative rate for sentinel lymph node biopsy in all studies, breast carcinoma studies, and 
melanoma studies per technique.
Pooled value Breast carcinoma Melanoma





Blue dye alone Whole period 3.4% 3.0–3.8% 3.2% 2.8–3.6% 6.1%* 5.2–7.1%
1992–2000 3.4% 1.1–5.8% 3.4% 1.1–5.8% No studies
2001–2006 3.5% 1.7–5.3% 3.5% 1.7–5.3% No studies
2007–2012 4.5% 1.3–7.6% 2.9%* 2.7–3.1% 6.1%* 5.2–7.1%
Radiocolloid alone Whole period 2.6% 1.9–3.3% 2.2% 1.8–2.6% 3.4% 2.6–4.2%
1992–2000 1.6% 0.7–2.4% 2.0% 1.3–2.7% 0.5% 0.0–1.3%
2001–2006 2.7% 0.7–4.7% 2.7% 0.7–4.7% No studies
2007–2012 4.5% 3.0–6.0% 2.3% 1.5–3.0% 6.9% 5.5–8.3%
Combination radio- 
colloid and blue dye
Whole period 2.1% 1.9–2.3% 1.5% 1.3–1.7% 2.6% 2.3–2.9%
1992–2000 1.9% 1.7–2.1% 1.9% 1.5–2.2% 1.9% 1.6–2.3%
2001–2006 1.9% 1.5–2.3% 1.1% 0.7–1.6% 2.5% 1.9–3.1%
2007–2012 3.7% 2.8–4.5% 1.7% 0.0–3.4% 3.4% 3.0–3.8%
ICG Whole period 4.4% 3.3–5.4% 2.8% 2.3–3.3% 14.3%* 12.9–15.7%
1992–2000 2.7%* 2.5–2.9% 2.7%* 2.5–2.9% No studies
2001–2006 4.3%* 3.9–4.7% 4.3%* 3.9–4.7% No studies
2007–2012 5.2% 2.6–7.8% 2.5% 2.3–2.7% 14.3%* 12.9–15.7%
Combination radio- 
colloid and ICG
Whole period 0.1% 0.1–0.1% 0.1% 0.1–0.1% 0.0% 0.0–0.0%
1992–2000 No studies No studies No studies
2001–2006 0.0% 0.0–0.0% 0.0% 0.0–0.0% No studies
 2007–2012 0.1% 0.1–0.1% 3.3% 0.0–9.8% 0.0% 0.0–0.0%
CI, con"dence interval; ICG, indocyanine green.
* Derived from only one study.
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Figure 1. Schematic overview of the sentinel lymph node procedure in a breast cancer patient. Before surgery, 
the patient is injected peritumorally with a radiocolloid (A) and/or vital blue dye (B). Both substances "ow along 
with the lymphatic "uid and accumulate in the sentinel lymph node. During surgery, the surgeon localizes 
the sentinel lymph node by visual inspection (blue dye) and a gamma probe (radiocolloid). After excision, the 
sentinel lymph node is evaluated for the presence of metastases (M) by a pathologist.
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Figure 3. Intraoperative sentinel lymph node localization using a near-infrared "uorescence (NIRF) imaging 
device in combination with indocyanine green (ICG). The NIRF imaging device is positioned above the patient 
(A) and can be covered in sterile drapes for intraoperative use (not shown). A color image of the surgical !eld 
is shown, representing the axillary region of a breast cancer patient (B). After peritumoral injection with ICG, 
the NIRF imaging device is applied to visualize the sentinel lymph node (SLN) and corresponding lymphatic 
vessels (C). By adjusting the threshold for the "uorescent signal, the SLNs (indicated by red circles) become 
visible (D). For anatomical positioning of the "uorescent signal, the signal can be superposed on a color image 
of the surgical !eld as a contrasting pseudocolor (e.g., green; E).  
Figure 2. Lymphoscintigraphy (A) and SPECT/CT (B) images of a patient with a primary melanoma on the scalp 




SLNB is a widely accepted prognostic procedure in breast carcinoma and melanoma patients. 
Although a survival bene!t compared to watchful waiting with ultrasound is yet to be shown, 
the status of the SLN is the most important predictor of prognosis and tumor recurrence for 
early-stage breast carcinoma and melanoma.19-21 In contrast to the worldwide acceptation of 
the procedure, controversies remain regarding the technical aspects of the procedure. The 
current study represents a systematic review of the published literature on SLNB in breast 
carcinoma and melanoma patients to evaluate the di#erent SLNB techniques and judge them 
on their merits.
Identi"cation rates of SLNB using blue dye and radiocolloid
The present study showed that pooled SLN IRs in breast carcinoma/melanoma patients are 
high for SLNB using solely blue dye (85/84%), solely radiocolloid (94/99%), and blue dye 
and radiocolloid combined (95/98%) and that FNRs are low (3.2/6.1%, 2.2/3.4%, 1.5/2.6%, 
respectively). In addition, IRs for all studied techniques steadily increased over time. For SLNB 
using solely radiocolloid, the IR of SLNB in breast carcinoma/melanoma patients has increased 
from 88/100% in 1992−2000 to 97/100% in 2007−2012. In the latter period, IR was similar 
compared to SLNB using a combination of radiocolloid with blue dye (97/99%). The increase 
in IR during the last 18 years is likely due to the increase in gained experience by the surgeons 
performing SLNB. Several studies have already reported that with the increase of gained 
experience by the surgeons, the IR of SLNB with solely radiocolloid also steadily increased with 
a decline in the marginal bene!t o#ered by using blue dye.22,23 
In addition, there are some disadvantages of the use of blue dye. First, the use of blue dye as 
a guide in SLNB may lead to increasing tissue damage when tracing blue-stained lymphatics 
to the SLN compared to the use of a gamma probe to guide the path of dissection.24 Second, 
allergic reactions to blue dye are seen in 0.14% to 3% of the patients, including urticaria, 
skin  rash, erythema, blue hives, cardiovascular collapse, and anaphylactic shock.25-31 Other 
side e#ects are temporary skin tattooing, blue discoloration of the operative !eld following 
peritumoral injection, blue-colored urine for up to 24 hr following administration, and a 
factitious drop in intraoperative oxygen saturation measured by pulse oximetry.24 Furthermore, 
pregnancy is a relative contraindication due to the unknown teratogenicity and long-term 
toxicity to the fetus. 
However, this should not preclude the use of blue dye by those surgeons who have mastered 
the technique of blue dye and have produced reliable results with high IRs and low FNRs. 
SLN mapping with a radiotracer is expensive and prohibited in most developing countries.32 
Moreover, not all hospitals are equipped with a cyclotron to produce radioisotypes. SLN 
mapping using blue dye only should be encouraged in hospitals where radiotracers are not 
available as the IR for blue dye only is acceptable.  Nevertheless, in the current study, the SLN 
IR when using solely blue dye was found to be 8% lower compared to solely radiocolloid and 
radiocolloid combined with blue dye. Furthermore, our results indicate that, in the present era, 
the addition of blue dye to radiotracers does not increase the SLN IR. Taken together with the 
disadvantages of blue dye, we advise surgeons working in hospitals where radiotracers are 
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False negative rate
The pooled FNR for all techniques in all articles was at its peak in the last period (2007−2012), 
while the IR of SLNB has increased over time. This apparent contradiction might be due to 
the fact that only few surgeons were experienced with the SLNB procedure shortly after its 
introduction. When the procedure got widely accepted, less experienced surgeons had to 
perform SLNB, leading to an increased FNR. It is expected that the FNR will decline when 
surgeons are more familiar with the SLNB technique.
Type of dye
Apart from the debate on whether SLNB should be performed with blue dye, radiocolloid, or 
a combination of the two, there are also controversies on the type of dye or radiocolloid. For 
both breast carcinoma and melanoma studies included in this review, we analyzed di#erent 
types of blue dye (patent blue, isosulfan blue, lymphozuran blue, or methylene blue) or 
radiocolloid (99mTc-sulfer colloid, 99mTc-human serum albumin, 99mTc-dextran 500, 99mTc-phytate, 
and 99mTc-tilmanocept). In the present study, univariate or multivariate analysis did not show 
an association with either the type of blue dye or the type of radiocolloid on IR or FNR. 
According to these results, the choice of the type of dye/radiocolloid should be based on the 
surgeon’s preference or on the type of dye with the least side e#ects.
Injection site
Another issue in lymphatic mapping concerns the optimal injection site for dye/radiocolloid 
in patients with breast carcinoma. Whereas a consensus exists on injection sites for SLNB in 
melanoma patients (intradermal injection),24 this is currently not the case in breast carcinoma.
In the studies included in this review, blue dye and radiocolloid were injected intradermally 
(18 and 19 studies), subdermally (4 and 4 studies), intraparenchymally (8 and 3 studies), 
and subareolarly (12 and 12 studies). The present study showed no di#erence in IR for 
di#erent injection sites. The choice on injection site can therefore be based on the surgeon’s 
preference, taking previously reported practical advantages of the di#erent injection sites into 
consideration.33-36 The injection of blue dye and radiocolloid in breast carcinoma is presented 
in Fig. 1.
Injection volume and massage
In breast carcinoma, a larger volume of injected blue dye was associated with a higher SLN 
IR, although this was only the case when blue dye was combined with radiocolloid. It is 
unclear why the volume of injected dye is only associated with a higher IR when using the 
combined technique. When SLNB was performed using solely blue dye, massage of the breast 
after dye injection was associated with higher IRs. Postinjection massage increases the "ow of 
lymph "uid, signi!cantly increasing the entry of blue dye and radiocolloid into the lymphatic 
capillaries.24
Lymphoscintigraphy
Lymphoscintigraphy was not used in 4 of 126 studies (3.2%, all breast carcinoma patients) that 
used radiocolloid solely or in combination with blue.37-40 In these studies, only a hand-held 
gamma probe was used before incision to identify hot spots representing the location of the 
SLNs. Preoperative lymphoscintigraphy is important for providing a road map to guide the 
surgeon in identifying the regional nodal basin and estimating the location of SLNs.41 It is used 
to identify the lymph drainage basin, determine the number of SLNs, di#erentiate SLNs from 
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subsequent nodes, locate the SLN in an unexpected location, and mark the SLN over the skin 
for biopsy. Moreover, single-photon emission computed tomography/computed tomography 
(SPECT/CT) has shown important bene!ts, as a complementary modality for planar lympho-
scintigraphy, in sentinel lymph node mapping.42 This type of image fusion provides better 
anatomical benchmarks, provides schematic information about the sentinel node site, and 
(perhaps most importantly) is easy to understand for surgeons, medical sta#, and patients.43 
Lymphoscintigraphy and SPECT/CT images of a melanoma patient are presented in Fig. 2.
De"nition of sentinel lymph node
Despite ongoing discussions, there is no consensus on the clinical de!nition of a SLN.24 For 
this reason, a fair number of studies that used unconventional de!nitions were excluded from 
our study.10,46-53 In the present review, only studies were included that de!ned a hot node as 
‘nodes hotter than the background’ or as ‘nodes with more than 10% of the hottest node’s 
radioactivity’ (Supplementary File 1). The use of either the !rst or the latter de!nition did not 
in"uence IRs or FNRs for SLNB in both breast carcinoma and melanoma patients, suggesting 
that less lymph nodes were removed when using the 10% rule while the IR and FNR remained 
similar.
Near-infrared !uorescence imaging with indocyanine green
As an alternative to the conventional SLNB procedure, SLNB using the "uorescent dye 
ICG was recently introduced in the clinic.17 ICG has been used for the last three decades in 
patients for the study of organ perfusion and ophthalmology and has a safe and well-known 
pharmacological pro!le. When excited at the appropriate wavelength, ICG emits photons in 
the near-infrared "uorescence (NIRF) range of around 800 nm. 
Because near-infrared light is invisible to the human eye, a special optical imaging system is 
needed to visualize the near-infrared signal in the surgical !eld. Already, several studies have 
reported on a prototype NIRF optical imaging system, with which the SLN can be detected 
noninvasively with high accuracy and sensitivity following subcutaneous injection with 
ICG.17,32,44-46 After injection, ICG "ows along with the lymph "uid and accumulates in the SLNs 
within minutes, enabling rapid detection and visualization of SLNs as "uorescent hot spots. No 
adverse reactions were reported in any of the conducted trials. 
NIRF optical imaging enhanced with ICG o#ers some considerable advantages to the current 
SLN procedure: the technique o#ers a high resolution, is relatively cheap, makes use of 
non-ionizing radiation, and o#ers high sensitivity and speci!city rates.47 The most important 
limitation of "uorescence imaging is the limited penetration depth of optical signals due 
to the absorption and scattering of photons when propagating through tissue.48 The use 
of "uorescent dyes in the near-infrared spectral range, e.g., ICG, reduces absorption and 
scattering of photons true tissue, thereby increasing tissue penetration of the optical signal 
up to several centimeters. Furthermore, tissue auto"uorescence in the near-infrared spectral 
range is minimized, resulting in an increased signal-to-noise ratio.48 
In the present study, the mean number of identi!ed SLNs per patient when using ICG was 
considerably higher (ICG: 2.85 SLNs, ICG + radiocolloid: 2.87 SLNs) compared to solely blue 
dye (2.09 SLNs), solely radiocolloid (2.17 SLNs), or a combination of the two (1.89 SLNs). This 
di#erence might be explained by the small molecular size of ICG, facilitating rapid di#usion 
throughout the lymphatic system. Indeed, IRs up to 100% are described only 5 to 15 minutes 
following peritumoral injection when using solely ICG. A potential drawback of this rapid 
spread is that lymph nodes are excised that are not truly sentinel nodes (i.e., no !rst-draining 
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lymph nodes), leading to overtreatment and accompanying comorbidity. To solve this 
problem, ICG can be noncovalenty linked to human serum albumin, of which the molecular  size 
is substantially higher.32 In addition to reducing the spread of ICG, the binding to human serum 
albumin also increases the brightness of the "uorescent signal as it reduces quenching of the 
"uorescent molecules (i.e., reduction of "uorescent signal due to photons being absorbed by 
nearby "uorescent molecules).
CONCLUSION
The current meta-analysis provided data that favor the use of radiocolloid solely or radiocolloid 
combined with a blue dye for the identi!cation of the SLN. Performing SLNB with radiocolloid 
solely is the technique of choice for experienced surgeons, since blue dye has multiple 
disadvantages. Moreover, NIRF imaging with ICG as a "uorescent dye seems a promising 
technique, although hurdles like the limited penetration depth of optical signals still reduces 
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SUPPLEMENTARY FILE 1
Search method and inclusion/exclusion criteria
A computer-aided search was conducted using the following databases: PubMed/Medline; 
Database of Abstracts of Reviews of E#ects (DARE) database; Embase; and Cochrane. PubMed 
was searched as the primary source for scienti!c articles. Search terms included: “breast 
carcinoma”, “breast neoplasm”, or “melanoma” in combination with “sentinel lymph nodes“, 
“lymphatic mapping”, “lymph node mapping”, “radioisotopes”, “radiocolloid”, “technetium”, 
“patent blue violet”, “methylene blue”, “isosulfan blue”, and “blue dye”.
We augmented our computerized literature search by manually reviewing the reference lists of 
identi!ed studies and relevant reviews. In addition, Google was searched as a complementary 
source for related studies. Two reviewers (MGN/RGP) independently assessed the eligibility 
of all identi!ed studies by checking titles and abstracts. Studies that clearly did not meet 
the inclusion criteria were excluded. Full text articles were retrieved of potentially relevant 
references. If there was any disagreement between the readers, a consensus was reached by 
discussion or by consulting a third reviewer (GMD/HJH). Data from the articles was retrieved 
and imported into a data abstraction spreadsheet (Microsoft Excel SP3, Microsoft Corp., 
Redmond, USA) speci!cally designed for the review.
Criteria for inclusion were: original study group, intraoperative SLN identi!cation in early-stage 
(stage I or II) breast carcinoma and/or melanoma using radiocolloid tracer, blue dye, ICG, or 
a combination of a radiocolloid tracer with a blue or ICG. Criteria for exclusion were: studies 
not in the English language, studies that were published before 1992, case reports, reviews 
and editorials, studies that did not describe the SLN identi!cation rate (IR), and articles lacking 
a clear de!nition of the SLN. Duplicate articles on the same group or follow-up studies with 
an included subset of previously reported patients were also excluded. The !nal decision 
regarding inclusion was based on the full article. 
The SLN is generally de!ned as the initial lymph node that directly drains the lymph "uid from 
the site of the primary lesion.1 Despite a good understanding of the theoretical de!nition of 
a SLN, there is no consensus on the clinical de!nition of SLNs detected with a radiotracer.2  
The SLN has been described as the hottest node, !rst node visualized on lymphoscintigraphy, 
and the node with radioactivity greater than twice or thrice the background radioactivity.1,3 
Data from the Sunbelt Melanoma Trial showed that resection of all blue-stained nodes and all 
nodes with more than 10% of the hottest node’s radioactivity (10% rule) was associated with a 
low estimated false negative rate.4,5 In this systematic review, articles were included only when 
SLNs were de!ned as all blue nodes and all hot nodes that had radioactive counts greater than 
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SYSTEMATIC REVIEW AND META-ANALYSIS OF SENTINEL LYMPH NODE IDENTIFICATION
SUPPLEMENTARY FILE 2
QUADAS quality assessment tool
The following core QUADAS items were assessed in the current review to assess 
methodological quality:
1. Was the spectrum of patients representative of the patients who will receive the test?
• Yes: at least 80% of patients had early-stage breast carcinoma or melanoma.
• No: less than 80% of patients had early-stage disease.
• Unclear: stage of disease was not clear from the available information; or, in studies 
which included both early and late disease, we could not clearly distinguish 
between information on patients with early disease and those with late disease.
2. Where selection criteria clearly described?
• Yes: all relevant information regarding how participants were selected                         
for inclusion in the study has been provided.
• No: selection criteria were not speci!ed.
• Unclear: selection criteria are only partially reported.
3. Is the reference standard likely to correctly classify the target condition? 
• Yes: reference standard is carried out adequately to correctly classify the target 
condition.
• No: reference standard has not been carried out adequately to correctly classify 
the target condition.
• Unclear: there is insu%cient information given to assess whether reference 
standard had been carried out adequately (e.g., no mention of number of SLN 
identi!ed).
4. Is the time period between reference standard and index test short enough to be 
reasonably sure that the target condition did not change between the two tests?
• Because the reference standard and index test are applied simultaneously in SLN 
identi!cation, all items will be scored ‘yes’. 
5. Was the execution of the index test described in su%cient detail to permit replication? 
• Yes: for SLN biopsy using blue dye, description of the execution of the test should 
include type and amount of tracer substance used, site and timing of application 
of tracer substance, and method of detection of tracer substance.
• No: the description does not include details as stated above.




6. Was the execution of the reference test described in su%cient detail to permit its 
replication? 
 
• Yes: for SLN biopsy using radiocolloid tracer, the description includes type 
and amount of tracer substance used, site and timing of application of tracer 
substance, method of detection of tracer substance, and use of scintigraphy.
• No: the above details were not clearly stated.
• Unclear: the description is not adequate to allow replication of the test.
7. Were the reference standard results interpreted without knowledge of the results 
of the index test? 
• Yes: identi!cation of SLNs using the reference standard test was interpreted 
without knowledge on SLN identi!cation using blue dye. 
• No: identi!cation of SLNs using the reference standard test was interpreted 
with knowledge on SLN identi!cation using blue dye. 
• Unclear: insu%cient details given as to whether the reference standard results 
were interpreted with or without knowledge of the results of the index test.
8. Were the index test results interpreted without knowledge of the results of the 
reference standard? 
• Yes: the identi!cation of SLNs using blue dye was interpreted without 
knowledge (blind) on SLN identi!cation using the reference standard.
• No: the identi!cation of SLNs using blue dye was interpreted with knowledge 
on SLN identi!cation using the reference standard.
• Unclear: no description of when and how the index tests results are 
interpreted.
9. Were the same clinical data available when test results were interpreted as would 
be available when the test is used in practice? 
• Yes: the same clinical information was available when the test results were 
interpreted as would be available when the test is used in practice such as age 
of patients, clinical history, any related investigation results.
• No: di#erent clinical information, or more or less clinical data, were available; 
e.g., if tests were interpreted without knowledge of standard clinical data as 
stated above.
• Unclear: insu%cient details given as to what clinical information was available. 
10. Were uninterpretable/intermediate test results reported? 
• Yes: all uninterpretable results were reported.
• No: not all uninterpretable results were reported.
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11. Were withdrawals from the study explained? 
• Yes: all withdrawals from the study were explained.
• No: not all withdrawals were explained.
• Unclear: insu%cient information to assess whether all withdrawals were 
explained.
12. Did the whole or a random selection of the sample receive veri!cation using           
a reference standard of diagnosis? 
• Yes: reference standard (intraoperative SLN identi!cation using 
radiocolloid tracer) has been carried out in the whole population.
• No: reference standard has not been carried out in the whole population.
• Unclear: no clear information about the proportion of patients receiving 
veri!cation using the reference standard.
13. Did patients receive the same reference standard regardless of the index test 
result? 
• Yes: all the patients received the same reference standard regardless of the 
result of the index test.
• No: not all the patients received the same reference standard regardless of 
the result of the index test.
• Unclear: insu%cient information to assess whether all the patients 
received the same reference standard.
14. Was the reference standard independent of the index test (i.e., the index test 
did not form part of the reference standard)? 
• Yes: it is clear that the index test did not form part of the reference 
standard.
• No: it appears that the index test formed part of the reference standard.
• Unclear: insu%cient information is available. 
15. Was the follow-up adequate and was the false negative rate clearly reported?
• Yes: follow-up was adequate (at least 12 months or additional lymph node 
dissection) and the false negative rate was clearly reported.
• No: follow-up was not adequate and the false negative was not clearly 
reported.
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ABSTRACT
Introduction
The use of targeted therapies has substantially increased in breast cancer treatment, exploiting 
the expression of certain tumor markers in cancerous tissue. In addition to systemic therapy, 
tumor markers could also be used to speci!cally deliver optical imaging agents to cancer cells, 
enabling (noninvasive) tumor visualization. The aim of this study was to identify tumor markers 
that bear potential for tumor-targeted optical imaging applications in breast cancer patients.
Methods
Ten membranous and/or extracellular tumor markers were assessed on tissue microarrays of 
invasive breast carcinomas from 449 patients using immunohistochemistry. Markers included 
αvβ3 integrin receptor, CXCR4, CA-IX, CA-XII, EpCAM, FR-α, HER2, MGB1, Notch1 receptor, and 
VEGF-A. Tumor markers were prioritized based on the target selection criteria (TASC) scoring 
system, with scores ≥18 indicating markers of particular interest. 
Results
A total of 439 (97.8%) invasive breast carcinomas were eligible for analysis. Immunohisto-
chemical scoring agreement between observers was 88% (kappa: 0.79, P<0.001). CXCR4, 
EpCAM, and CA-XII were assigned modi!ed TASC-scores of 21, 18, and 18, respectively, 
indicating them to be of particular interest for probe development. When combined, at 
least one of these three markers was expressed in 76.5% of all breast carcinomas. Modi!ed 
TASC-scores for the remaining tumor markers ranged between 9 and 16 points.
Conclusion
We systematically assessed the potential of ten tumor markers for tumor-targeted optical 
imaging in breast cancer patients. CXCR4, EpCAM, and CA-XII were identi!ed as markers of 
particular interest for development of tumor-targeted probes for clinical translation. At least 
one of these tumor markers was homogeneously expressed in approximately 80% of the 




Breast cancer is the most common malignancy in women worldwide.1 In the past decade, 
there has been a substantial change in the treatment of breast cancer, including a steep 
increase in the use of targeted therapies. Several drugs have been developed to complement 
breast cancer treatment by targeting intra- and extracellular tumor markers of the oncogenic 
pathways.2 In addition to functioning as targets for systemic therapy, membranous and 
extracellular tumor markers can also be exploited through targeted delivery of optical imaging 
agents.3,4 Tumor-speci!c optical imaging is considered safe and o#ers some advantages 
over conventional techniques, including high resolution, lack of ionizing radiation, and high 
sensitivity and speci!city.5,6 In particular, the use of near-infrared "uorescence (NIRF) holds 
great promise due to the preferable optical characteristics of near-infrared light, resulting in 
low background (auto)"uorescence and increased tissue penetration, even in women with 
dense glandular tissue.7 
As optical imaging is fundamentally depth limited, one of the most promising applications 
of optical imaging in breast cancer patients is image-guided surgical excision of the tumor 
during breast-conserving surgery. With current techniques, breast-conserving surgery results 
in an inadequate excision of the primary tumor in 20% to 40% of patients.8 This relatively high 
percentage is mainly due to di%culty in localizing the primary tumor and evaluating the extent 
of surgery during surgical procedures. Tumor-targeted optical imaging could complement 
surgery by allowing for intraoperative image-guided tumor localization, tumor excision 
and assessment of surgical margin status in real-time. Several animal and clinical studies 
have already shown the potential of optical imaging to improve the therapeutic outcome of 
surgery by localizing the primary tumor and pinpointing remnant disease following tumor 
resection.6,9-11 
Current research on intraoperative NIRF imaging is directed primarily towards the re!nement 
of imaging systems and the development of non-toxic tumor-targeted imaging agents for 
clinical use.4,11,12 A single tumor-targeted imaging agent that can be applied for all types of 
breast cancers, however, is not yet available and is unlikely to be discovered in the near future 
due to marked breast cancer heterogeneity. A panel of imaging agents targeting di#erent 
tumor markers is therefore needed to make patient-tailored optical imaging available for 
general use.13 Because the portfolio of markers known to be associated with breast cancer 
is still expanding and the development and translation of targeted imaging agents is 
time-consuming and costly, it is necessary to identify those tumor markers that bear potential 
for targeted imaging applications. The aim of the current study was to identify those tumor 
markers that are of particular interest for intraoperative NIRF imaging applications in breast 
cancer patients. Tissue microarrays (TMAs) were used to enable high-throughput analysis of 
hundreds of breast carcinoma samples simultaneously.
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TUMOR MARKERS FOR TARGETED IMAGING APPLICATIONS IN BREAST CANCER
METHODS
Selection of tumor markers
As optical imaging requires the use of relatively large imaging agents which are unlikely to 
pass the membrane of tumor cells, we focused on membranous and/or extracellular tumor 
markers that are known to play a role in breast cancer. From these, we selected a panel of ten 
markers based on availability of selective targeted agents on the market or in clinical trials to 
facilitate clinical translation. Evaluated tumor markers included alpha v beta 3 (αvβ3) integrin 
receptor, C-X-C-chemokine receptor 4 (CXCR4), carbonic anhydrase (CA) IX and XII, epithelial 
cell adhesion molecule (EpCAM), folate receptor alpha (FR-α), human epidermal growth factor 
receptor 2 (HER2), mammaglobin 1 (MGB1), Notch1 receptor, and vascular endothelial growth 
factor A (VEGF-A). 
The αvβ3 integrin receptor is expressed on activated endothelial cells and tumor cells, 
and is reported to play a key role in tumor angiogenesis and metastasis.14,15 CXCR4 is a 
membrane-bound cell surface receptor that plays a role in chemotaxis and cell adhesion and 
is reported to be consistently expressed in human breast cancer cells and metastases.16,17 CA-IX 
and CA-XII are both integral plasma membrane proteins with large extracellular components 
that belong to the carbonic anhydrase (CA) family of zinc metalloenzymes. The enzymes are 
involved in the regulation of the microenvironment acidity and tumor malignant phenotype.18 
CA-XII is associated with good prognosis,19 whereas CA-IX is a marker of poor prognosis in 
breast cancer.20 EpCAM is a transmembrane protein that is involved in cell-cell adhesion in 
normal epithelial cells, and is linked to proliferation of tumor cells.21 FR-α is a membrane-
associated glycoprotein that binds folate with high a%nity and is reported to be associated 
with reduced survival.22 A similar correlation with poor prognosis is reported for the 
well-known transmembrane tyrosine kinase receptor HER2.23 MBG1 is a membrane-associated 
glycoprotein that is expressed in breast cancer and, to a lesser extent, in normal breast tissue.24 
MGB1 is also a member of the epithelial secretoglobin family, of which di#erent secretoglobins 
seem to be involved in cell signaling, immune response, and chemotaxis.25 Notch1 receptor 
is a cell surface protein with a single transmembrane domain that regulates a number of 
cellular properties important in cancer, including cell division, di#erentiation, and survival.26 
VEGF-A comprises a group of growth factors that play a key role in angiogenesis.27 VEGF-A, the 
most important subtype, is associated with invasive tumor growth, metastasis, and reduced 
survival.28-31 VEGF-A can be either membrane-bound or present in the interstitial cell space 
with highest concentrations observed in close proximity of tumor cells.32 
Selection of tumor specimen
A previously described cohort of 449 invasive breast carcinoma specimens collected between 
January 1996 and December 2005 was obtained from the archive of the Department of 
Pathology and Medical Biology, University Medical Center Groningen, The Netherlands.33 
Specimens were selected on the availability of su%cient para%n-embedded tissue. Clinical and 
histopathological data of patients were gathered from pathology reports and medical charts. 
All data were anonymized and the study was conducted in accordance with the Declaration 




Construction of tissue microarrays
Slides from all sample blocks were evaluated for representative areas containing invasive breast 
carcinoma. TMAs were prepared as previously described.34 In brief, the most representative 
area of invasive carcinoma was marked on the original haematoxylin and eosin (H&E) stained 
section. From this marked section, three 0.6 mm punches were taken from the donor blocks 
and mounted in a recipient block using a tissue arrayer (Beecher Instruments, Sun Prairie, USA). 
Immunohistochemistry
Immunohistochemistry (IHC) was performed for all ten tumor markers to assess functional 
extracellular marker expression. Brie"y, 3 μm thick TMA sections were depara%nized with 
xylene and gradually rehydrated through changes of graded ethanol from 100% to distilled 
water. Endogenous peroxidase activity was blocked by incubating TMAs in phosphate-bu#ered 
saline (PBS), pH 6.8, containing 0.3% H2O2 for 30 minutes. In the case of VEGF-A, endogenous 
biotin was additionally blocked using a Blocking Kit (Vector Laboratories, Burlingame, USA). 
Information concerning the primary antibodies used in this study is shown in Table 1. 
Following incubation with the primary antibody, sections were washed with PBS and 
incubated with secondary and tertiary antibodies where appropriate. FR-α was incubated with 
mouse MACH3 (Biocare Medical, Walnut Creek, USA). For visualization of the antibody-antigen
complex, 3,3-diaminobenzidine (DAB) was used. After a !nal wash with distilled water, 
counterstaining was performed with haematoxylin. Sections were then dehydrated through 
rising concentrations of ethanol, mounted with mounting medium, and coverslipped. 
Negative controls consisted of sections processed in the same way but with omission of the 
primary antibody step. Positive control tissue was included as usual.
Digitalization of tissue microarray slides
TMA slides were digitalized using the ScanScope GL Scanner (Aperio Technologies Inc., Vista, 
USA), creating high-resolution !les suitable for IHC scoring. All slides were produced with core 
images linked to a Microsoft AccessTM database containing relevant tissue core information. 
After importing the digital slides into ImageScope® (Aperio Technologies Inc., Vista, USA), each 
individual TMA core on the slide was captured using a snapshot tool, coded, and exported as a 
separate industry-standard TIFF !le.
Scoring of immunohistochemistry
In order to eliminate variation in lighting conditions when using a light microscope, manual IHC 
scoring was performed on digital TMA cores. All cores were randomized prior to IHC scoring to 
minimize bias e#ects. Scoring was performed by a single observer (RGP) after extensive training 
by an experienced pathologist (BvdV). As manual IHC scoring is a time-consuming process, 
especially for more than 13,000 TMA cores, we chose not to duplicate our results. Instead, 
data quality was assessed through validation of IHC scoring in a sample of 100 randomly 
selected TMA cores. Hereto, a senior pathologist (JB) independently performed IHC scoring on 
all selected TMA cores. IHC scores obtained by the observer and the senior pathologist were 
compared and the level of agreement was calculated. 
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Functional tumor marker expression was assessed by evaluating the proportion of tumor cells 
showing no (0), weak (1+), moderate (2+) or strong (3+) membranous staining. Evaluation 
of staining pattern (di#use or focal) was performed both on a microscopic (within spot) 
and a macroscopic (between spots) level. To account for tumor heterogeneity, the average 
proportion and staining intensity were calculated for each tumor. An average membranous 
staining intensity of ≥2+ in ≥10% of tumor cells was considered positive. For VEGF-A and 
CXCR4, thresholds for positivity were set to staining intensity 3+ in ≥10% of tumor cells to 
correct for background staining in normal breast epithelium. Tumors were excluded from 
analysis in the event that all (3 out of 3) TMA cores were missing. 
Assessment of tumor-to-normal ratio
Tumor markers for tumor-targeted imaging applications should provide adequate 
tumor-to-normal (T/N) ratios in order to discriminate between tumor and normal breast tissue. 
For this reason, glandular expression of all ten tumor markers was also evaluated using IHC 
in a set of 15 TMAs derived from normal breast tissue. Tissue specimens were obtained from 
patients who underwent mammoplasty in the absence of breast cancer. The T/N ratio was 
calculated by multiplying the mean staining intensity with the proportion of stained tumor 
cells for the tumor (three-item severity score; TIS-score) and dividing it by the TIS-score for 
normal breast tissue. A T/N ratio ≥3 was considered adequate for imaging purposes.35
Evaluation of target selection criteria
All markers were ranked according to the target selection criteria (TASC) scoring system, which 
was recently proposed by van Oosten et al. to serve as a directive to gain objectivity and insight 
in target selection.36 The scoring system is based on seven favorable target characteristics for 
optical imaging purposes for which each tumor marker is scored: I) extracellular tumor marker 
localization; II) expression pattern; III) tumor-to-normal ratio (T/N); IV) target expression rate; V) 
reported successful use in vivo; VI) enzymatic activity, and VII) internalization. 
TASC was applied to indentify tumor markers that are of special interest for targeted imaging. 
As described above, the scoring system is based on seven favorable target characteristics for 
which each tumor marker is scored. For each characteristic, 0−6 points are granted in order 
of importance (Supplementary Table 1). The maximum TASC score that can be obtained is 22 
points. If a marker scores a total of ≥18 points, it is considered to be a potential target for 
tumor-targeted optical imaging and should be prioritized with regards to clinical translation. 
Markers that are granted <18 points have less favorable characteristics, deeming them less 
suitable for targeted imaging modalities. 
Modi"ed target selection criteria score
The original TASC score is dominated by the percentage of tumors that express the tumor 
marker on their cell membranes or in the extracellular matrix adjacent to the tumor cells. 
TASC assigns up to 6 out of 22 points to expression rates as high as 90%, whereas expression 
rates below 50% are assigned no points (Supplementary Table 1). For intraoperative targeted 
imaging applications, however, tumor markers expressed in less than 50% of the tumors 
can still be of value as long as other characteristics crucial for optical imaging are favorable. 
Importantly, intraoperative imaging allows for analysis of a sample of the tumor prior to the 
surgical procedure (e.g., by core needle biopsy), enabling assessment on whether or not the 
individual tumor expresses the speci!c marker. 
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As the focus in the present study lies on the identi!cation of tumor markers for intraoperative 
NIRF imaging applications, we calculated a modi!ed TASC score, in which the marker is granted 
0, 3, 5, or 6 points based on an expression rate of 0−10%, 10−25%, 25−50%, or 50−100%, 
respectively (Supplementary Table 1).
Preoperative biomarker panel
Besides evaluating each marker individually, we also evaluated the proportion of breast 
cancers that stained positive to at least one of a panel of markers. For this, we evaluated all 
possible panels of two through nine marker combinations out of the ten prospective markers. 
All possible marker combinations were evaluated and ranked according to tumor detection 
rate. Subgroup analyses were performed based on tumor size and grade of di#erentiation. 
Statistical analysis
Descriptive statistics including medians and frequencies were used for the description of 
clinicopathological characteristics. Fisher’s exact test was performed to test for signi!cant 
di#erences between the proportion of tumor marker expression and clinicopathological 
parameters. To account for sampling variability and assess the robustness and generalizability 
of the biomarker panel results, we performed all combination analyses under 2000-fold 
bootstrap resampling and report the mean rank of each panel over these bootstrap resamples 
as well as the chance that a particular biomarker panel belongs to the top 10 best combinations. 
The kappa statistic was used to compare interobserver agreement between IHC scoring results. 
Kappa values of 0.40−0.60, 0.61−0.80, and 0.81−0.99 were considered to resemble moderate, 
substantial, and almost perfect agreement, respectively.37
A two-sided P-value of ≤0.05 was considered signi!cant. All calculations were performed 
using Excel (Microsoft® O%ce Professional Edition 2003 SP3, Microsoft Corporation, Redmond, 
USA), SPSS 12.01 (SPSS Inc., Chicago, USA), and R version 3.0.1 (R Foundation for Statistical 
Computing, Vienna, Austria).38 
RESULTS
The characteristics of ten membranous and extracellular tumor markers were assessed in 
our study population that comprised breast cancer specimen of 449 patients. Ten patients 
(2%) were excluded from the study due to the absence of representative TMA cores for all 
stains, leaving 439 patients eligible for analysis. Histological types consisted of invasive 
ductal carcinomas (97%) and other histological types (3%). Additional clinicopathological 
characteristics are shown in Table 2. 
Immunohistochemistry scoring
A representative IHC image for each stain is shown in Fig. 1. Depending on the staining, 
62−78% of the tumors were represented by three TMA cores, 17−26% by two TMA cores, and 
2−10% by only one TMA core. Acceptable IHC (de!ned as at least one of the three cores stained 
su%ciently) was achieved in 423 cases (97%) for CXCR4, 422 cases (96%) for αvβ3 integrin 
receptor, 415 cases (95%) for CA-IX, 426 cases (97%) for CA-XII, 427 cases (97%) for EpCAM, 416 
cases (95%) for FR-α, 418 cases (95%) for HER2, 427 cases (97%) for MGB1, 424 cases (97%) for 
Notch1 receptor, and 431 cases (98%) for VEGF-A. In total, 379 (84%) cases had su%cient data 




Age (years), median (range) 58 (27–91)
     <35 11 2.5
     35−50 99 22.7
     >50 329 74.8
Tumor size (mm), median (range) 23 (1–140)
     <20 228 53.0
     20−50 170 39.5
     >50 32 7.5
Histological type
     Invasive ductal carcinoma 425 96.8
     Other types 14 3.2
Carcinoma in situ present
     Yes 204 46.5
     No 235 53.5
Histological grade
     I 115 26.4
     II 187 42.9
     III 134 30.7
Progesterone receptor
     Positive 264 63.6
     Negative 151 36.4
Estrogen receptor
     Positive 318 76.4
     Negative 98 23.6
Nodal status
     Positive 198 46.6
     Negative 227 53.4
Table 2. Clinicopathological characteristics of 439 breast cancer patients.
Tumor-to-normal ratios
Expression of all tumor markers was assessed in 15 specimens of normal glandular breast 
tissue. T/N ratios were calculated using the aforementioned formula (Table 3). For VEGF-A and 
CXCR4, di#use cytoplasmic and/or extracellular staining was seen in the majority of normal 
breast specimen with staining intensities ranging between 1+ and 2+ (Fig. 1). Thresholds for 
tumor marker positivity were therefore set to 3+ for these two markers in order to maintain 
adequate tumor-to-normal ratios. 
Expression of individual tumor markers
An overview of the expression rates for each individual tumor marker is shown in Table 3. The 
most frequently expressed tumor markers were CXCR4, CA-XII, and EpCAM, showing di#use 
expression in 60.2%, 29.6%, and 22.6% of breast carcinomas, respectively. Individual expression 
rates for αvβ3 integrin receptor, CA-IX, CA-XII, EpCAM, FR-α, HER2, Notch1 receptor, MGB1, and 
VEGF-A ranged from 0.3% to 17.4%.  Subgroup analysis was performed regarding tumor marker 
expression for tumor size and grade of di#erentiation. Results are shown in Supplementary 
Figs. 1−2. In brief, tumors were found less likely to express VEGF-A with increasing tumor size 
(P=0.031). FR-α (P<0.001), CA-IX (P<0.001), and HER2 (P=0.004) are more frequently expressed 
in less di#erentiated breast carcinoma. On the contrary, VEGF-A (P<0.001), MGB1 (P=0.036), 
and CA-XII (P=0.041) showed higher expression levels in well-di#erentiated tumors.  
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Validation of immunohistochemistry scoring
Overall agreement between IHC scoring by the observer and the senior pathologist was 88%. 
The corresponding kappa value for interobserver agreement was 0.79 (P<0.001), indicating 
substantial agreement.37
αvβ3, alpha v beta 3 integrin receptor; CA-IX, carbonic anhydrase IX; CA-XII, carbonic anhydrase XII, CXCR4, 
C-X-C chemokine receptor 4; EpCAM, epithelial cell adhesion molecule; FR-α, folate receptor alpha; HER2, human 
epidermal growth factor receptor 2; MGB1, mammaglobin 1; VEGF-A, vascular endothelial growth factor A.
Figure 1. Extracellular tumor marker expression in breast cancer and normal breast tissue. Immunohisto-
chemical staining of positive breast cancer cases and representative normal breast tissue. The majority of tumor 
markers showed no to weak staining in normal breast tissue. In the case of CXCR4 and VEGF-A, di#use weak to 
moderate cytoplasmic and extracellular staining was observed in part of the normal breast specimen. For HER2 
receptor, weak to moderate cytoplasmic staining was observed in normal breast with no signs of extracellular 
involvement. Mammaglobin 1 showed intens focal staining in normal breast tissue. Scalebar equals 50 μm.
8
137









































































































































































































































































































































































































































































































Figure 3. Patient-tailored selection of tumor markers for target optical imaging. Schematic example of the 
selection of tumor markers for targeted optical imaging applications in an individual breast cancer patient. 
Prior to imaging, the expression pro!le of the tumor is assessed for multiple tumor markers using cancerous 
tissue obtained by core needle biopsy (A). Immunohistochemical analysis is performed to enable selection 
of tumor markers that show strong and di#use staining throughout the samples (B). Based on the functional 
marker expression assay, the appropriate targeted optical contrast agent is selected for the individual patient 
(C). Several hours after systemic injection with the targeted agent (D), super!cial tumors could be visualized 
noninvasively using a dedicated optical imaging system (E).
Target selection criteria analysis
The (modi!ed) TASC-scores for all ten tumor markers are shown in Table 3. An extended version 
of this table including an overview of expression rates in tumor and normal breast tissue as 
reported in the literature is provided in Supplementary Table 2. In brief, CXCR4 (21 points), 
EpCAM (18 points), and CA-XII (18 points) were identi!ed as the most promising tumor markers 
for targeted imaging of primary breast tumors of our current panel, ful!lling the TASC criteria 
of ≥18 points. HER2, VEGF-A, and FR-α are considered less suitable with 16, 15, and 15 points, 
respectively, although they exhibit some favorable characteristics for targeted imaging. The 
Notch1 receptor (12 points), αvβ3 integrin receptor (11 points), CA-IX (11 points), and MGB1 
(9 points) are regarded unsuitable for targeted imaging based on marker characteristics.
Optimization of preoperative  biomarker panel
An optimal combination of markers, i.e., detecting the largest number of breast cancers 
using the least possible amount of tumor markers, was calculated overall for the total study 
population. Subgroup analyses were performed for tumor size and grade of di#erentiation 
(Fig. 2). When combined, at least one of the three most frequently expressed tumor markers 
(CXCR4, CA-XII, and EpCAM) was expressed in 76.5% of all breast carcinomas in our cohort. 
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Beyond the combination of !ve markers, with an overall combined detection rate of 83%, 
adding additional markers did not improve the detection rate substantially. Overall, and 
in subgroups according to grade and tumor size, the maximum combined detection rate 
varied between 80% to 90%, with di#erent optimal panels between subgroups. The highest 
detection rates were observed in poorly di#erentiated breast carcinoma relatively large in size, 
representing the category of tumors that are considered most aggressive and have the worst 
prognosis. 
Di#erent combinations of equal numbered biomarker panels yielded similar detection rates.  For 
instance, the top 5 best combinations of !ve markers showed overall detection rates between 
82% and 83% (all including CXCR4, CA-XII, EPCAM, and HER2 but varying in the !fth marker; 
Supplementary Table 4). Nevertheless, the observed top ranking biomarker combinations also 
proved to be the best ranking biomarker combinations under 2000-fold bootstrap resampling 
to account for sampling variation and overoptimism, showing the robustness of our !ndings.
 
DISCUSSION
In the current study, we aimed to identify tumor markers that are of particular interest for 
clinical translation towards targeted optical imaging in breast cancer.36 Because the portfolio 
of markers known to play a role in breast cancer is large and still expanding, we con!ned 
our search by focusing on those markers with membranous and/or extracellular expression 
as reported in the literature. From this group, we selected a panel of ten markers based on 
the availability of selective targeted agents on the market or in clinical trials (Supplementary 
Table 4), facilitating the development and translation of tumor-targeted optical contrast agents 
towards the clinic. Although our study does not cover all potential tumor markers in  the !eld, 
it does contribute to the identi!cation of promising targets for optical imaging in an objective 
manner. Further studies are needed to complement our work, judging additional promising 
markers on their merits for targeted optical imaging applications.
Recently, Vermeulen et al. evaluated the expression of a selected set of tumor markers for 
targeted molecular imaging in breast cancer patients.35 The most widely expressed tumor 
marker in their cohort was glucose transporter 1 (GLUT1), which was expressed in 20% of the 
cases. When a panel of 6 tumor-speci!c markers was applied (GLUT1, epidermal growth factor 
receptor, HER2, insulin-like growth factor 1 receptor, hepatocyt growth factor receptor, and 
CA-IX), 46% of all cases could be detected. This result underlines that no single tumor marker 
is likely to be sensitive enough to detect al breast cancers. Four tumor markers described 
by Vermeulen et al. show overlap with the present study (HER2, MGB1, CA-IX, and CA-XII). 
However, although the authors evaluated membranous expression and T/N ratios for each 
tumor marker, they did not systematically assess all seven tumor marker characteristics that 
are part of the TASC scoring system and are considered important for targeted optical imaging. 
Tumor maker expression patterns
Membranous staining is of particular interest for targeted optical imaging as imaging agents 
can more easily target tumor markers situated on the surface of tumor cells or in the extracellular 
matrix. The expression rates reported in the literature with regards to our tumor marker panel 
tend to di#er substantially between studies (Supplementary Table 2). The majority of studies 
do not di#erentiate between cytoplasmic and membranous staining, thus explaining part of 
the di#erence. In addition, the use of di#erent antibodies and staining protocols results in 




We used IHC as a means to evaluate functional extracellular tumor marker expression on the 
cell membrane of tumor cells and/or in the extracellular matrix adjacent to tumor cells. IHC can 
easily be performed on large numbers of tumor samples and is a well-established technique 
for evaluating marker expression in clinical practice.39 The most important drawbacks of IHC 
are the lack of assay standardization and variance in the interpretation of IHC stains.40, 41 Scoring 
results obtained using IHC should therefore be considered semi-quantitative, as quanti!able 
internal reference standards for calibration are lacking.42 In addition, it is unsure to what extent 
IHC scoring results are representative for results obtained during in vivo imaging. Despite the 
abovementioned, IHC is considered as a powerful tool for screening purposes and selecting 
tumor markers of interest for further probe development. In the current study, validation of a 
randomly selected subset of manual IHC scoring results was performed by a senior pathologist 
and showed substantial agreement. Although we chose not to duplicate the entire dataset, 
this result implies that IHC scoring as performed by the single observer was consistent.
Tumor markers for tumor-targeted imaging
The most promising tumor markers indenti!ed in the current study using TASC was CXCR4, 
which showed homogenous extracellular expression in 60.3% of the tumor specimen while 
maintaining adequate tumor-to-normal ratios. In addition, CA-XII and EpCAM were identi!ed 
as tumor markers of value for targeted imaging with extracellular expression observed in 29.6% 
and 22.6% of evaluated breast carcinoma, respectively. Although exhibiting some favorable 
characteristics for targeted imaging, HER2, VEGF-A, and FR-α did not reach the TASC threshold 
of ≥18 points to be prioritized as markers of particular interest for clinical translation. However, 
these markers do have considerable value when combined in a panel. The characteristics of 
αvβ3 integrin receptor, CA-IX, MGB1, and Notch1 receptor were considered unfavorable for 
tumor-targeted imaging applications, with TASC scores of 12 and lower. 
Already, a number of targeted imaging agents have been described for CXCR4.43 Meincke et 
al. recently synthesized conjugates of CXCL12 and the near-infrared "uorescent dye IRDye 
800CW enabling visualization of tumors in vivo.44 Nimmagadda et al. succeeded in imaging 
CXCR4 expressing tumors in mice through the use of AMD3100, which is a clinically approved 
molecule conjugated to a radionuclide targeted towards CXCR4 (Supplementary Table 4).45 
Kuil et al. reported the !rst hybrid CXCR4-targeted imaging agent, which consists of the cyclic 
peptide Ac-TZ14011 and a multifunctional single attachment point (MSAP) label to which 
"uorophores can be attached.46  
Sun et al. successfully labeled anti-EpCAM antibodies with "uorescent dyes of di#erent 
wavelengths and determined their in vivo distribution in a breast cancer xenograft model.47 
Very recently, Zhu et al. showed that NIRF optical imaging in combination with a "uorescent 
probe targeted against EpCAM enabled image-guided surgery in an orthothopic model of 
human prostate cancer.48 Accuracy of the technique in detecting tumor margins was reported 
to be 96%. 
To our knowledge, no targeted NIRF imaging of primary breast carcinoma has yet been 
performed using CA-XII as a target. Tafhreshi et al., however, used a NIRF-labeled antibody 
against CA-XII for noninvasive detection of breast cancer lymph node metastasis in a xenograft 
mouse model.18 As few as 1,000 cancer cells could be detected using NIRF imaging, indicating 
the sensitivity of the technique. Although markers suitable for imaging of lymph node 
metastasis do not necessarily make good targets for primary breast cancer, the current study 
suggests that this is the case for CA-XII.  
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Selection of tumor-targeted agents
Nowadays, core needle biopsy is a common procedure for IHC analysis of ER, PR, and HER2 
expression as a lead for patient-tailored therapies. Using IHC, functional expression of those 
tumor markers throughout the tumor could be identi!ed at diagnosis/prior to imaging 
and used to select the appropriate targeted optical contrast agent (Fig. 3). This would allow 
to select those tumor markers that result in the highest signal-to-noise ratio or that exhibit 
speci!c favorable characteristics like enzymatic activity or internalization upon binding of the 
tumor-targeted optical contrast agent. 
Development of tumor-targeted agents
In recent years, signi!cant progress has been made in the development of optical imaging 
systems and non-toxic "uorophores.3,4,12,49 Already, a substantial amount of bio-engineered 
monoclonal antibodies are available for preclinical and clinical use (Supplementary Table 4). 
Monoclonal antibodies can be conjugated to optical contrast agents with relative ease and 
therefore facilitate the translation of targeted optical imaging towards the clinic.39 Moreover, 
the development of so-called ‘activatable’ probes has added to the potential of optical 
imaging by providing exceptionally high signal-to-noise ratios. These imaging agents are 
optically silent in their native state, but become brightly "uorescent upon activation through 
cleavage by enzymes expressed by the tumor (e.g., CA-IX or CA-XII).9 
CONCLUSION
Based on the seven tumor marker characteristics that are considered important for 
tumor-targeted optical imaging applications in breast cancer, we identi!ed CXCR4, EpCAM, 
and CA-XII as markers of particular interest for development of tumor-targeted probes for 
clinical translation. At least one of these tumor markers was homogeneously expressed in 
approximately 80% of the patients included in our study. Although exhibiting some favorable 
characteristics for targeted imaging, HER2, VEGF-A, and FR-α did not reach the (modi!ed) 
TASC threshold of ≥18 points to be prioritized as markers of particular interest for clinical 
translation. However, these markers do have considerable value when combined in a panel. The 
characteristics of αvβ3 integrin receptor, CA-IX, MGB1, and Notch1 receptor were considered 
unfavorable for tumor-targeted imaging applications.
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Tumor marker Grade I Grade II Grade III P-value
CXCR4 67.4% 58.3% 57.6% 0.170
CA-XII 29.3% 35.7% 21.2% 0.041
VEGF-A 27.2% 12.5% 11.0% <0.001
EpCAM 17.4% 20.2% 27.1% 0.168
HER2 9.8% 14.9% 27.1% 0.004
MGB1 4.3% 7.1% 0.8% 0.036
FR-α 2.2% 3.6% 13.6% <0.001
αvβ3 1.1% 0.0% 1.7% 0.274
Notch1 1.1% 0.0% 0.0% 0.234
CA-IX 0.0% 1.2% 11.9% <0.001
Supplementary Figure 1. Tumor marker expression levels subdivided to grade of di#erentiation. FR-α (P<0.001), 
CA-IX (P<0.001), and HER2 (P=0.004) are more frequently expressed in less di#erentiated breast carcinoma. 
On the contrary, VEGF-A (P<0.001), MGB1 (P=0.036), and CA-XII ( P=0.041) showed higher expression levels in 
well-di#erentiated tumors.  
αvβ3, alpha v beta 3 integrin receptor; CA-IX, carbonic anhydrase IX; CA-XII, carbonic anhydrase XII, CXCR4, C-X-C 
chemokine receptor 4; EpCAM, epithelial cell adhesion molecule; FR-α, folate receptor alpha; HER2, human epidermal 
growth factor receptor 2; MGB1, mammaglobin 1; VEGF-A, vascular endothelial growth factor A.
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Tumor marker <10 mm 10−20 mm 20−50 mm >50 mm P-value
CXCR4 64.7% 65.5% 52.9% 67.9% 0.075
CA-XII 31.4% 33.8% 30.1% 14.3% 0.251
VEGF-A 21.6% 17.3% 11.8% 7.1% 0.031
EpCAM 19.6% 17.3% 26.8% 17.9% 0.871
HER2 19.6% 16.5% 17.0% 21.4% 0.643
MGB1 2.0% 7.9% 2.6% 0.0% 0.513
FR-α 5.9% 7.2% 6.5% 3.6% 0.585
αvβ3 2.0% 0.0% 1.3% 0.0% 0.464
Notch1 2.0% 0.0% 0.0% 0.0% 0.228
CA-IX 2.0% 1.4% 5.9% 14.3% 0.111
Supplementary Figure 2. Tumor marker expression levels subdivided to tumor size. Tumors were found less 
likely to express VEGF-A with increasing tumor size (P=0.031). A trend was seen between increasing tumor size 
and CA-IX expression, although not reaching statistical signi!cance (P=0.111). The same accounts for the trend 
between decreasing tumor size and CA-XII expression (P=0.251).
αvβ3, alpha v beta 3 integrin receptor; CA-IX, carbonic anhydrase IX; CA-XII, carbonic anhydrase XII, CXCR4, C-X-C 
chemokine receptor 4; EpCAM, epithelial cell adhesion molecule; FR-α, folate receptor alpha; HER2, human epidermal 
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In breast cancer patients with a positive sentinel lymph node, an axillary lymph node dissection 
(ALND) is generally performed. In 50-80% of these patients, no additional positive axillary 
lymph nodes are found, suggesting substantial overtreatment. Near-infrared "uorescence 
(NIRF) imaging has the potential to enable noninvasive intraoperative detection of lymph node 
metastases and may thereby lead to a reduction in unnecessary removal of non-metastatic 
lymph nodes. We aimed to identify viable tumor markers for targeted NIRF imaging of lymph 
node metastases in breast cancer patients.
Methods
A panel of 10 membranous and/or extracellular tumor markers were assessed on tissue 
microarrays from 104 lymph node macrometastases and their corresponding primary tumors. 
Markers included αvβ3 integrin receptor, CXCR4, CA-IX, CA-XII, EpCAM, FR-α, HER2, MGB1, 
Notch1 receptor, and VEGF-A. Tumor markers were prioritized based on a modi!ed target 
selection criteria (TASC) scoring system consisting out of ten items, with scores ≥25 indicating 
viable markers. 
Results
A total of 98 (94,2%) patients for whom histological material was available for both lymph 
node metastases and their corresponding primary tumor were eligible for analysis. Modi!ed 
TASC scores were 25 for both EpCAM and CA-XII. At least one of these markers was expressed 
in 57.4% of the study population. Modi!ed TASC scores for HER2, FR-α, CA-IX, CXCR4, MGB1 
and VEGF-A were 22, 21, 21, 20, 18, and 13, respectively. No membranous and/or extracellular 
marker expression of su%cient intensity was observed for αvβ3 integrin receptor and Notch1 
receptor. 
Conclusion
We systematically assessed the potential of ten tumor markers for targeted optical imaging 
of lymph node metastases in breast cancer patients. On the basis of ten tumor marker 
characteristics, EpCAM and CA-XII are considered promising markers for targeted NIRF imaging, 




Assessing the presence of tumor in axillary lymph nodes (ALNs) of patients with breast cancer 
is an important aspect in clinical staging of the disease.1 Tumor cells migrating from the 
primary tumor tend to metastasize to the !rst draining lymph node, also known as the sentinel 
lymph node (SLN), before spreading to other lymph nodes.2 After removal, the SLN is assessed 
by a pathologist using step sectioning and immunohistochemistry.3 In the case of a positive 
SLN, an axillary lymph node dissection (ALND) is performed.4 However, in 47% of the patients 
who underwent ALND, the SLN is found to be the only lymph node containing metastasis.5 
In these patients, ALND can be considered overtreatment with the known accompanying 
risks of nerve injury, lymph edema, shoulder dysfunction, and seroma formation.6,7 To reduce 
comorbidity associated with the unnecessary removal of non-metastatic ALNs, information 
on the tumor burden status of (sentinel) lymph nodes should ideally be available prior to or 
during surgery. Hereto, novel approaches are being developed that could enable noninvasive 
targeted imaging of lymph node metastases. In particular, near-infrared "uorescence (NIRF) 
optical imaging seems of interest for this purpose as it may allow for noninvasive assessment 
of the SLN and surrounding lymph nodes, potentially eliminating the need for extensive 
lymphadenectomy for assessment of the axillary lymph node status.
NIRF optical imaging makes use of a "uorescent optical contrast agent that emits light in 
the near-infrared (NIR) spectral range.8 The use of NIR light minimizes auto"uorescence 
(i.e., intrinsic "uorescent activity of tissues) and photon absorption and scattering, while tissue 
penetration of photons in the NIR spectral range is maximized.9 Because NIR light is invisible to 
the human eye, a dedicated camera system is needed to detect the "uorescent signal.10 
NIRF optical imaging is considered safe, inexpensive, fast, and uses non-ionizing radiation.11
Already, several studies reported on the clinical feasibility of NIRF imaging to localize the 
SLN noninvasively in breast cancer patients.12-17 In these studies, patients were injected 
peritumorally with the nonspeci!c "uorescent dye indocyanine green (ICG), which distributes 
randomly across the lymphatic system, providing an anatomic map of lymph vessels and 
nodes instead of detecting cancer cells.18 For noninvasive assessment of the tumor burden of 
lymph nodes, however, "uorescent contrast agents have to be developed that are targeted 
speci!cally to tumor markers expressed by lymph node metastases. 
As the portfolio of tumor markers that are known to be associated with breast cancer is still 
expanding and the development of targeted "uorescent probes is costly and time-consuming, 
we aimed to identify those tumor markers that are of particular interest for targeted NIRF 
imaging of lymph node metastases in breast cancer patients. Tissue microarrays were used 
to enable high-throughput analysis of a large sample of lymph node metastases and their 
corresponding primary tumors. 
METHODS
Selection of tumor markers
A total of 10 tumor markers were selected that are know from literature for their role in breast 
cancer. Because targeted NIRF imaging requires the use of relatively large molecules that are 
unlikely to enter cancer cells (i.e., "uorescent contrast agents conjugated to a target-speci!c 
molecule), only membranous and/or extracellular markers were selected to ensure adequate 
marker accessibility. Selected tumor markers included C-X-C-chemokine receptor 4 (CXCR4), 
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alpha v beta 3 (αvβ3) integrin receptor, carbonic anhydrase (CA) IX and XII, epithelial cell 
adhesion molecule (EpCAM), folate receptor alpha (FR-α), human epidermal growth factor 
receptor 2 (HER2), mammaglobin 1 (MGB1), Notch1 receptor, and vascular endothelial growth 
factor A (VEGF-A).
Selection of patients
Patients with lymph node macrometastasis (de!ned as metastasis ≥2.0 mm) were selected 
from previously described cohorts of invasive breast carcinoma specimen collected between 
1996 and 2005 at the University Medical Center Groningen (UMCG).19,20 Patients for who 
insu%cient para%n-embedded tissue was available for lymph node metastases and/or their 
corresponding primary tumor were excluded. Clinical and histopathological data of eligible 
patients were reviewed from pathology reports and medical charts. All data were anonymized 
and the study was conducted in accordance with the Declaration of Helsinki and with the rules 
and regulations posed by the Institutional Review Board of the UMCG.
Construction of tissue microarrays
Tissue microarrays (TMAs) were constructed to enable high-throughput immunohisto-
chemical analysis of a large amount of lymph node metastases and their corresponding 
primaries simultaneously. Para%n-embedded tissue from eligible patients was obtained from 
the archives of the Department of Pathology and Medical Biology from the UMCG. Slides 
from all sample blocks were evaluated for representative areas containing tumor tissue. TMAs 
were prepared as previously described.21 In brief, the most representative area of lymph node 
metastasis or invasive carcinoma was marked on the original haematoxylin and eosin (H&E) 
stained section. With this marked section for orientation, three 0.6 mm punches were taken 
from the selected area in the donor blocks and mounted in a recipient block using a tissue 
arrayer (Beecher Instruments, Sun Prairie, USA). 
Immunohistochemistry
Semiquantitative immunohistochemistry (IHC) for all 10 biomarkers was performed on TMAs 
from lymph node metastases and their corresponding primary tumors. Brie"y, 3 μm thick 
TMA sections were depara%nized with xylene and gradually rehydrated through changes of 
graded ethanol from 100% to distilled water. Endogenous peroxidase activity was blocked by 
incubating TMA sections in phosphate-bu#ered saline pH 5.8 containing 0.3% H2O2 for 30 min. 
In the case of VEGF-A, endogenous biotin was additionally blocked using a Blocking Kit (Vector 
Laboratories, Burlingame, USA). 
Primary antibodies against CXCR4 (ab2074, Abcam, Cambridge, UK) 1:50; αvβ3 integrin 
(ab7166, clone BV3, Abcam, Cambridge, UK) 1:100; CA-IX (SAB1300310, Sigma Aldrich, 
Zwijndrecht, The Netherlands) 1:200; CA-XII (HPA008773, Sigma Aldrich, Zwijndrecht, The 
Netherlands) 1:50; EpCAM (IR637, clone Ber-EP4, DAKO) 1:100; FR-α (mAb-343, clone 3D2, 
a generous gift form prof. P.S. Low) 1:500; HER2 (RM9103S, clone SP3, Neomarkers, Duiven, 
The Netherlands) 1:80; MGB1 (ab101137, clone 31A5, Abcam, Cambridge, UK) 1:100; 
Notch1 (ab44986, clone A6, Abcam, Cambridge, UK) 1:50; and VEGF-A (sc-152, Santa Cruz 
Biotechnology, Heidelberg, Germany) 1:50 were diluted in PBS containing 1% bovine serum 
albumin and incubated at room temperature for 1 h. FR-α sections were incubated with mouse 
MACH3 (Biocare Medical, Walnut Creek, USA) for 3 h. Sections were then washed in phosphate- 
bu#ered saline and incubated with secondary and tertiary antibodies where appropriate. For 
visualization of the antibody-antigen complex, 3,3-diaminobenzidine was used. After a !nal 
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wash with distilled water, counterstaining was performed with haematoxylin. Sections were 
then dehydrated through rising concentrations of ethanol, mounted with mounting medium, 
and coverslipped. Negative controls consisted of sections processed in the same way but with 
omission of the primary antibody step. Positive control tissue was included as usual.
Digitalization of slides
TMA slides were digitalized using the ScanScope GL Scanner (Aperio Technologies Inc., Vista, 
USA), creating high-resolution !les suitable for image analysis. All slides were produced 
with core images linked to a Microsoft AccessTM database containing relevant tissue core 
information. After importing the digital slides in ImageScope® (Aperio Technologies Inc., 
Vista, USA), each individual TMA section on the slide was captured, coded, and exported as a 
separate industry-standard TIFF !le.
Assessment of tumor-to-background ratio
Tumor markers for targeted NIRF imaging should provide adequate tumor-to-background 
ratios (TBRs) to discriminate between lymph node metastases and normal lymphatic tissue. 
For this reason, expression of all 10 tumor markers was also evaluated in a set of 25 normal 
lymph node specimens using IHC. The TBR was calculated by multiplying the mean staining 
intensity with the proportion of stained tumor cells (three-item severity score; TIS-score) for 
lymph node metastases and dividing it by the TIS-score for normal lymphatic tissue. A TBR ≥3 
was considered adequate for imaging purposes.22
Scoring of immunohistochemistry
Manual IHC scoring was performed on digital TMA sections to allow for randomization of TMA 
cores, thereby minimizing bias e#ects. Tumor marker expression was assessed by evaluating 
the staining pattern (di#use or focal) as well as the proportion of cancer cells showing no (0), 
weak (1+), moderate (2+), or strong (3+) membranous and/or extracellular staining. Evaluation 
of staining pattern (di#use or focal) was performed both on a microscopic (within spot) 
and a macroscopic (between spots) level. To account for tumor heterogeneity, the average 
proportion and staining intensity was calculated for each tumor. An average membranous 
staining intensity of ≥2+ in ≥10% of tumor cells was considered positive. For CXCR4 and 
VEGF-A, only cases that showed an average membranous staining intensity of 3+ in ≥10% of 
tumor cells were considered positive due to high background staining. Lymph node metastasis 
or primary tumor specimens were excluded from analysis in the event that all (3 out of 3) TMA 
sections were missing. 
Marker expression in metastases and primary tumors
To account for potential heterogeneity in marker expression, expression levels were evaluated 
separately for lymph node metastasis and their corresponding primary tumor. Agreement 
of marker expression between lymph node metastasis and primary tumor was assessed 
separately for each individual tumor marker.
Modi"ed target selection criteria scoring system
The scoring system used in the present study was based on the target selection criteria 
(TASC) scoring system, as recently introduced by van Oosten et al.23 In brief, TASC provides a 
method for identifying markers that are of speci!c potential for targeted optical imaging of 
tumors by assigning points to each individual marker on the basis of seven characteristics: 
9
163
TUMOR MARKERS IN LYMPH NODE METASTASES FOR TARGETED IMAGING 
I) tumor marker localization; II) expression pattern; III) tumor-to-background ratio; IV) target 
expression rate; V) reported successful use in vivo; VI) enzymatic activity, and VII) internalization 
of the marker upon binding of its ligand. 
Because the focus of the current study is on lymph node metastasis instead of the primary 
tumors, some adjustments were made to the TASC scoring system. First, the amount of points 
awarded to tumor markers with a TBR >10 was increased from 3 to 6 points as a high TBR is 
important to obtain an adequate overall image resolution when imaging small structures like 
lymph node metastases. Second, the amount of points awarded for marker expression rate 
was altered. The original TASC score is dominated by the percentage of tumors that express 
the tumor marker on their cell membranes or in the extracellular matrix adjacent to tumor 
cells. Up to 6 points are assigned to expression rates as high as 90%, whereas expression rates 
below 50% are assigned no points. For targeted imaging applications, however, tumor markers 
expressed in less than 50% of the lymph node metastasis can still be of value as long as other 
characteristics crucial for optical imaging are favorable. Markers were therefore granted 0, 3, 5, 
or 6 points based on expression rates of 0−10%, 10−25%, 25−50%, or 50−100%, respectively 
(Supplementary Table 1).
Lastly, we complemented TASC with three additional selection criteria regarding marker 
expression of both lymph node metastasis and the corresponding primary tumor 
(Supplementary Table 1). In brief, points are granted for a high level of marker expression 
agreement and the possibility to apply a single tumor marker for targeted NIRF imaging of 
both lymph node metastases and their corresponding primary tumor. Moreover, points are 
granted when marker expression of lymph node metastases can be predicted by analyzing a 
sample of the primary tumor prior to surgery (e.g., by core needle biopsy). 
The modi!ed TASC score for each individual marker serves as a directive to objectify the 
value of di#erent tumor markers for targeted NIRF imaging. Individual tumor markers can be 
awarded a total of 30 points at maximum. A total score of ≥25 points indicates that the tumor 
marker is of potential interest and justi!es further exploration.   
Statistical analysis
Descriptive statistics including medians and frequencies were utilized for the description of 
clinicopathological characteristics. Agreement of marker expression between lymph node 
metastases and corresponding primaries was assessed using the Kappa statistic. Kappa values 
of 0.41−0.60, 0.61−0.80, and 0.81−0.99 were considered to resemble moderate, substantial, 
and almost perfect agreement, respectively.24 A P-value of ≤0.05 was considered statistically 
signi!cant. All calculations were performed using Excel (Microsoft® O%ce Professional Edition 
2003 SP3, Microsoft Corporation, Redmond, USA), SPSS 12.01 (SPSS Inc., Chicago, USA), and 
R version 3.0.1 (R Foundation for Statistical Computing, Vienna, Austria).25 
RESULTS
A total of 104 out of 439 (23.7%) patients with invasive breast carcinoma had lymph node 
macrometastases. Histologic material of lymph node metastases and corresponding primary 
tumors was retrieved from the pathology archive of the UMCG. Two out of 104 (1.9%) patients 
were excluded due to insu%cient histologic material of the primary tumor for TMA construction, 
an additional 4 (3.8%) patients were excluded due to insu%cient histologic material of lymph 
node metastases. A total of 98 out of 104 (94.2%) patients were therefore eligible for analysis. 
Clinicopathological characteristics of the study group are shown in Table 1.  
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Characteristics   N %
Age (years), median (range)  56 (27−89)
     <45  13 13.3
     45−65  60 61.2
     >65  25 25.5
Tumor size (mm), median (range)  25 (5−140)
     <20  30 30.9
     20−50  60 61.9
     >50  7 7.2
Lymph node metastasis size (mm), median (range) 4.5 (1−23)
    <5 mm 34                        34.7
    5−10 mm 19     19.4
    >5 mm 45 46.0
Number of metastasis, median (range) 3 (1−33)
Number of excised lymph nodes, median (range) 11 (1−36)
Histological type
     Invasive ductal carcinoma 93 94.9
     Other types 5 5.1
In situ carcinoma present
     Yes 54 55.1
     No 44 44.9
Histological grade
     I 14 14.3
     II 30 30.6
     III 53 54.1
Progesterone receptor
     Positive 51 52.0
     Negative 42 49.9
     Unknown 5 5.1
Estrogen receptor
     Positive 60 61.2
     Negative 32 32.7
     Unknown 6 6.1
Extranodal growth
     Yes 52 53.1
     No 46 46.9
Table 1. Clinicopathological characteristics of 98 breast cancer patients with lymph node metastases 
eligible for analysis.
Manual immunohistochemistry scoring
A representative immunohistochemistry image indicating membranous and/or extracellular 
staining intensities for both lymph node metastasis and their corresponding primary tumor is 
shown in Fig. 1. For all 98 eligible patients, acceptable IHC (de!ned as at least one of the three 
cores stained su%ciently) di#ered between stains and was obtained for 97.9% to 100% of the 
lymph node metastases and 92.2% to 96.6% of the breast carcinoma specimen (Table 2). The 
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Marker expression in lymph node metastasis
An overview of the expression rates for each individual tumor marker is provided in Table 2. 
The most frequently expressed tumor marker in lymph node metastases was CXCR4 (49.5%), 
followed by HER2 (48.05%), CA-XII (37.1%), and EpCAM (28.9%). Expression rates for CA-IX, FR-α, 
MGB1, and VEGF-A ranged from 5.1% to 16.5%. No membranous or extracellular tumor marker 
expression of su%cient intensity (moderate to strong) was observed for Notch1 receptor and 
αvβ3 integrin receptor. Supplementary Table 2 provides a summary of marker expression rates 
as reported in the literature for lymph node metastases in breast cancer patients.
Marker expression related to primary tumor
Tumor marker expression was evaluated separately for lymph node metastases and 
corresponding primaries to evaluate heterogeneity (Table 2). The level of agreement of 
between both categories ranged from 0.44 to 0.81 for individual tumor markers (Table 3). 
Moreover, we evaluated whether marker expression in the primary tumor predicted for 
expression of the same marker in lymph node metastases (Table 4). Predictability of marker 
expression in lymph node metastases ranged from 53.8% to 78.7% for FR-α, CXCR4, and VEGF-A. 
For EpCAM, CA-XII, MGB1, HER2, and CA-IX, predictability ranged from 80.0% to 100.0%. 
Tumor-to-background ratio
Mean TIS-scores were calculated for individual tumor markers using the aforementioned 
formula. Mean TIS-scores for lymph node metastases were 0.0 for αvβ3 integrin receptor, 0.13 
for CA-IX, 0.71 for CA-XII, 1.27 for CXCR4, 0.58 for EpCAM, 0.04 for FR-α, 1.23 for HER2, 0.23 
for MGB1, 0.0 for Notch1 receptor, and 1.85 for VEGF-A. For normal lymphatic tissue, mean 
TIS-scores were 0.25 for αvβ3 integrin receptor, 0.02 for CA-IX, 0.04 for CA-XII, 1.24 for CXCR4, 
0.01 for EpCAM, 0.0 for FR-α, 0.38 for HER2, 0.0 for MGB1, 0.0 for Notch1 receptor, and 1.43 for 
VEGF-A. TBRs were calculated for each individual tumor marker and are provided in Table 4.
Modi"ed target selection scores
Modi!ed TASC scores were calculated for each individual tumor marker (Table 4) on the basis 
of ten aforementioned marker characteristics. EpCAM and CA-XII were identi!ed as the most 
promising markers for targeted NIRF imaging of lymph node metastasis, ful!lling the criteria 
of a total score ≥25 points. At least one of these two markers was expressed in 57.4% of the 
study population. Modi!ed TASC scores for HER2, FR-α, CA-IX, CXCR4, MGB1, and VEGF-A were 
22, 21, 21, 20, 18, and 13, respectively. No modi!ed TASC score could be calculated for αvβ3 
integrin receptor and Notch1 receptor because no membranous and/or extracellular marker 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In the present study, we aimed to identify viable tumor markers for targeted NIRF imaging of 
lymph node metastases in breast cancer patients. A total of 10 membranous and extracellular 
tumor markers that are reported in the literature for their role in breast cancer were evaluated. 
For all markers assessed, targeted moieties are already in clinical trial or available for clinical use, 
facilitating clinical translation. By conjugating these moieties with "uorescent optical contrast 
agents that emit light in the near-infrared spectral range, "uorescent probes are obtained for 
targeted NIRF imaging.  
Markers for imaging lymph node metastasis
The most potential tumor markers identi!ed using our modi!ed TASC scoring system 
were EpCAM and CA-XII, which were both awarded a total of 25 points.  
EpCAM is a transmembrane protein that is involved in cell-cell adhesion in normal epithelial 
cells, while in cancer it can actually loosen cell-cell adhesions by functioning as an antagonist 
to E-cadherin.26 In breast cancer, EpCAM expression is associated with poor prognosis in 
node-positive patients.27 To date, several humanized monoclonal antibodies are available for 
targeted imaging of EpCAM in patients (e.g., catumaxomab and edrecolomab), facilitating 
clinical translation. 
CA-XII is an extracellular enzyme involved in the regulation of the microenvironment acidity 
and tumor malignant phenotype.28,29 A humanized monoclonal antibody, known als EXO-6A10, 
was recently developed for speci!c targeting of CA-XII in patients (European patent 2384766) 
and is awaiting approval.
Although not identi!ed as a marker of particular interest (i.e., modi!ed TASC score ≥25 
points), HER2 contains favorable marker characteristics for targeted NIRF imaging. HER2 is a 
well-known marker for breast cancer that is overexpressed in 25−30% of all breast carcinoma 
and is associated with a poor prognosis. In patients with tumor-positive lymph nodes, 
even higher rates of HER2 expression are reported.30 In the current study, HER2 expression 
was moderate to strong in 48.0% of the lymph node metastases compared to 25.8% of the 
corresponding primary tumors. When a primary tumor was HER2 positive, its corresponding 
lymph node metastases also showed moderate to strong membranous HER2 expression in all 
cases. This observation is in accordance with the literature and indicates that HER2 expression 
pro!ling of the primary tumor (e.g., by core needle biopsy) can be used to select those patients 
suitable for HER2 targeted imaging of lymph node metastases.31 In 21.5% of the patients with 
HER2 positive lymph node metastases, the primary tumor was negative for HER2, suggesting 
that a substantial amount of patients with HER2 positive lymph node metastases would be 
missed when marker expression is solely based on the expression level of the corresponding 
primary tumor.  
FR-α is a transmembrane receptor that shows limited expression in normal tissue but is 
over-expressed on a variety of human cancers, including breast cancer.32 Although, FR-α and 
its ligand (folic acid) seem an attractive ligand/receptor combination for targeted imaging 
of cancer cells, FR-α was not identi!ed as a potent marker for the detection of lymph node 
metastases due to heterogeneity in marker expression and low expression rate. 
CXCR4 is a transmembrane chemokine receptor that allows for migration of hematopoietic 
cells from the bone marrow to the peripheral lymph nodes.33 It has been implicated in the 
invasion and metastasis of breast cancer.34 Although CXCR4 was identi!ed as a promising 
marker for targeted NIRF imaging of primary breast carcinoma,35,36 the applicability of CXCR4 
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for targeted imaging of lymph node metastases seems limited. First, we found the TBR of CXCR4 
positive lymph node metastasis to be insu%cient for imaging purposes due to the expression 
of CXCR4 on the surface of T lymphocytes that are abundantly present in lymph nodes.
Moreover, CXCR4 expression was found to decrease as breast cancer cells metastasize to the 
lymph nodes. Shim et al. reported that 45 out of 74 (61%) primary tumors showed strong (≥3+) 
CXCR4 expression, while for lymph node metastases this was only 6 out of 20 (30%; P<0.001).37 
In our study a similar trend was observed with strong staining being present in 49.5% (primary 
tumors) and 64.3% (lymph node metastases) of the patients (P<0.001). The di#erence in 
expression of CXCR4 may be mediated by high levels of SDF-1 in the lymph nodes that lead 
to CXCR4 internalization and degradation through the lysosome pathway.38 Moreover, CXCR4 
levels in the primary tumor may be high due to the relatively hypoxic environment in primary 
tumors compared with metastases in the lymph nodes.37 Taken together, although suitable for 
targeted imaging of primary breast carcinoma, we recommend not to use CXCR4 as a marker 
for targeted NIRF imaging of lymph node metastases. 
MGB1 expression is reported in 40% to 84% of the lymph node metastases and corresponding 
primary tumors, with the expression pattern being primarily cytoplasmic (Supplementary 
Table 3).39  Because only moderate to strong membranous and extracellular marker expression 
was counted as positive, the MGB1 expression rate in our study is considerably lower (8.2%). No 
di#erence in MGB1 expression was found between primary and metastatic breast carcinoma, 
which is in agreement with the literature.40
VEGF-A is an endothelial growth factor that plays a key role in tumor angiogenesis and is 
associated with invasive tumor growth, metastasis, and reduced survival.41-44 VEGF-A can be 
either membrane-bound or present in the interstitial cell space with highest concentrations 
observed in close proximity of tumor cells.45 To date, several preclinical studies have 
reported good results using VEGF-A as a marker for targeted imaging of primary tumors.46,47 
At our institution, a clinical study is currently being performed in order to detect primary breast 
carcinoma using bevacizumab labeled with the "uorescent dye IRDye 800CW (NCT01508572). 
For targeted imaging of lymph node metastases, however, VEGF-A seems less suitable due to 
heterogeneity in marker expression and a relatively low TBR (Table 4).
No membranous and/or extracellular staining of su%cient intensity was observed in any of 
the lymph node metastases and corresponding primaries for both αvβ3 integrin receptor 
and Notch1 receptor, while positive controls were adequate. As integrins regulate the 
interaction between epithelial cells and the extracellular matrix, a decrease in the expression 
of αvβ3 integrin could make cancer cells more prone to metastasize to the lymph nodes.48 
This could explain the low αvβ3 integrin expression level observed in our study population of 
node-positive patients. Indeed, several studies reported a signi!cant loss of integrin receptor 
expression on primary breast cancer cells in the presence of axillary metastasis.49,50 Conversely, 
in bone metastases, αvβ3 integrin receptor was reported to be overexpressed.51,52 
As for αvβ3 integrin receptor, no membranous and/or extracellular Notch1 receptor expression 
of su%cient intensity was observed in any of the 98 evaluated lymph node metastases. To our 
knowledge, no other studies previously reported on Notch1 receptor expression in lymph 
node metastasis from breast cancer patients. Zhu et al. evaluated expression of Notch1 
receptor in hematologic metastases and corresponding primary tumors for several cancers, 
including breast cancer.53 At least 10% of the cancer cells was reported to show moderate to 
strong Notch1 receptor expression in 1 out of 5 (20%) evaluated metastases. No assessment 
of lymph node metastases was performed. Further studies are therefore desirable to con!rm 
our !ndings concerning the weak expression of Notch1 receptor in lymph node metastases.  
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Assessment of marker expression
We used manual IHC scoring to assess functional membranous and/or extracellular 
expression of 10 di#erent tumor markers in lymph node metastases and their corresponding 
primaries. Although IHC is easy to perform on a variety of tumor samples and is considered a 
predominant method for evaluating functional tumor marker expression in clinical practice, 
there also are a number of drawbacks with IHC. The most important drawback is the lack of 
assay standardization and variance in the interpretation of the IHC staining.54,55 Given the 
lack of quanti!able internal reference standards for calibration, results obtained using IHC 
stains should be considered semiquantitave, comparing the staining intensity and number of 
positive cells with other cases.56 
With the exception of HER2 receptor and MGB1, only limited data is available on the expression 
of di#erent tumor markers in lymph node metastases (Supplementary Table 2). When 
marker expression as observed in the current study is compared with data reported in the 
literature, overall expression rates are quite similar. Di#erences can be largely explained by the 
semiquantitative nature of IHC, di#erent thresholds that were used for marker positivity, and 
the small sample size of some studies. Moreover, the majority of studies did not di#erentiate 
between cytoplasmic and membranous staining, the latter being of particular interest for 
targeted optical imaging as imaging agents will only be able to bind those biomarkers situated 
on the exterior of tumor cells. Because the focus of our study was on the identi!cation of tumor 
markers suitable for targeted NIRF imaging, cytoplasmic staining was not taken into account 
when assessing marker expression. 
Targeted imaging of lymph node metastasis
Targeted NIRF imaging holds great promise to improve breast cancer care by providing the 
surgeon with a high-resolution noninvasive imaging modality for the detection of lymph node 
metastases. Several animal and clinical studies have already shown the potential of targeted 
optical imaging to improve the therapeutic outcome of surgery.
Tafreshi et al. successfully applied a high-resolution NIRF imaging system to noninvasively 
detect lymph node metastases in a xenograft bioluminescent breast cancer model.57 NIRF 
imaging was performed 24 hours following injection of a near-infrared "uorescent dye 
conjugated to a monoclonal antibody targeted towards MBG1. One year later, the same 
group reported on the applicability of CA-IX and CA-XII as markers for targeted imaging of 
lymph node metastases in mice.30 Again, targeted probes were developed by conjugation of 
monoclonal antibodies speci!c for CA-IX and CA-XII to a near-infrared "uorescent dye. Results 
indicated that the targeted dye was retained in positive lymph nodes for up to at least 7 days 
postinjection. As few as 1,000 breast cancer cells could be detected in the lymph nodes, 
indicating the high sensitivity of targeted NIRF imaging. 
Wu et al. reported on a "uorescent probe targeted against HER2 receptor to di#erentiate 
metastatic lymph nodes from non-metastatic nodes.58 Using an animal model, they showed 
that lymph node metastases were easily distinguishable from surrounding normal (lymphatic) 
tissue with sensitivity and speci!city rates of 78% and 100%, respectively. 
According to our modi!ed TASC scoring system, HER2, CA-IX, and MGB1 (awarded 22, 21, and 
18 points, respectively) have rather favorable characteristics for targeted optical imaging, but 
should not be prioritized for clinical translation. CA-XII and EpCAM, on the other hand, seem of 
particular interest for clinical translation based on our current !ndings.
To our knowledge, no clinical studies have yet been published concerning the detection of 
lymph node metastases using targeted NIRF imaging in humans. There has been some early 
9
173
TUMOR MARKERS IN LYMPH NODE METASTASES FOR TARGETED IMAGING 
work, however, towards targeted NIRF imaging in a clinical setting. In 2011, the !rst-in-human 
use of intraoperative tumor-speci!c NIRF imaging was reported by our group, concerning 
the real-time surgical visualization of tumor tissue in patients undergoing an exploratory 
laparotomy for suspected ovarian cancer.59 It was shown that intraoperative NIRF-guided 
imaging allowed the surgeon to detect tumor spots of less then 1 millimeter in diameter 
that were undetected with visual inspection alone. For targeted NIRF imaging of lymph node 
metastases, the same principle could be applied to support surgeons during lymph node 
status assessment by pinpointing suspicious lymph nodes. 
Preoperative assessment of marker expression
Nowadays, core needle biopsy of the primary tumor is a common procedure for IHC analysis of 
ER, PR, and HER2 expression as a lead for patient-tailored therapies. Using IHC, those markers 
that are expressed throughout the tumor could be identi!ed and used to predict marker 
expression of lymph node metastases that originated from the same tumor. This information 
could then be used to select matching optical contrast agents that are targeted speci!cally 
to the marker of choice. However, to prevent false negative results, heterogeneity in tumor 
marker expression should be taken strictly into account. 
Marker expression between lymph node metastases and their corresponding primary tumor 
was evaluated separately in our study and was found to closely match for some markers, while 
di#ering substantially for others (Table 2−4). 
CONCLUSION
Using a modi!ed TASC scoring system as a directive, we identi!ed EpCAM and CA-XII as 
tumor markers of particular interest for targeted NIRF imaging of lymph node metastases in 
breast cancer patients, covering with the highest chance of success both the primary tumor 
and potential lymph node metastases with one and the same tracer. Moderate to strong 
membranous expression was observed for at least one of these two markers in 57.4% of the 
evaluated patients. Further studies are needed to validate our !ndings in vivo and to evaluate 
the applicability of a one-stage intraoperative evaluation of the tumor burden of lymph nodes. 
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Combining innovative molecular biology and chemistry, scientists in the !eld of cancer 
research have developed optical imaging modalities for visualization of a wide variety of 
cellular and molecular processes in vivo. Whereas optical imaging has primarily been used 
in the last decade for research in cells and small laboratory animals, the next frontier is to 
translate this technology towards a clinical setting. Already, vibrant developments have been 
made in both imaging systems and "uorescent probes. This thesis provides an overview of 
the technical and biological requirements for NIRF imaging, with the emphasis on potential 
imaging applications to complement the surgical treatment of breast cancer.  
A general introduction on optical imaging and its potential applications in breast cancer 
treatment is provided in Chapter 1. In the case of clinical T1-2N0M0-x breast carcinoma, breast- 
conserving surgery followed by radiotherapy is considered standard treatment. Inadequate 
removal of the primary tumor results in positive surgical margins, which is considered to be 
one of the most important risk factors of local recurrence. More than focal positive margins 
therefore form an indication for additional surgery and, consequently, adverse e#ects on delay 
of adjuvant treament, cosmesis, psychological distress, and health costs. NIRF-guided surgery 
may reduce the frequency of positive surgical margins following lumpectomy by providing 
the surgeon with real-time feedback on surgical margin status during the surgical procedure. 
Chapter 2 comprises a review of the di#erent pre- and intraoperative techniques that are 
currently available as well as potential future techniques for obtaining negative surgical 
margins following breast-conserving surgery. The percentage of patients reported with 
positive surgical margins following lumpectomy ranges from 20% to 40% in the majority of 
studies. E#orts to reduce the number of positive margins should focus on optimizing the 
surgical procedure itself, as the main problem is the lack of real-time intraoperative feedback 
on the presence of positive surgical margins during lumpectomy. Innovative intraoperative 
approaches, such as positron emission tomography, magnetic resonance imaging, radioguided 
occult lesion localization, and NIRF optical imaging, could complement breast-conserving 
surgery by providing real-time feedback on surgical margin status during lumpectomy. 
To identify whether patients at high risk for positive surgical margins could be identi!ed prior 
to breast-conserving surgery, a multicenter study was conducted within twenty hospitals in 
the Northern- and Eastern region of the Netherlands. Chapter 3 describes the development 
of a predictive tool (nomogram) based on preoperative variables from 1185 patients, 
enabling preoperative estimation of the risk of positive margins on an individual basis. The 
nomogram was validated in an independent dataset consisting of 331 patients, showing 
adequate discrimination and calibration. To facilitate the use of our prediction tool in the clinic, 
a userfriendly web-based application was developed as an alternative to a graphical nomogram.
 
Chapter 4 focuses on the potential of NIRF imaging in demarcating cancerous tissue as 
a step-up towards NIRF-guided breast-conserving surgery. With the current diversity in 
"uorescent agents and the accompanying di#erences in biodistribution, we aimed to develop 
a methodology that enables correction for discrepancies in tumor demarcation as a result 
of the application of di#erent imaging systems and "uorescent probes in NIRF imaging. 
Bioluminescence and NIRF imaging were performed in a xenograft breast cancer mouse model 
using di#erent imaging systems and "uorescent probes in separate groups. Bioluminescence 
served as a gold standard for cancerous tissue. Segmentation-based comparative analysis 
of planar optical signals (SCAPOS) was applied as a novel methodology to correct for false 
negative NIRF signals in each group.
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Chapter 5 describes a technical feasibility study for pre- and intraoperative NIRF imaging 
applications using tissue-like breast phantoms. Breast-shaped phantoms were produced 
with optical properties that closely match those of normal breast tissue. Fluorescent 
tumor-like inclusions containing indocyanine green were positioned at prede!ned locations 
in the phantoms to allow for simulation of (i) preoperative tumor localization, (ii) real-time 
NIRF-guided tumor resection, and (iii) intraoperative margin assessment. Optical imaging 
was performed using a customized clinical prototype NIRF intraoperative camera. Tumor-like 
inclusions in breast phantoms could be detected up to a depth of 21 mm using the 
intraoperative camera system. Real-time NIRF-guided resection of tumor-like inclusions proved 
feasible. Moreover, intraoperative NIRF imaging reliably detected residual disease in case of 
inadequate resection. Clinical studies are needed to further validate these results.
Chapter 6 outlines a clinical study investigating the technical feasibility of NIRF-guided 
visualization of the sentinel lymph node using a nonspeci!c "uorescent dye in ten patients 
with biopsy-proven cT1-2N0 breast carcinoma. All patients underwent the standard sentinel 
lymph node procedure, consisting of a preoperative injection with radiolabeled colloid and 
intraoperative injection with vital blue dye. In addition, all patients received a peritumoral 
injection with 1 ml (0.5 mg/ml) indocyanine green intraoperatively. The sentinel node was 
successfully identi!ed in all patients using a customized multispectral "uorescence camera 
system. The total number of lymph nodes detected with radiolabeled colloid, vital blue dye, 
and indocyanine green was 18, 9, and 14, respectively. The use of the NIRF camera system did 
not interfere with the standard operative procedure. No adverse reactions were encountered 
following administration of indocyanine green. 
Chapter 7 comprises a systematic review of current techniques used for sentinel lymph node 
mapping in breast cancer and melanoma. Pooled detection rates using radiocolloid alone 
gradually increased from 92% in 1995 to 98% in 2012, which is likely to be attributable to a 
gradual sophistication of the technique over time. Addition of vital blue dye did not increase 
sentinel lymph node detection rates compared to the use of radiocolloid alone, while its use 
led to allergic reactions in up to 5% of the patients. Addition of the nonspeci!c "uorescent 
dye indocyanine green to radiocolloid increased detection rates to 100%. No anaphylactic 
reactions were described when indocyanine green was applied.  
Chapter 8 describes the assessment of tumor marker characteristics from 10 preselected 
markers using the recently introduced target selection criteria (TASC) scoring system. The 
scoring system is based on seven favorable target characteristics for imaging purposes for 
which each marker is scored: I) extracellular tumor marker localization; II) expression pattern; 
III) tumor-to-normal ratio (T/N); IV) target expression rate; V) reported successful use in vivo; 
VI) enzymatic activity, and VII) internalization. Evaluated tumor markers included alpha v beta 3 
(αvβ3) integrin receptor, C-X-C-chemokine receptor 4 (CXCR4), carbonic anhydrase (CA) IX and 
XII, epithelial cell adhesion molecule (EpCAM), folate receptor alpha (FR-α), human epidermal 
growth factor receptor 2 (HER2), mammaglobin 1 (MGB1), Notch1 receptor, and vascular 
endothelial growth factor A (VEGF-A). All ten tumor markers were assessed on tissue microarrays 
of invasive breast carcinomas from 439 eligible patients using immunohistochemistry. CXCR4, 
CA-XII, and EpCAM were identi!ed as the most potent tumor markers for probe development 




Chapter 9 focuses on tumor marker expression in lymph node metastases from 98 breast 
cancer patients, evaluating the same panel of ten tumor markers mentioned in Chapter 8. 
To evaluate whether a single targeted "uorescent probe could be applied for simultaneous 
imaging of both lymph node metastases and the primary tumor, marker expression levels 
were compared between lymph node metastases and their corresponding primaries. CXCR4 
was deemed unsuitable for targeted imaging of lymph node metastasis due to expression of 
CXCR4 on the outer membrane of lymphocytes, resulting in high background signals in lymph 
nodes. CA-XII and EpCAM were identi!ed as the most potent markers for targeted imaging of 
lymph node metastases.    
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In this thesis, we describe intraoperative NIRF imaging as a novel and highly promising 
technique to complement the surgical treatment of breast cancer. Optical imaging modalities 
have become essential for studying small animal models, providing unique insights into 
disease pathogenesis, drug development, and e#ects of therapy. Herein, the concept of using 
NIR light has proven a crucial step in the development of optical technologies that can o#er 
high integration in a clinical setting. Further development of intraoperative imaging systems 
should be directed towards maximizing signal penetration of optical signals in deep tissues 
and enabling accurate, quantitative imaging that eliminates the appearance of false negatives 
or positives. Although challenges will continue to arise, optical imaging has the potential to 
become a powerful and practical tool for a wide array of applications in cancer research and 
treatment, including detection of early-stage cancer, image-guided biopsies and surgical 
procedures, and therapeutic monitoring of cancer.
Targeted NIRF imaging in animals
The incidence of breast cancer is expected to rise to 17,500 newly diagnosed cases in 2020, 
indicating that breast cancer will continue to be the most common malignancy in women in the 
Netherlands in the years to come.1 Intraoperative NIRF imaging o#ers a promising technique 
for real-time "uorescence-guided surgery that is safe, simple to operate, fast, relatively 
inexpensive, makes use of non-ionizing radiation, and enables imaging at high resolution 
(as low as 10 μm).2 Application of tumor-targeted "uorescent probes could di#erentiate 
malignancy from surrounding breast tissue, enabling NIRF-guided resection of the primary 
tumor as well as sites of regional disseminated disease without unnecessary damage to healthy 
tissue.3 Indeed, animal studies reported the outcome of cancer surgery to improve when 
real-time NIRF imaging feedback was enabled during surgery using tumor-targeted "uorescent 
probes.4 Con!rmatory ex vivo imaging, bioluminescence imaging, and histopathology were 
used to validate the in vivo !ndings. NIRF imaging detected all tumors and successfully guided 
total tumor excision by e#ectively detecting small tumor residuals, which occasionally were 
missed by the surgeon. It should be mentioned, however, that a xenograft animal model 
was used with subcutaneously implanted tumors that do not necessarily exhibit the same 
invasiveness and disease characteristics as in humans. Caution should therefore be used when 
extrapolating these results to humans. 
Targeted NIRF imaging in humans
Recently, our group reported on the !rst-in-human use of intraoperative tumor-speci!c NIRF 
imaging in patients undergoing an exploratory laparotomy for suspected ovarian cancer.5 The 
potential value of intraoperative NIRF imaging for the detection of tumor tissue in ovarian 
cancer was assessed using the targeted "uorescent probe folate-FITC, which was synthesized 
by conjugating folate (a vitamin) to the "uorescent dye "uorescein isothiocyanate (FITC). 
Folate-FITC is targeted speci!cally towards folate receptor α, which is overexpressed in 90-95% 
of the malignant ovarian carcinoma.6 The targeting ligand, folate, is especially attractive as 
it is non-toxic, inexpensive, and relatively easy conjugated to a "uorescent dye. However, 
its applicability in breast cancer seems limited due to the relatively low expression of folate 
receptor α in breast tumors (Chapter 8) and the unfavorable emission wavelength of FITC 
(~500 nm), reducing penetration depth of the optical signal to several millimeters. Moreover, 
there are concerns regarding potential toxicity of folate-FITC on the long term, as the 
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compound is internalized in living cells upon binding to its receptor. Alternative tumor 
markers are therefore needed as well as "uorescent agents in the near-infrared spectral range 
for successful NIRF imaging in breast cancer. So far, the only two "uorescent agents that made 
it towards the process of clinical translation are IRDye 800CW (LI-COR Biosciences, Lincoln, 
USA) and ZW800-1 (The FLARE Foundation, Wayland, USA). Both agents have favorable 
toxicity pro!les and are expected to be applied for NIRF imaging of di#erent solid cancers in 
the near future.   At the University Medical Center of Groningen and Utrecht, the BIRDye CTMM 
MAMMOTH optical imaging study (NCT01508572) is currently being performed, in which the 
tracer bevacizumab-IRDye 800CW will be administered to 20 breast cancer patients prior to 
surgery.7 The tracer consists of the near-infrared "uorescent dye IRDye 800CW conjugated to 
the VEGF-A targeting humanized monoclonal antibody bevacizumab. VEGF-A has proven to 
be a valid target for molecular imaging with radioactive labeled tracers.8 However, in view of 
radiation safety, infrastructure, costs, and stability, "uorescent labeling of bevacizumab has 
potential advantages over radioactive labeling. The purpose of the BIRDye study is to provide 
insight in the uptake of bevacizumab-IRDye 800CW in breast cancer tissue, surrounding 
healthy tissue, tumor margins, and lymph nodes. Also, the safety will be assessed as well as the 
intraoperative detectability of the bevacizumab-IRDye 800CW "uorescent signal.
Tumor markers for targeted NIRF imaging
In addition to VEGF-A, alternative tumor markers are available that are of particular interest for 
tumor-targeted imaging in breast cancer (Chapter 8), including CXCR4, EpCAM, and CA-XII. For 
the majority of tumor markers, humanized monoclonal antibodies are already available that 
can be conjugated with NIR "uorescent agents, facilitating clinical translation. As NIRF optical 
contrast agents translate from preclinical studies to patients, applications of optical imaging in 
clinical care are expected to expand rapidly.
Whether or not a speci!c marker is expressed, can be assessed prior to surgery by performing 
immunohistochemistry on a core needle biopsy. Through the assessment of multiple markers 
simultaneously using a preoperative marker panel, the most suitable tumor marker and its 
corresponding "uorescent probe can be selected for each individual patient. Several hours 
to days after injection with the selected probe, tumor-targeted NIRF-guided surgery can be 
performed. Implementation of such a preoperative marker panel is considered an important 
step towards patient-tailored imaging.
NIRF-guided sentinel lymph node mapping
Although the sentinel node detection rate is already 97% using the current standard technique 
of radiocolloid combined with vital blue dye (Chapter 7), the true added value of NIRF imaging 
lies in its potential to visualize lymph node metastasis. By using a multispectral imaging 
system, multiple "uorescent agents can be used simultaneously as long as their emission 
wavelengths are distinct.9 For example, the nonspeci!c "uorescent dye indocyanine green 
could be combined with a tumor-targeted "uorescent dye for visualization of the sentinel 
lymph node and potential lymph node metastasis, respectively (Fig. 1).
Tafreshi et al. showed the feasibility of targeting lymph node metastases using a NIRF imaging 
system in a xenograft breast cancer mouse model.10,11 NIRF imaging was performed 24 hours 
following injection of a NIR "uorescent dye conjugated to a monoclonal antibody targeted 
towards mammoglobin 1, carbonic anhydrase IX, or carbonic anhydrase XII. Results indicated 
11
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Figure 1. NIRF-guided lymph node mapping using a dual probe approach in combination with a multispectral 
imaging system. After localization of the sentinel lymph node using a nonspeci!c "uorescent probe (A), the 
identi!ed lymph node is scanned for the presence of the tumor-targeted probe (B) bound to metastases (M).
that the "urorescent probe was only retained in the primary tumor and lymph node  metastases. 
As few as 1,000 breast cancer cells could be detected in the lymph nodes, indicating the high 
sensitivity of this methodology. Theoretically, this approach o#ers considerable potential for 
the staging of breast cancer. Already, tumor markers were identi!ed that are of particular 
interest for targeted imaging of lymph node metastasis (Chapter 9). However, extensive 
scienti!c testing is needed to con!rm this hypothesis. 
Technical improvements to NIRF imaging systems
Several NIRF epi-illumination systems have been developed for interventional imaging 
applications, providing the surgeon with real-time information concerning the distribution of 
"uorescent molecules in tissue. Imaging over a range of NIR wavelengths enables correction 
for photon-tissue interaction and spectral unmixing of multiple "uorescent signals.12 
To date, three new intraoperative camera systems have been developed that can detect and 
unmix NIRF signals in real-time. The T3-platform© (SurgOptix Inc., Redwood Shores, USA) 
resolves true "uorescence biodistribution, eliminating false positive and negative results 
common to other epi-illumination "uorescence imaging systems. The implementation is 
based on the use of three cameras operating in parallel, utilizing a common main objective 
that allows for the concurrent collection of color, "uorescence, and light attenuation images 
from the same !eld of view.13 The T3-platform is currently in clinical trial related to breast 
cancer patients (NCT01508572). 
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The second camera system is the ArtemisTM (Quest Medical Imaging, Middenmeer, The 
Netherlands), which is a real-time stereoscopic imaging system that combines visible light 
with NIR light images. The ArtemisTM creates multispectral images by using a !ve-channel 
prism (covering the range from 400−1000 nm), enabling the capture of !ve di#erent color 
bands simultaneously.3 
The third intraoperative camera is the !uorescence-assisted resection and exploration (FLARETM) 
system, which acquires color video and NIR "uorescence images simultaneously in real-time.14 
The FLARE™ system underwent considerable re!nements over the years, including the addition 
of hands-free operation and the integration of high-power, multi-channel, and computer-con-
trolled LED light source required for human surgery.
The current intraoperative NIRF imaging systems enable superposition of the "uorescent signal 
on a color video of the surgical view, facilitating anatomical positioning of the optical signal.2 
The current frame-rate of about 10−20 frames per second enables video-rate visualization 
of the "uorescent signal. Although some groups are working on holographic projections of 
the "uorescent signal on the surgical !eld, this methodology seems prone to artefacts due to 
movement of the patient. Because nowadays all surgeons are trained in laparoscopic surgery 
and are therefore used to working with 2D screens, visualizing the "uorescent signal as an 
overlay image on the operating room monitor seems the most straightforward approach. 
In addition, a NIRF camera was integrated into robotic systems like the da Vinci Si HDTM system 
(Intuitive Surgical Inc., Sunnyvale, USA), providing a combination of technical and minimally 
invasive advantages.15 However, only a few articles have been published thus far regarding this 
technique which is still experimental and evolving.16-21
Photoacoustic imaging
Beyond epi-illumination "uorescence imaging, photoacoustic methods are emerging to 
o#er high-resolution optical imaging through up to centimeters of depth.22 Photoacoustic 
imaging is based on the fact that local thermal expansion occurs directly following photon 
absorption by endogenous molecules or exogenously administered optical contrast agents. 
This local expansion results in the emission of ultrasound waves, which can be detected using 
an ultrasound transducer and used to generate a photoacoustic image.23 
Although photoacoustic imaging also su#ers from depth limitation, the maximum signal 
penetration depth is inherently greater than that with conventional optical imaging 
techniques. At greater depths, the e#ect of light scattering and absorption by tissue decreases 
the photon "ux reaching deep tissue, thereby weakening the ultrasound signal. Because 
ultrasound scatters orders of magnitude less than photons in tissue, high spatial resolutions 
can be preserved through millimeters to centimeters of tissue.24 Some preliminary studies 
have already reported on the detection of suspected breast carcinoma based on increased 
absorption due to tumor vasculature.25 In addition, handheld photoacoustic systems for 
noninvasive sentinel lymph node mapping are being developed.
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Door het combineren van moleculaire biologie en chemie, hebben wetenschappers in het veld 
van kankeronderzoek optische beeldvormingstechnieken ontwikkeld om een variëteit aan 
cellulaire en moleculaire processen zichtbaar te maken in vivo. Hoewel optische beeldvorming 
primair wordt toegepast voor wetenschappelijk onderzoek in cellijnen en proefdieren, zullen 
patiënten pas rechtstreeks baat hebben bij deze techniek wanneer deze vertaald wordt naar 
de kliniek. De laatste jaren hebben belangrijke ontwikkelingen plaatsgevonden van zowel de 
camerasystemen als de optische contrastmiddelen. Dit proefschrift verschaft een overzicht 
van de technische en biologische benodigdheden voor nabij-infrarood "uorescentie (NIRF) 
beeldvorming, met de nadruk op toepassingen van optische beeldvorming als aanvulling op 
de chirurgische behandeling van borstkanker.  
Een algehele introductie met betrekking tot optische beeldvorming en de potentiële 
toepassingen hiervan bij de chirurgische behandeling van het mammacarcinoom is 
opgenomen in Hoofdstuk 1. Bij patiënten met een T1-2N0M0-x mammacarcinoom bestaat 
de standaard behandeling uit borstsparende chirurgie gevolgd door radiotherapie. Indien 
de tumor niet volledig is verwijderd is er sprake van positieve snijvlakken, welke worden 
beschouwd als een belangrijke risicofactor voor het optreden van een lokaal recidief. Meer 
dan focaal positieve snijvlakken vormen daarom een indicatie voor aanvullende chirurgie 
met als gevolg een nadelig e#ect op cosmetiek, een toegenomen psychologische belasting 
en een stijging in de kosten van de gezondheidszorg. Fluorescentiegeleide chirurgie zou de 
frequentie van positieve snijvlakken na borstsparende chirurgie mogelijk kunnen reduceren 
door de chirurg intraoperatief te voorzien van real-time feedback ten aanzien van de locatie 
en grootte van de tumor.
Hoofdstuk 2 omvat een uiteenzetting van de verschillende pre- en intraoperatieve 
technieken die heden ten dage beschikbaar zijn evenals potentieel toekomstige technieken 
voor het verkrijgen van vrije snijvlakken bij borstsparende chirurgie. Het merendeel van de 
wetenschappelijke studies rapporteren een percentage patiënten met positieve snijvlakken 
na borstsparende chirurgie variërend van 20% tot 40%. Inspanningen om dit relatief hoge 
percentage te reduceren zouden zich moeten richten op de chirurgische procedure zelf, 
waarbij het hoofdprobleem het ontbreken van real-time intraoperatieve feedback ten aanzien 
van de status van de snijvlakken wordt geacht. Innovatieve intraoperatieve toepassingen, 
waaronder positron emissie tomogra!e (PET), radiogeleide lokalisatie van occulte tumoren en 
nabij-infrarood "uorescentie beeldvorming, zouden een belangrijke aanvulling kunnen zijn op 
borstsparende chirurgie door de chirurg real-time feedback te verstrekken ten aanzien van de 
status van de snijvlakken.
Om patiënten met een hoog risico op positieve snijvlakken te identi!ceren voorafgaand aan 
borstsparende chirurgie, werd een multicenter studie verricht met medewerking van twintig 
ziekenhuizen in de regio Noord- en Oost-Nederland. Hoofdstuk 3 beschrijft de ontwikkeling 
van een predictiemodel (nomogram), gebaseerd op preoperatieve variabelen van 1.185 
patiënten, waarmee preoperatieve inschatting van het risico op positieve snijvlakken mogelijk 
wordt op individuele basis. Het nomogram werd gevalideerd in een onafhankelijke dataset 
bestaande uit 331 patiënten. Om gebruik van het predictiemodel in een klinische setting te 




Hoofdstuk 4 focust op het potentieel van NIRF beeldvorming ten aanzien van het markeren 
van  tumorweefsel als opstap naar NIRF-geleide borstsparende chirurgie. Gezien de diversiteit 
in beschikbare optische contrastmiddelen en de daarmee gepaard gaande verschillen in 
biodistributie, werd een methode ontwikkeld waarmee kan worden gecorrigeerd voor 
discrepanties in demarcatie van tumorweefsel ten gevolge van het gebruik van verschillende 
camerasystemen en/of optische contrastmiddelen. Bioluminescentie en NIRF beeldvorming 
werden verricht in een borstkanker model in muizen, waarbij per groep gebruik werd gemaakt 
van verschillende camerasystemen en optische contrastmiddelen. Bioluminescentie diende 
hierbij als gouden standaard voor de aanwezigheid van tumorweefsel. Segmentation-based 
comparative analysis of planar optical signals (SCAPOS) werd toegepast als nieuwe methode 
voor het corrigeren van vals negatieve signalen in elke groep.  
Hoofdstuk 5 beschrijft een technische haalbaarheidsstudie naar de pre- en intraoperatieve 
toepassingsmogelijkheden van NIRF beeldvorming met behulp van weefsel-gelijkende
borstfantomen. Fantomen met optische eigenschappen gelijkend op die van normaal 
mammaweefsel werden geproduceerd in de vorm van een vrouwelijke borst. Fluorescente 
tumor-gelijkende inclusies werden gepositioneerd op verschillende diepten in de 
borstfantomen voor het simuleren van (i) preoperatieve tumor lokalisatie, (ii) real-time 
NIRF-geleide tumor resectie, en (iii) intraoperatieve beoordeling van de chirurgische 
snijvlakken. Optische beeldvorming werd verricht door middel van een prototype NIRF 
camera. De tumor-gelijkende "uorescente inclusies konden worden gedetecteerd tot op 
een diepte van 21 mm in de borstfantomen. Real-time "uorescentie-geleide resectie van 
tumor-gelijkende inclusies bleek technisch haalbaar. Klinische studies zijn noodzakelijk om 
deze resultaten te valideren.
   
In Hoofdstuk 6 wordt een klinische studie beschreven, waarin de technische haalbaarheid van 
"uorescentie-geleide detectie van de poortwachterklier met behulp van een non-speci!ek 
"uorescent contrastmiddel in tien patiënten met een bewezen cT1-2N0 mammacarcinoom. 
Alle patiënten ondergingen de standaard poortwachterklier procedure, bestaande uit een 
preoperatieve injectie met radiogelabeled colloïd en intraoperatieve injectie met patent blauw. 
Daarnaast werden alle patiënten intraoperatief rondom de primaire tumor geïnjecteerd met 1 
ml (0,5 mg/ml) indocyanine groen. De poortwachterklier kon succesvol worden geïdenti!ceerd 
in alle patiënten met behulp van een NIRF camera systeem. Het totaal aantal lymfeklieren dat 
werd gedecteerd met radiogelabeled colloïd, patent blauw en indocyanine groen bedroeg 
18, 9, en 14. Het gebruik van een NIRF camera systeem interfereerde niet met de standaard 
chirurgische procedure en er werden geen nadelige e#ecten waargenomen van het gebruik 
van indocyanine groen. 
Hoofdstuk 7 behelst een systematische review van technieken die heden ten dage worden 
toegepast voor het detecteren van de poortwachterklier. Het percentage successvolle 
poortwachterklierprocedures waarbij alleen radiocolloïd wordt gebruikt steeg van 92% in 
1995 tot 98% in 2012, waarschijnlijk door toegenomen ervaring en een geleidelijke verbetering 
van de techniek. Toevoeging van blauwe kleurstof (patent blauw) leidde niet tot een toename 
van het percentage succesvolle poortwachterklierprocedures in vergelijking tot het gebruik 
van radiocolloïd alleen. Toevoeging van het nonspeci!eke "uorescente contrastmiddel 





Hoofdstuk 8 beschrijft een beoordeling van de eigenschappen van tien voorgeselecteerde 
tumor markers aan de hand van het recent geïntroduceerde target selection criteria (TASC) 
evaluatie systeem. Deze methode is gebaseerd op zeven gunstige karakteristieken van tumor 
markers voor optische beeldvorming: I) extracellulaire lokalisatie van de tumor marker, II) 
expressie patroon, III) tumor/achtergrond ratio, IV) mate van marker expressie, V) succesvolle 
toepassing van de marker in vivo, VI) enzymatische activiteit, en VII) internalisatie. De 
geëvalueerde tumor markers waren: alpha v beta 3 (αvβ3) integrine receptor, C-X-C-chemokine 
receptor 4 (CXCR4), koolzuuranhydrase (CA) IX en XII, epitheliaal cel adhesie molecuul (EpCAM), 
folaat receptor alfa (FR-α), humane epidermale groei factor receptor 2 (HER2), mammaglobine 1 
(MGB1), Notch1 receptor en vasculair endotheliale groei factor A (VEGF-A). De beoordeling van 
tumor markers vond plaats middels immunohistochemische analyse van tissue microarrays 
(TMA’s) van 439 patiënten met een invasief mammacarcinoom. CXCR4, CA-XII en EpCAM 
werden aan de hand van TASC geïdenti!ceerd als markers met de meeste potentie voor de 
ontwikkeling van tumor-gerichte "uorescente contrastmiddelen.
  
Naast "uorescentie-geleide resectie van de primaire tumor, zou pre- en/of intraoperatieve 
identi!catie van lymfekliermetastasen een belangrijke toepassing kunnen zijn van 
tumor-gerichte NIRF beeldvorming. Hoofdstuk 9 focust op de expressie van tumor markers 
in lymfekliermetastasen van 98 patiënten met mammacarcinoom, waarbij dezelfde markers 
werden beoordeeld als besproken in Hoofdstuk 8. Om te evalueren of een speci!ek "uorescent 
contrastmiddel gelijktijdig zou kunnen worden toegepast voor het detecteren van zowel 
de lymfekliermetastasen als de primaire tumor, werd de expressie van tumor markers in 
beide groepen vergeleken. CXCR4 werd ongeschikt geacht voor gerichte beeldvorming 
van lymfekliermetastasen door de hoge mate van CXCR4 expressie op de membraan van 
lymfocyten, wat resulteert in een hoog achtergrond signaal in de lymfeklier zelf. CA-XII en 
EpCAM werden geïdenti!ceerd als markers met de meeste potentie voor gerichte NIRF 















AIC  Aikaike’s information criterion
αvβ3  Alpha v beta 3 
ALN  Axillary lymph node
ALND  Axillary lymph node dissection
AUROC  Area under the receiver-operating characteristic curve
BC  Breast cancer
BCS  Breast-conserving surgery
BCT  Breast-conserving therapy
BI-RADS  Breast imaging reporting and data system
BLI  Bioluminescence imaging
CA-IX  Carbonic anhydrase IX
CA-XII  Carbonic anhydrase XII
CAL  Cryoprobe-assisted localization
CCD  Charge-coupled device
CCMO  National committee for clinical research
CI  Con!dence interval
CNB  Core needle biopsy
CT  Computed tomography
CXCR4  C-X-C chemokine receptor 4 
DAB  3,3-Diaminobenzidine
DARE   Database of abstracts of reviews of e#ects
DCIS   Ductal carcinoma in situ
EpCAM  Epithelial cell adhesion molecule
ER  Estrogen receptor 
FDA  Food & drug administration
FDG   Fluoro-desoxyglucose
FISH  Fluoresent in site hybridization
FITC  Fluorescein isothiocyanate
FLARE  Fluorescence-assisted resection and exploration system
FNR  False negative rate
FPS  Frames per second
FR-α  Folate receptor alpha
FRI   Fluorescence re"ectance imaging 
FSA   Frozen section analysis
FWHM  Full width at half maximum
GLUT1  Glucose transporter 1
HCL  Hydrochloric acid
H&E  Haematoxylin and eosin
HER2  Human epidermal growth factor receptor 2
ICD  International classi!cation of diseases
ICG  Indocyanine green 
IDC   Invasive ductal carcinoma
IHC  Immunohistochemistry 
IOTPC   Intraoperative touch preparation cytology 
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IOUS   Intraoperative ultrasound 
IR  Identi!cation rate
IRB  Institutional review board
IVIS  In vivo imaging system
LED  Light-emitting diode
LND  Lymph node dissection
LR   Local recurrence
MGB1   Mammaglobin 1 
MMP  Matrix metalloproteinase
MRI   Magnetic resonance imaging
MSAP  Multifunctional single attachment point
MVA  Multivariate regression analysis
NIR  Near-infrared
NIRF  Near-infrared "uorescence
OR  Odds ratio
PB  Patent blue 
PBS  Phosphate-bu#ered saline
PET   Positron emission tomography 
PR  Progesterone receptor
QUADAS   Quality assessment of diagnostic accuracy studies
RCT   Randomized controlled trial 
ROI  Region of interest
ROLL   Radioguided occult lesion localization 
RSL   Radioguided seed localization
SCAPOS   Segmentation-based comparative analysis of planar optical signals
SD  Standard deviation
SLN  Sentinel lymph node
SLNB  Sentinel lymph node biopsy
SLNM  Sentinel lymph node mapping
SN   Signal-to-noise
SPECT  Single-photon emission computed tomography
TBR  Tumor-to-background ratio
TBS  Tris-bu#ered saline
TFT  Thin-!lm transistor
TIS  Three-item severity score
TMA  Tissue microarray
US  Ultrasound
VEGF-A  Vascular endothelial growth factor A
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